A study of invariant NKT cell biology in health and disease by Gao, Yifang
University of Southampton Research Repository
ePrints Soton
Copyright © and Moral Rights for this thesis are retained by the author and/or other 
copyright owners. A copy can be downloaded for personal non-commercial 
research or study, without prior permission or charge. This thesis cannot be 
reproduced or quoted extensively from without first obtaining permission in writing 
from the copyright holder/s. The content must not be changed in any way or sold 
commercially in any format or medium without the formal permission of the 
copyright holders.
  
 When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given e.g.
AUTHOR (year of submission) "Full thesis title", University of Southampton, name 
of the University School or Department, PhD Thesis, pagination
http://eprints.soton.ac.uk  
 
UNIVERSITY OF SOUTHAMPTON 
 
FACULTY OF MEDICINE, HEALTH AND LIFE 
SCIENCES 
 













Thesis for the degree of Doctor of Philosophy 
September 2010 
   
 
UNIVERSITY OF SOUTHAMPTON 
ABSTRACT 
FACULTY OF MEDICINE, HEALTH AND LIFE SCIENCES 
SCHOOL OF MEDICINE, CANCER SCIENCES DIVISION 
Doctor of Philosophy 
A STUDY OF INVARIANT NKT CELL BIOLOGY IN HEALTH AND 
DISEASE 
By Yifang Gao 
Invariant  NKT  cells  (iNKT  cells)  have  been  increasingly  recognised  as  an 
important  cell  type  in  regulating  certain  immune  responses.  Advances  in  the 
understanding of iNKT biology have provided opportunities for manipulating 
their  functions  for  combating  malignant,  infective  and  autoimmune  diseases. 
During the tenure of my thesis I have explored aspects of iNKT function in 
healthy individuals, assessed the activity of novel iNKT compounds in an ex 
vivo human system and evaluated this important conserved T cell subset in a 
human disease setting.   
iNKT cells were initially evaluated in healthy individuals to explore whether 
there were differences in their function and development that co-associated with 
an enumeration that extended over a three log range. We performed phenotypic 
and  functional  assessments  of  ex  vivo,  polyclonal  iNKT  cells  in  47  healthy 
donors. We established that those individuals with low numbers of iNKT cells 
(<200/10
5 T cells) displayed a different iNKT phenotype and functional profile 
to those with a high numbers of iNKT cells (>500/10
5 T cells).  
Following  the  establishment  of  a  robust  screening  platform  for  human  iNKT 
responses a series of 14 novel iNKT cell ligands were designed and analysed for 
functional distinctiveness from the prototypic  -GC ligand. We identified ligands 
that  had  been  modified  in  the  acyl  and  sphingosine  chains,  which  both 
dissociated  iNKT  proliferation  from  cytokine  production  and  skewed effector 
responses  in  a  Th1,  Th2  or  Th17  direction.  We  similarly  identified  novel 
compounds that were able to reduce iNKT anergy after initial activation. Finally 
we showed that these functional differences were modified by CD1d affinity and 
the  nature  of  the  antigen  presenting  cell,  co  existent  cytokines  and  donor 
phenotype.  
Lastly, we applied our iNKT investigative tools to a clinical disease where the 
link  between  iNKT  cells  and  B  cell  help  for  antibody  production  was  a 
possibility.  We showed that in the commonest antibody deficiency syndrome, 
common variable immunodeficiency, iNKT were absent or functionally impaired 
in the majority of cases and that their number was correlated with presence of 
memory B cells.   
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The  immune  system  is  designed  to  defend  the  host  against  a  variety  of 
pathogenic microbes, including bacteria, fungi and viruses. An effective immune 
system  can  protect  the  host  against  disease  by  identifying,  targeting  and 
eliminating such pathogens.  
 
The immune system has developed a wide variety of immune responses from 
soluble  factors  to  cellular  activities.  The  different  immune  responses  can  be 
broadly defined into two types, namely innate and adaptive immune responses. 
The  innate  immune  responses  have  a  broad  range  of  recognition,  and  can 
normally  give  rise  to  immediate  responses;  whereas  the  adaptive  immune 
components are highly specific, usually with a delay between the exposure to 
antigen and the maximal response. The adaptive immune response leads to a 
persistent  immune  memory  for  that  particular  antigen.  In  contrast,  the  innate 
immune responses do not develop any immunological memory after repeated 
exposure to the foreign antigens. 
 
The bridging of innate and adaptive immune responses is very important for 










    
 
1.1 The innate immune system 
 
Pathogenic microbes can enter the body by various ways, through many different 
sites. Various barriers are present that initially protects against infection. There 
are  three  main  types  of  surface  barrier  including  mechanical,  chemical  and 
biological (1).   
 
Microorganisms may first encounter the epithelial barrier of the skin or those of 
the lungs, intestines and the genitourinary tract. In the lungs, pathogens may be 
mechanically  removed  from  the  respiratory  tract  by  means  of  coughing  and 
sneezing.  Likewise,  the  respiratory  and  gastrointestinal  tracts  can  secrete 
mucosal substances that serve as traps for invading microorganisms (2). 
 
Biological  barriers  protect  the  host  from  the  pathogens  in  the  form  of 
antimicrobial  peptides.  An  example  of  such  peptides  include  the   -defensin 
proteins  (3).  The  majority  of  human     defensins  are  produced  by  mucosal 
epithelial cells, which are active against a wide range of pathogens. They have 
direct  anti-microorganism  effects  and  may  aid  the  recruitment  of  additional 
innate,  cellular  and  humoral  immune  responses  (4).  Some  inflammatory 
mucocutaneous diseases such as Crohn’s disease and atopic dermatitis may be 
related  to  abnormalities  in  this  area  of  immunity  and  be  targets  for  the 
therapeutic development of these agents (4). 
 
Besides  biological  and  mechanical  barriers,  chemical  barrier  may  eliminate 
microorganisms by altering the pH of the invasion site of bacteria or limiting 
available food resources i.e. the availability of iron (1).  Once microorganisms 
breach this initial line of barrier defence, invasive infectious can occur, leading 
to the development of disease. 
 
The key feature of the innate immune system is its rapid reaction to pathogens 
once they enter the body. Failure to develop an efficient innate immune response    
 
may lead to lethal infections, as has been demonstrated in murine and human 
single  gene  defects  (5,  6).    The  immediate  innate  response  is  important  in 
establishing an inflammatory environment that can direct the appropriate form of 
an adaptive immune response (7). For example:  
 
1) Mycobacterial pathogens, TH1 responses and IFN-  
The effective control of mycobacterial pathogens is mainly reliant upon adaptive 
Th1 responses. The initial priming of naïve T cells is particularly dependent on 
the innate immune response. Successful priming responses require the engulfing 
of mycobacterial pathogen derived antigens and their presentation by dendritic 
cells.  This  process  additionally  requires  the  recognition  of  mycobacterial 
signatures by specific toll like receptors as well as a competent IFN-  response 
from the host (8). 
 
2) Fungal pathogens, TH17 responses and IL-17 
Recent studies have suggested that a specific CD4 T cell subset is important for 
protecting against candidiasis. These Th17 cells are notable for their production 
of IL-17A, which can support neutrophil recruitment. This subset of cells can be 
activated by APCs following contact with a number of fungal components that 
set up a distinctive cytokine milieu that includes IL-6, TGF-  and IL-23 (9). 
 
3) Parasitic pathogens, TH2 responses and IgE  
It has been recognized for many years that parasite infections, such as helminths, 
can prime naïve T cells for a Th2 response and IgE production from antigen 
specific B cells. It has been suggested that the priming to a Th2 response is 
highly dependent on the initial signal received from the parasite to the innate 
immune response.  In contrast to the activation conditions that are typical for 
priming  Th1  responses,  optimal  Dendritic  Cell  (DC)  conditions  for  Th2 
differentiation are correlated with down regulation of costimulatory molecules. 
The process of limited DC activation also leads to a reduction in Th1 type T cells 
in such infections.    
 
1.1.1 Cells comprising the innate immune system 
 
The range of cells involved in the innate immune response is broad and includes 
monocytes,  macrophages,  neutrophils,  basophils,  mast  cells,  eosinophils, 
dendritic cells (DC), natural killer cells (NK cells), and natural killer T cells 
(NKT cells). Amongst these, NK and NKT cells arise from lymphoid progenitor 
cells;  whereas  monocytes,  macrophages,  neutrophils,  basophils,  mast  cells, 
eosinophils and dendritic cells arise from myeloid progenitor cells (7).  
 
                                    
The common origin of monocytes, macrophages and neutrophils suggest there 
might  be  a  functional  similarity  between  these  cell  types.  Indeed,  these  cells 
share  many  characteristics  including  their  functional  categorization  as 
professional  phagocytes  (10).  One  common  feature  is  that  all  utilize  defense 
mechanisms  that  involve  the  production  of  cytotoxic  oxidants  (11).  The 
nicotinamide  adenine  dinucleotide  phosphate  (NADPH)  complex  produces 
reactive oxygen species following phagocytosis of pathogens in these cells. In 
addition, nitric oxide can combine with reactive nitrogen species produced by the 
phagocytes, to become highly toxic to pathogens (10).  Secondly, these cell types 
have very similar chemokine and cytokine profiles. Neutrophils and monocytes 
are  both  recruited  to  the  sites  of  infection  by  chemotactic  agents  such  as 
interleukin-8 (IL-8). Upon engulfing the foreign pathogen, they produce similar 
chemokines  such  as  CXCL1/2/3,  CXCL8,  CCL2,  and  CCL3/4  (10,  12,  13). 
These  responses  are  then  further  amplified  by  the  release  of  inflammatory 
cytokines such as IL-1, IL-6 and TNF- . Thirdly, these cells all express pattern 
recognition receptors (PRRs); a portfolio of receptors that can identify foreign 
components that are distinctive to invading pathogens. PRRs include the toll like 
receptors (TLRs 1-9), the mannose receptor and the scavenger receptors. The 
PRRs recognize a limited set of patterns that are present in foreign pathogens, 
namely pathogen associated molecular patterns (PAMPs). These PAMPs may be 
on  bacterial  cell  walls  i.e.  lipopolysaccharide  (LPS).  The  TLRs  may  also    
 
recognize certain intracellular features, such as motifs on DNA (i.e. TLR9 and 
CpG) and single stranded RNA (i.e. TLR 7,8). The recognition of PAMPs by 
TLRs triggers an inflammatory response that induces expression of chemokine 
receptors  and  intergrins,  facilitating  the  recruitment  of  additional  phagocytic 
cells to the site of inflammation (10).  
 
                                              
NK cells are another early defender, first characterized more than 20 years ago 
(14). They are important in viral infections, responding quickly after the initial 
exposure through expansion and immediate effector functions. Cytotoxic killing 
is undertaken through the release of perforin and production of cytokines such as 
IFN-  and TNF-  (15). NK cells are also becoming recognised as pivotal in 
shaping the sequential adaptive response (15). Rather than undergoing somatic 
rearrangement of their receptors, NK cells have a limited number of activation 
and inhibition receptors. These recognize classical MHC class I complexes as 
well as non classical MHC class I molecules such as HLA-E and G (16). The 
killer immunoglobulin-like receptors (KIRs) recognise the classical MHC class I 
complexes; leading to either activation or inhibitory signals depending on the 
intracellular  domain.  The  intracellular  domains  with  a  short  tail  contain  the 
activation  motifs  (ITAMs)  and  those  with  long  intracellular  tails  contain 
inhibitory  motifs  (ITIMs).  The  activation  of  NK  cells  is  dependent  upon  the 
combinatorial  signal  received  by  their  surface  receptors,  when  there  is  an 
imbalance between the activation and inhibitory signals, these cells may become 
activated (17). NK cells can also respond to MHC class I independent signals 
provided by the environment, for example cytokines such as IL-7 and IL-15, 
mediating NK responses (18).  
 
In humans, there are two major NK cells subsets; defined with the phenotypic 
markers  CD56  and  CD16.  These  different  NK  cell  subsets  have  different 




- status (19). The 




+. This population of NK cells is known to express perforin and 
exhibit  potent  cytotoxicity.  The  CD56
brightCD16
-  population  is  known  to  lack 
perforin but possess marked cytokine production (20).
  
 
More recently, NK cells have been purported to acquire a ‘memory’ function as 
an  innate  effector  cell.  A  recent  study  showed  that  adaptive  transfer  of 
phenotypically  similar  pre-activated  or  control  NK  cells  (including  CD69, 
CD11b  and  B220  expression)  into  RAG  knockout  mice  led  to  significant 
differences  in  IFN-   production.  It  was  noted  that  upon  re-stimulation,  pre-
activated NK cells showed a two times higher IFN-  production compared to 
their counterpart control. The study demonstrated that the NK “memory” lasted a 
minimum of three weeks (21, 22). This “memory” was considered to be long 
standing since the half-life of the NK cells is less than three weeks (23).  
The cytokine portfolio of NK cells has also been expanded recently with the 
identification that they are also programmed to produce Th17 type cytokines, i.e. 
IL-22. The IL-22 cytokine production in human NK cells is activated by IL-23. 
This type of NK cell has now been named NK-22, mainly CD3
-CD56
bright and 
residing  around  mucosal  sites  (24).  This  subset  expresses  several  Th17 
expression factors including ROR  and ROR  (25, 26) and is derived from cells 









    
 
1.2 Adaptive Immune system   
 
Unlike innate immune responses, the adaptive immune system is more specific 
and finely-tuned. B cells and T cells are the key players in the adaptive immune 
system and memory cells will typically develop after the first exposure to the 
foreign antigen (1).  
 
The adaptive immune system is thought to have first arisen in jawed vertebrates. 
Compared to its evolutionary older innate counterpart it is more specialized in 
function  and  responsiveness.  It  generally  builds  upon  the  conserved  innate 
immune  system  of  vertebrates  and  non-vertebrates  to  provide  a  more  robust, 
finely tuned immune response that possesses transferable memory for offspring 
protection and neutralising herd immunity (1). The distinguishing features of the 
adaptive immune system are: 
1)  Cooperation  with  the  innate  system,  to  generate  functionally  specialised 
immune responses that are best suited to nature of the invading pathogen, often 
leading to sterilising immunity (1).   
2) Development of immunological memory that provides a quicker and enhanced 
response to future infections as well as offering protection to offspring (1). 
 
1.2.1 T cell development and activation 
T cells originate from bone marrow and move to thymus for development and 
maturation (27). IL-7 is the primary cytokine that commits T cells precursors to 
further  differentiation,  facilitating  the  early  expansion  of  thymocytes  by 
signalling  through  the  common     chain  (27).  In  humans,  mutations  in  this 
common   chain lead to X-linked severe combined immunodeficiency with an 
absence of T and NK cells (28). The expression of Notch-1 is an additional key 
step in committing lymphoid precursors to T cell lineage development. It has    
 
been proposed that Notch is essential for the early development of T cells, whilst 
in the later stages it plays a role in CD4/CD8 lineage choice. The current model 
of  early  T  cell  development,  suggests  that  the  Notch  complex  binds  to  a 
transcriptional regulator CSL. Upon binding, Notch may then bind to Deltex and 
the IKK complex (29, 30). Following the expression of these early signalling 
molecules, the pre-T cells subsequently undergo TCR gene rearrangement (31). 
 
The TCR locus contains variable region (V), diversity region (D) and joining 
region (J) genes. All the TCR loci contain the V and J region, but the D region is 
only present in the   and   TCR loci. The V, D and J regions are randomly 
arranged together by the recombines-activating genes 1 and 2 (RAG1/RAG2), 
which initiate the rearrangement process. The VDJ random rearrangement allows 
various  combinations  to  occur  contributing  to  the  great  variability  of  TCR 
antigen specificity. Successful rearrangement of two TCR genes with either an 
    or      TCR  configuration  marks  the  end  of  the  pre-T  cell  stage  and  the 
beginning of double positive T cell stage. These T cells now express both CD4 
and CD8 co-receptors together with a fully functional CD3 receptor with  ,  ,  , 
and   chain components (32, 33). 
 
The double positive T cells then further differentiate to single positive T cells 
through positive and negative selection, guided by MHC I and II affinities. The T 
cells are positively selected when the TCR binds to the MHC complex with low 
avidity.  A  high  avidity  of  TCR  and  MHC  binding,  indicating  potential 
autoreactivity, will lead to negative selection i.e. deletion of the T cell clone. If 
the  double  positive  T  cells  have  successfully p assed  through  both  positive 
selection and negative selection, those restricted to MHC class I will become 
CD8 T cells. Those restricted to MHC class II will become CD4 positive T cells 
(33). Such mature T cells then leave the thymus to circulate as naïve T cells. 
T  cells  become  fully  activated  upon  interaction  of  their  TCR  with  the 
MHC/antigenic  peptide  complex  in  association  with  CD4/CD8  co-receptor    
 
ligation. CD8 positive T cells will engage with MHC class I complexes (HLA-A, 
B and C) bearing short peptides (9-11 amino acids), whereas CD4 positive T 
cells will recognize MHC class II (HLA-DR, DQ and DP) complexes with longer 
peptides.  The  aggregation  of  the  TCR  and  co-receptor  complex  at  the 
immunological synapse leads to the recruitment of early signalling molecules for 
T  cell  activation.  Lck  is  recruited  early  by  the  co-receptor  complex  and 
subsequently  activates  a  further  tyrosine  kinase,  ZAP-70,  which  binds  to  the 
tyrosine-based activation motifs of the CD3 chains. This leads to the downstream 
phosphorylation  of  several  other  signalling  molecules  including  Lymphocyte 
cytosolic protein 2 (SLP-76), Phospholipase C   1 (PLC 1), Phosphatidylinositol 
4, 5-bisphosphate (PIP2) and Inositol trisphosphate (IP3). These ultimately lead 
to  Protein  kinase  C  (PKC)  activation  (34,  35).  The  PKC  further  activates 
transcription factors AP2 and Nfka, leading to the production of cytokines (35). 
It  has  been  long  recognized  that  calcium  signalling  is  important  for  T  cell 
maturation. Studies have shown that failure to convert from double positive T 
cells  to  single  positive  T  cells  was  observed  in  the  presence  of  calcineurin 
inhibitors. Studies have also found that defects in the catalytic subunit, regulatory 
subunit as well as early signalling molecules such as NFATc3 and Bcl-2 may 
restrict double positive T cell development (36-39). The calcium signalling is 
orchestrated  by  the  binding  of  PI3  to  the  calcium  store  membrane,  and  this 
allows the release of calcium from endoplasmic reticulum to cytoplasm by a 
process called store depletion. This allows the opening of the cell membrane 
calcium channel. The activated store operated calcium channel is the main source 
of  calcium  influx  in  lymphocyte  development.  The  opening  of  the  calcium 
channel allows further signalling transduction pathways to occur (40). 
The production of cytokines and calcium dependent processes allows naïve cells 
to  initially  proliferate  and  then  differentiate  to  activate  phenotypes.  These 
phenotypes are shaped by the innate system to allow a T cell response to be 
appropriate for the activating pathogen.    
 
1.2.2 Population of T cells   
 
The  classical  description  of  T  cells  in  humans  comprises  CD4
+,  CD8
+  and 
double-negative cells within both TCR    and    compartments. 
CD4
+ T cells are the most abundant T cells present in human, performing many 
helper functions to both CD8
+ T cells and B cells, hence the name Thelper (Th). 
Depending on the activating conditions and environment, Th cells can produce a 
wide  range  of  cytokines.  Initially,  two  different  types  of  helper  cells  were 
identified 20 years ago, namely Th1 and Th2 (41). These were characterized by 
their mutually exclusive cytokine production with IFN-  in Th1 and IL-4 in Th2 
cells.  We  now  recognize  at  least  five  different  types  of  Th  cells  broadly 
characterized by their predominant cytokine profiles and functional associations 
(42-45). The different subsets of Th cells are summarized in Fig 1.1.  
 
 
Figure 1.1 Major CD4 T cell subsets. T cell subsets are indicated as purple, 
the  key  transcription  factors  for  driving  the  T  cell  differentiation  are 
indicated as blue, the differentiating cytokines are indicated as pink and the 
effector cytokines produced by the T cell subset are indicated as black.    
 
 
Th1, Th2 and Th17 cells secrete different cytokines and mediate different types 
of responses. Th1 type cells mainly produce pro-inflammatory cytokines such as 
IFN- , TNF-  and lymphotoxin. These cytokines are important for mediating 
inflammatory responses and promoting the activation of CD8 cytotoxic T cells. 
In contrast, Th2 type cells produce IL-4, IL-5, IL-10 and IL-13. These cytokines 
are  regulatory  cytokines  and  contribute  significantly  to  development  of  the 
humoral  immune  response.  Th17  can  secrete  IL-17,  IL-21,  IL-22  and  IFN- . 
These  cytokines  are  important  inflammatory  cytokines,  and  appear  to  have  a 
major role in many autoimmune diseases (46).  
Another subset of CD4
+ T cells is the CD4
+CD25
+ regulatory T cell (Treg). Treg 
cells  are  an  auto-reactive  T  cell  subset  that  can  regulate  and  suppress  host 
immune  responses.  This  subset  of  CD4
+  T  cells  expresses  the  critical 
transcription factor Foxp3. Treg cells regulate the immune responses by a variety 
of mechanisms including the release of suppressive cytokines such as IL-10 and 
TGF-  (47). These cytokines are additional to other mechanisms of suppression 
including  cell  contact  mediated  inhibition  (i.e.  CTLA-4)  that  can  suppress 
effector CD4 and CD8 populations (48).  
 
IL-9 producing Th9 cells are a newly discovered cell type (44), described two 
years ago by two independent groups (45, 49). The production of IL-9 by CD4+ 
T  cells  was  described  more  than  10  years  ago  (50).  Until  recently,  the  IL-9 
producing cells have not been recognized as an unique subset due to the fact that 
they  do  not  share  a  unique  cytokine  signature  compared  to  other  T  cell 
counterparts, as summarized in Figure 1.1. The exact function of Th9 T cells is 
currently unknown. Early studies have suggested they might be involved in the 
defence against helminth infection (51). Recent studies have shown that Th1 type 
cytokines  are  inhibitory  towards  the  development  of  Th9  cells;  whilst  the 
presence of IL-21 promotes the differentiation of this Th subtype (52).   
    
 
CD8
+ T cells are the 2
nd major subset of T cells, often termed cytotoxic T cells 
(CTL) secondary to their primary role as an effector cytotoxic T cell to MHC 
class  I  restricted  targets.  The  CTL  kills  target  cells  through  cell-cell  contact 
following  the  recognition  of  foreign  peptides  presented  by  MHC  class  I 
molecules, and the release of perforin and granzymes that activate an apoptosis 
programme in the target cell. CTL may also release cytokines such as IFN- , and 
this can lead to inhibition of viral production and increase the activation of other 
cell types involved in host defence (33). 
 
Double negative T cells are not as abundant as CD4
+ and CD8
+ T cells, however, 
they too posses very important functions. The major cell types include    T cells 
as well as certain subtypes of    T cells, including iNKT cells and mucosal-
associated invariant T (MAIT) cells.    T cells are represented at approximately 
1/10
th the number of    T cells. These cells may be selected upon peptide loaded 
MHC class I or II molecules or upon Group 1 CD1 molecules (53). MAIT cells 
are distinguished by having an invariant V  chain and a restricted V  chain. 
These T cells are selected upon a distinctive MHC class I like molecule termed 
MR1 and require the presence of peripheral B cells for full maturation/survival.  
Invariant NKT cells are discussed in detail in a following section.  
 
1.2.3 B cell development and activation 
Unlike T cells, which originate in the bone marrow and develop in the thymus, B 
cells develop in the same place as they originate i.e. bone marrow. Several non-
redundant transcription factors are necessary to ensure that the development of B 
cells is under tight control. These include zinc finger family molecules IKAROS, 
early  B  cell  factor  1  and  interferon  regulatory  factor  8  (54,  55).  The  gene 
rearrangement of B cells is very similar to the TCR rearrangement. The heavy 
chain consists of four segments including VH, D, JH and CH; the light chain 
consists of variable, joining and constant domains of either kappa or lambda loci. 
Successful rearrangement of heavy and light variable gene segments leads to the    
 
formation of a surface immunoglobulin. Immature B cells that reside in the BM 
and can be further divided into Pro, Pre and Transitional subsets. IgM is the first 
antigen detectable in the early B cell subset. It can be detected in the cytoplasm 
as  early  as  the  pre-B  cell  stage.  Surface  expression  of  such  subtype  can  be 
identified in the late immature B cell stage.  IgD is expressed at the mature B cell 
stage marking the mature, naïve step in development (56).  B cells move out the 




.  The  development  of  immature  B  cells  to  mature  B  cells  is  a  antigen-
independent process (57).  
 
1.2.4 Populations of B cells 
In mice, CD5 has been a very useful tool to identify sub populations of mature B 
cells. It was found that the population of CD5
+ B cells, namely B1 B cells; tend 
not  to  undergo  somatic  hypermutation  and  to  largely  respond  to  T  cell 
independent antigens (58). The CD5
- B cell subset is considered to represent 
conventional B cells (B2). Although CD5 is expressed on some B cells in man, 
this approach has not been found to be as useful as in mice (58).   
 
In humans, there are several subsets of B cells that have been identified based on 
the cell surface expression of certain phenotypic markers. The subsets of B cells 
broadly  include,  IgM
+IgD
-CD27
-  -  immature,  IgM
+IgD
+CD27




+  marginal  zone  memory,  IgM
-IgD
-CD27
+  switched  memory 
(germinal  center),  CD38
highIgM





Naïve  B  cells  are  present  in  the  secondary  lymphoid  organs  and  circulate  in 
peripheral blood. Marginal zone memory B cells are thought to be important in 
responding to polysaccharide antigens and may form short-lived plasmablasts 
that produce IgM. B cells that have been activated within the germinal centre 
undergo somatic hypermutation and class switching to become memory cells, 
plasmablasts and eventually plasma cells. Plasma cells lose expression of surface    
 
immunoglobulin and home to the bone marrow where they remain as long-lived 
memory B cells producing high affinity antibody (33). There are nine different 
types of immunoglobulins based on the isotypes of heavy chain; they are IgM, 
IgD, IgG1-4, IgA1-2 and IgE) (33).    
 
1.3 Bridging innate and adaptive immunity 
 
For  effective  immune  function,  ‘cross  talk’  between  innate  and  adaptive 
immunity is extremely important. It is essential that the adaptive immune system 
is suitably informed by the innate immune system regarding the most appropriate 
effector  response  (i.e.  Th1>Th1  or  IgA>IgE).  Whilst  many  innate  cells  may 
interact  with  pathogens,  dendritic  cells  are  uniquely  placed  in  being  able  to 
capture antigens, contribute to the inflammatory milieu and present the foreign 
material to the naïve T cells within secondary lymphoid organs. Furthermore, 
they can provide the requisite co-stimulatory signals to naïve T cells to instruct 
them for further division and differentiation.  For these reasons they have been 
considered  as  the  most  important  professional  antigen  presenting  cell  linking 
innate and adaptive immunity.  
 
1.3.1 The master of directing – dendritic cells 
 
The term “Dendritic Cell” was first introduced in 1973 by Ralph M. Steinman 
and Z.A. Cohn (59, 60). Soon after the initial description of dendritic cells, they 
were then identified in lymphoid and some non-lymphoid tissues i.e. skin (61). 
Dendritic  cells  (DCs)  have  since  become  further  subtyped  either  according 
maturational status i.e. immature or mature or origin i.e. myeloid or plasmacytoid 
(62, 63).  Dendritic cells are also distinguished from other cells by their high 
expression of adhesion molecules, which include CD11c, ICAM-1, 2 and 3 and 
CD11a,  and  co-stimulatory  molecules  i.e.  CD80/CD86  (64,  65).    In  mice, 







+ DCs. These phenotypic divisions align 
with  functional  differences  such  that  CD8
+  dendritic  cells  are  thought  to  be 
responsible  for  cross  presentation  of  cellular  antigens,  for  cross-priming  and 
cross-tolerance. In contrast, CD4
+ dendritic cells do not cross present as well as 
CD8
+ dendritic cells, but they are the most abundant cell type in the spleen (66).    
 
Dendritic  cells  may  act  as  an  initial  bridge  between  innate  and  adaptive 
immunity due to their residence in most organs and their pathogen recognition 
receptor  portfolio  allowing  them  to  respond  to  most  “danger  signals”  (67). 
Dendritic cells are able to secrete a variety of cytokines that influence naïve T 
cell development including IL-2, IFN- , IL-12 and IL-4 (68). The different types 
of  dendritic  cells  have  also  been  found  to  have  different  functions  in 
Th1/Th2/Th17  priming.  CD8
+CD4  DC  have  been  noted  to  promote  Th1 
responses whilst CD8
-CD4
- DC promote Th2 responses (Figure 1.2). 
 Figure  1.2.  Subsets  of  dendritic  cells  and  cytokine  production.  Adapted 
from (68).  
 
In addition to MHC class I and class II presentation, DC’s may present antigens 
upon CD1d. The glycolipid antigen cargo of CD1d is presented to a subtype of T 
cells termed NKT cells. Recent studies have suggested that cooperative activity 
between  NKT  cells  and  dendritic  cells  is  central  to  an  effective  immune 
responses (69).     
 
1.3.2 Natural Killer T cells 
 
Natural Killer T cells (NKT) are a subpopulation of T cells. The name “Natural 
Killer T cells” was first used in 1995 (70) and was initially derived from murine 
studies through the analysis of T cells bearing the NK cell marker NK 1.1. The 
terminology has been further complicated by the description of other T cells 
subsets as NKT cells when cell surface antigens such as CD56 and CD57 are 
seen on such cells.  These T cells with NK markers (‘TNK’) are fundamentally 
different as they are restricted by conventional MHC class I and II molecules and 
have  a  variable  TCR      usage  (71,  72).  NKT  cells  recognize  glycolipids 
presented by a MHC class I like molecule, CD1d. Recently a new classification 
has been proposed and this considers at least three different subsets of NKT 
cells. These three subsets of cells are Type I classical NKT cells (also sometimes 
referred to as invariant NKT cells), Type II Non-Classical NKT cells and NKT 
like CD1d-independent T cells (72) (Table 1.1). 
  Type I NKT cells  Type  II  NKT 
cells 
NKT like cells 
Restriction  CD1d  CD1d  MHC / others 
T  cell  receptor 
expression 
V 14-J 18 (mice) 
V 24-J 18(human) 
Diverse  Diverse 
CD161 expression  Yes (resting mature) 
No  (immature  or  post-
activation) 
Yes/no  Yes 
 –GalCer reactivity  Yes  No  No 
Subsets  CD4
+, DN and CD8
+  CD4
+, DN  CD4
+, DN and 
CD8
+ 
Major  Cytokine 
produced 
IL-4, IFN-    IL-4, IFN-   IFN-  
Table 1.1 NKT subset classfication 
    
 
1.4 The glycolipid responsive immune system. 
 
1.4.1 The extended CD1 family 
The CD1 family represent a group of antigen presentation molecules that unlike 
the peptide accommodating MHC class I and II complexes, accept lipid antigens. 
This  family  of  molecules  were  first  detected  by  monoclonal  antibodies  that 
recognized these structures on human thymocytes (73). Historically these were 
the first immune molecules to be named within the cluster differentiation system 
(74). Two groups of CD1 molecules are identified in humans. Group 1 CD1 
molecules  include  CD1a,  CD1b,  CD1c  and  CD1e;  the  only  group  2  CD1 
molecule is CD1d. In contrast to the human system, the genes encoded for group 
1 CD1 molecules are deleted in the mouse, hence, only CD1d is present in the 
mouse CD1 family (74). CD1 family members are type I integral membrane 
proteins with  1,  2, and  3 domains (75, 76). In contrast to MHC complexes 
the CD1 family members are non polymorphic (77). More than 200 donors were 
sequenced from a wide range of ethnic groups showing that CD1b and CD1c 
possessed silent mutations across all the individuals, and only two CD1a, CD1c 
and CD1d alleles were seen secondary to amino acid changes (78, 79). Further 
studies have suggested that these few allelic forms do not contribute to a greater 
susceptibility to infection (80).  
 
1.4.2 Group 1 CD1 
The group 1 CD1 molecules are found on professional antigen presenting cells 
including dendritic cells and B cells. In contrast to MHC class I and II complexes 
they are not expressed on circulating monocytes, unless activated to become a 
DC. This makes them an excellent marker for the differentiation of DC (74, 81). 
CD1a and CD1b have been used widely to identify monocyte derived dendritic 
cells (82, 83), CD34
+ precursor dendritic cells (84, 85), and also Langerhans cells 
(86).  The  expression  of  group  1  CD1  molecules  on  dendritic  cells,  further 
supports the key role of DCs as the professional antigen presenting cell bridging    
 
innate and adaptive immunity. Interestingly, besides the phenotypic differences, 
CD1a has been found to be an important functional marker. Several studies have 
identified  that  in  DC  populations,  when  CD1a  is  deficient,  there  will  be  a 
reduction  in  IL-12  production,  and  an  upregulation  of  IL-10  production 
compared to their CD1a
+ counterpart (87-89). Studies have also found that in 
plasmacytoid  DC,  unlike  myeloid  DC  and  monocyte  derived  DC  described 
above, there is no expression of CD1a, CD1b or CD1c (90). CD1c has also been 
found to be expressed on certain subsets of B cells, both circulating (91) and in 
the marginal zones of the spleen (92). 
 
   T cells represent the majority of T cells that recognize the group 1 family (83, 
93),  with  some  CD1  reactive      T  cells  also  recognized  (94-96).  Sequence 
analysis  from  these      CD1  reactive  T  cells  has  identified  a  high  level  of 
diversity in the V-J junction and template independent N nucleotides. Currently, 
no crystal structure of a group 1 CD1 antigen complex has been resolved, thus 
the  interaction  between  CD1  and  the  TCR  are  currently  predicted  through 
mutagenesis studies on the TCR  CDR3 and CDR1 loops (97, 98). These studies 
suggest that the CD1 reactive T cell receptors dock diagonally, similar to that for 
MHC class I and Class II complexes. For the subset of    CD1 reactive T cells, 
most were found to be CD1c reactive, with a V 1 predominant usage (99).  
 
1.4.2.1 Lipid recognition by group 1 CD1 molecules 
The first member of the group to be shown to recognize lipid antigen was CD1b, 
presenting  a  lipid  antigen,  myolic  acid,  from  the  cell  wall  of  M.tuberculosis 
(100). A selection of subsequently described group 1 CD1 antigens is shown 
below.     
 
 
Figure 1.3. Lipids recognized by CD1 molecules. Adapted from (81). Lipids 
recognize by CD1a, CD1b, CD1c and CD1d. 
 
As shown above, the main group of lipids recognized by group 1 CD1 molecules 
include mycolic acids, mycobactin, and acylated sulfoglycolipids (81). Many of 
these lipids are only present at low levels in humans but are critical in pathogens. 
For  example,  mycobactin  is  essential  for  bacterial  survival  due  to  its  iron-
scavenging  properties  (81)  with  its  precursor  (DDM)  being  presented  and 
recognized by CD1a (101). This promotes CD1a restricted cytotoxic responses 
resulting  in  the  killing  of  the  infected  cells  (102,  103).  Lipoarabinomannan 
(LAM)  is  another  lipid,  which  plays  a  role  in  microbial  pathogenesis; 
maintaining the structure of the microbial membrane and promoting cell binding 
to enable cell infection. This lipid is presented by CD1a and leads to antigen 
specific cytotoxicity.    
 
Additional components of the mycobacterial wall can also be recognized by the 
other CD1 members, such as CD1b restricted Ac2SGL (104) and CD1c restricted 
Hexoysl-1-phosphoisoprenoid lipids (105).  
 
1.4.3 Group 2 CD1 family 
CD1d is the only member of the group 2 CD1 family and it is the only CD1 
family member present in mice. Compared to CD1a, b and c, the expression of 
CD1d  is  considerably  boarder.  It  is  expressed  on  most  professional  antigen 
presenting cells including monocytes, macrophages, dendritic cells and B cells; 
in addition, it is also present on certain non-lymphoid cells such as epithelial 
cells, parenchymal cells as well as smooth muscle cells in the gut and liver (106, 
107). It was also found to be highly expressed on double positive thymocytes in 
the thymus, playing a crucial role in CD1d restricted T cell selection. 
 
Unlike  MHC  restricted  T  cells,  invariant  NKT  cells  do  not  engage  with 
conventional MHC antigen presenting pathways, but recognise the ‘MHC class I 
like molecule’ CD1d. As a ‘class I like molecule’, CD1d has a similarity to MHC 
class I molecules in terms of protein sequence homology, domain organisation 
and  association  with   2m  (108).  However,  distinctive  differences  are  also 
observed which makes CD1d only distantly related to MHC Class I molecules. 
Based  on  the  crystal  structure  of  CD1d,  several  differences  to  MHC  class  I 
molecules  were  found.  Firstly,  the  binding  groove  of  CD1d  is  significantly 
narrower compared to MHC Class I molecules. Secondly, the docking mode of 
the TCR to CD1d-glycolipid complex is parallel to CD1d; whilst the TCR is 
diagonally docked to MHC-Class I molecules (Figure 1.4) (109, 110). 







Figure  1.4.  Crystal  structures  of  CD1d  and  MHC  class  I  molecules  with 
TCR docking alignment. Adapted from (109, 110) 
(a) TCR docking of CD1d and MHC class I (b) Ribbon diagram of CD1d 
 
CD1d  complexes  present  glycolipid  antigens  such  as  the  marine  sponge 
derivative  -galactosylceramide ( -GalCer), which has become the archetypal 






b    
 
CD1d ligand for iNKT activation. This was initially identified through an anti-
tumour compound screening programme. This revealed the potential of CD1d in 
anti-tumour  responses  (111).  The  glycolipid  contains  a  ceramide  with  an  18 
carbon phytosphingosine chain and a 26 carbon acyl chain. An  -linkage links 
the two chains to the galactose head. The glycosidic bond found in the marine 
sponge   -galactosylceramide  is  not  naturally  present  in  mammalian 
sphingolipids  (112).  Other  than   -galactosylceramide,  bacterial 
glycosphingolipids can also be presented by CD1d including  -glucuronosyl-
ceramide  and   -galacturonosyl-ceramide  (113-115).  Most  of  these 
glycosphingolipids  specifically  stimulate  NKT  cells. T wo  other 
glycosphingolipids,  namely  ganglioside  (GD3)  and  sulphatide,  can  also  be 
recognized by CD1d and stimulate type II CD1d restricted T cells (116). 
 
CD1d may also present immunogenic lipids of plant origin. Examples of these 
lipids including phosphatidylcholine and phosphatidylethanolamine, which are 
also commonly recognized by the group1 CD1 family (112). Many attempts have 
been undertaken to find the self lipid for CD1d. Several lipids were claimed to be 
the self lipids for CD1d, including lysophospholipids and sphingomyelin (117). 
A study by Bendelac’s group identified a self lipid that was reactive to iNKT 
cells in mice, namely iGb3 (118). Interestingly, subsequent studies have failed to 
identify  this  ligand,  even  by  mass  spectrometry  in  lymphoid  tissue  (119).Of 
additional  note  was  the  recent  observation  of  normal  iNKT  cells  in  iGb3 
synthase deficient mice and the finding that the gene encoding for iGb3 synthase 
in humans, was not functional (120). Currently, there is no definitive evidence 
for the identity of the endogenous self lipid proven to be involved in the thymic 
selection of CD1d restricted T cells. 
  
 
    
 
1.4.4 Processing the fat 
Lipids are highly insoluble in water, necessitating the use of carrier proteins that 
allow  them  to  traffic  in  the  extracellular  and  intracellular  compartments. 
Lipoproteins  are  the  main  elements  involved  in  the  presentation  of  the  lipid 
antigens, with ApoE being identified as important for facilitating the uptake and 
presentation of lipid antigens for antigen presenting cells (121). 
 
CD1d  molecules  emerge  from  the  endoplasmic  reticulum  as a   heterodimer 
destined for the cell surface, where they will be internalized through the adaptor 
proteins AP-2/AP-3 in the clathrin-dependent pathway. The newly synthesised 
CD1d molecule is likely associated with a self-lipid during this early trafficking, 
permitting  access  to  the  late  lysosome/endosomal  compartments.  In  this 
compartment,  a  dedicated  chaperone  protein,  saposin  is  present  which  can 
facilitate  lipid  exchange.  Repeated  travel  between  the  plasma  membrane  and 
lysosomal/endosomal  compartments  allows  continuous  lipid  exchange  (122). 
Additional lipid exchange proteins have been identified more recently, including 
the microsomal triglyceride transfer protein (MTP). Deletion of MTP has led to a 
down-regulation of CD1d on the cell surface, secondary to its important role in 
loading lipids onto CD1d in the ER (123). 
 
In the case of exogenous lipids, it was suggested that they enter cells together 
with  the  very  low  density  lipid  when  bound  to  lipoproteins  (122).  Foreign 
microbial lipids may also fuse with the membrane of APC, prior to transportation 
to  other  compartments.  The  trafficking  ability  is  highly  dependent  upon  the 
polarity, size and physical properties of the lipids (112). Studies have also shown 
that bacterial lipid antigens can form antigenic complexes with CD1d following 
traffic through the lysosomes (124) (112).  
    
 
1.4.5 Factors influencing lipid antigen presentation 
Infection is one factor that can influence lipid antigen presentation. One example 
is infection by Herpes simplex virus-1 (HSV-1), which actively subverts CD1d 
presentation  through  an  interference  with  the  recycling  of  CD1d  through  the 
endosome (125). In contrast some infections i.e. salmonella typhimurium (112) 
can  upregulate  CD1d  expression  on  myeloid  dendritic  cells  through  the 
activation  of  TLR  or  production  of  cytokines  i.e.  interferon- .  A  similar 
upregulation is also seen when myeloid dendritic cells are recruited to the site of 
inflammation (126). Alternatively bacterial infections may cause changes in self-
lipid metabolism by means of increasing the synthesis of self-glycosphingolipids. 
This allows CD1 restricted T cells to recognize the infected APC and generate an 
effective immune response against the intracellular pathogen (127). 
 
One of the major differences in terms of the classical presentation pathway of 
MHC  class  II  molecules  compared  to  CD1  molecules  is  the  timing  of 
presentation.  MHC  class  II  molecules  will  rapidly  traffic  to  the  plasma 
membrane from the phagolysosomes for loading only upon infection by foreign 
pathogens. On the contrary, CD1 molecules are continually recycling between 
the  different  compartments,  which  allows  for  a  foolproof  mechanism  to  be 







    
 
1.5 Invariant NKT cells 
 
Type 1 invariant NKT cells are the most well characterised CD1d restricted T 
cell. They develop in the thymus, and are present at a very low number in most 
tissues. In human peripheral blood, approximately 0.01-1% of the T lymphocytes 
are iNKT, characterised by their hallmark TCR- invariant chain V 24 – J 18 and 
variant  V 11  (128).  Besides  the  expression  of  the  TCR  invariant  chains, 
expression of CD161 is also found on most of the resting and mature invariant 
NKT cells, but it is not seen on immature or post-activated cells (72). 
 
A few different approaches were initially used to identify invariant NKT cells 
following their original description. The first approach was to sequence a set of 
mouse hybridomas, which were suggested to be suppressor T cells (129-131). 
The  sequencing  results  identified  a  conserved  V 14-J 18  TCR  (129-131). 
Subsequent studies identified a subset of double negative V 8 T cells with the 
same V 14-J 18 sequence (132, 133). Lastly, the conserved V 24-J 18 double 
negative  T  cells  were  identified  in  human  in  1994  (134).  Following  the 
identification  of  the  CD1d-iNKT  ligand   -GC,  these  cells  have  attracted 
increased attention.  
 
iNKT cells were subsequently found to be highly conserved in terms of TCR 
rearrangement in both human and mice. In mice, the majority of such cells are 
V 14-J 18 paired with V 8, 7 or 2. A more conserved rearrangement was found 
in humans, which were V 24-J 18 with V 11. Both human and mouse iNKT 
cells react with  -GC (135).  
 
Unlike other T cells, iNKT cells were considered to be “memory/activated/non 
naive” when they emerge from the thymus. In mice, these reside in different    
 
lymphoid tissues including the spleen, lymph nodes and liver. The distribution of 
iNKT cells in human is unclear, but they are found to be 10 times less common 
compared to murine studies (122). 
 
1.5.1 Invariant NKT cell development 
 
                                                  
The generation of the correct CD1d restricted, semi-invariant TCR (V 24V 11 
in human; J 18 in mouse) is the crucial factor for the development of iNKT 
cells. It was shown in early studies that complete absence of iNKT cells was 
found in mice deficient in either RAG or the J 18 gene segment (136). A similar 
finding was also shown in patients with Omenn’s syndrome, which is caused by 
hypomorphic mutations of the RAG2 gene (137, 138). Similar to other TCRs, the 
semi-invariant TCR is generated by the random recombination of the VDJ region 
(135).  Even  though  the  process  of  VDJ  rearrangement  is  a  random  selection 
process, the likelihood of selection of individual TCR genes is highly dependent 
on the prolonged lifespan of double positive thymocytes (139). Due to this, genes 
responsible for double positive thymocyte survival (i.e. RoR t and Bcl-xL) are 
crucial for the development of iNKT cells. Targeted deletion of these genes again 
results in diminished iNKT cell numbers (140), whilst overexpression of these 
genes significantly increases the number of iNKT cells (141).  
 
Following the assembly of the invariant TCR within a double positive thymocyte 
population, the pre iNKT cell requires a subsequent interaction with CD1d for 
full development (135). A complete absence of invariant NKT cells is observed 
in  CD1d  knockout  mice  (72).  Unlike  MHC  restricted  T  cells  where  thymic 
epithelial  cells  are  important  for  selection,  iNKT  are  selected  upon  CD1d 
expressed  by  other  thymocytes  (142).  Self-antigen  is  also  required  for  their 
development; and early studies have identified the glycosphingolipid iGb3 as    
 
important in mice (118). However, the equivalent of iGb3 in humans is yet to be 
identified. 
 
                                                  
Negative selection is a physiological process in the development of T cells that 
eliminates self-reactive lymphocytes with excessive self ligand reactivity. From 
the viewpoint of invariant NKT cell development, they emerge from the thymus 
as post naïve cells (memory or activated), with self ligand reactivity. However, 
these self-reactive cells are found to be in the resting state in vivo (72, 122). This 
may suggest that due to the random TCR rearrangement and the diversity of their 
TCR in the   chain, these cells have undergone a negative selection process 
sufficient enough for a partial activation phenotype. Several studies have shown 
that invariant NKT cells do undergo such a negative selection process (135, 143, 
144) and that in the presence of high affinity lipid, such as  -GC (144) or over-
expression of CD1d in dendritic cells (143), a reduction in the number of iNKT 
cells is found. Interestingly, when  -GC in used in the above context it was 
found that the emergent iNKT cells had a bias to V 2 usage, which has the 
lowest  affinity  for  CD1d- -GC  (144).  Other  studies  have  shown  that  mice 
engineered  to  only  express  CD1d  on  thymocytes  appear  to  bypass  negative 
selection, but are hyper-responsive to  -GC in the periphery (142). This suggests 
that  negative  selection  of  iNKT  cells  is  not  principally  undertaken  on 
thymocytes, but most occur on other CD1d expressing thymic cells. 
 
                      
SLAM and SAP 
In conventional T cells, thymic epithelial cells are responsible for providing the 
signals for their early development. In contrast to this, thymocytes are believed 
to be the important cells in the selection and development of iNKT cells, with 
signalling via lymphocytic activation molecule (SLAM) family member proteins 
being crucial. The SLAM family member proteins have also shown importance    
 
in Th2 cell priming, the generation of memory B cells, as well as NK activation, 
MHC-independent NK cell inhibition and iNKT cell development (145).  
 
The SLAM family members include SLAM1, 2B4, CD84, NTBA, Ly9, CD319, 
SLAM8  and  SLAM9  (135,  145).  Most  of  these  receptors  have  two 
immunoglobulin-like extracellular domains; with the exception of Ly9 which has 
four such domains (145). Within the family, 2B4 is the only member that does 
not undergo self-association through its extracellular domain but recognizes a 
glycosyl  phophatidyl  inositol  anchored  cell  surface  protein  CD48,  which  is 
widely expressed on immune cells (146).  SLAM1 and NTBA are expressed by 
thymocytes suggesting a role in regulating iNKT cell development (147).  
 
The  crucial  step  played  by  SLAM  proteins  in  T  cell  development  is  their 
interaction with the SLAM associated proteins (SAP) family, through tyrosine-
based motifs present in both the cytoplasmic region of SLAM receptor and the 
SH2 domain of SAP receptor (148). iNKT cells are uniquely dependent on this 
compared to other T cell subsets (135). Following a SAP:SLAM engagement 
phosphorylation  events  allow  the  recruitment  of  FYN  and  Lck  to  the  TCR 
complex (149). Both murine and human studies have proven that iNKT cells are 
highly dependent on signals provided by the SLAM proteins. Mice that lack SAP 
have  shown  an  absence  of  iNKT  cells,  whereas  no  effect  was  found  in 
conventional T cells. In agreement with this, a similar absence of iNKT cells has 
been identified in patients with X linked proliferative disease (XLP) secondary to 
an absence of the SAP gene (150-152).   
 
A  summary  of  our  current  understanding  of  early  iNKT  signalling  events  is 
shown  in  Figure1.5.  Following  a  productive,  CD1d/TCR  and  SLAM/SLAM 
interaction  a  series  of  key  transcription  factors  are  triggered.  The  early 
transcription  factors  initiate  three  independent  but  related  pathways.  The    
 
recruitment of PKC initiates the NF- B pathway, further ligation of RasGAP 
leads mitogen-activated protein kinase pathway signalling whilst PLC  supports 








Two  independent  studies  have  recently  shown  that  c-Myc  is  another  early 
signalling regulator (153-155). In the study by Gounari et al., they showed that c-
Myc is not essential for the selection of the thymic iNKT cells but is key for 
promoting  their  proliferation,  as  well  as  long-term  survival  (153).  The 
importance of c-Myc is also apparent for conventional T and B cells, supporting    
 
proliferation  and  maintaining  their  homeostasis.  It  is  also  responsible  for 
continuously renewing hematopoietic stem cells (156). Selectivity for iNKT cells 
in c-Myc knockouts could be achieved when a targeted deletion of c-Myc in 
double positive thymocytes was engineered (153-155). 
 
Promeylocytic Leukemia Zinc Finger (PLZF) 
Recent  studies  have  shown  that  the  transcription  factor  PLZF  might  be  the 
master control of iNKT cell development (157, 158). PLZF is not present in 
conventional  T  cells,  but  is  present  in  all  iNKT  cells,  regardless  of  subset. 
However, the PLZF expression was identified in other unconventional T cells 
such as MAIT cells and    T cells (157, 159). Interestingly, the induction of 
PLZF in iNKT cells is independent of a SLAM-SAP interaction (157, 158). In 
PLZF deficient mice a significant reduction of iNKT was observed, with most of 
the  remaining  iNKT  cells  failing  to  complete  maturation,  displaying  a  naïve 
phenotype, with the expression of CD62L (25, 26). These residual iNKT cells 
also  failed  to  display  the  normal  activated  and  memory  phenotype  upon 
stimulation (135).  
 
                                                          
The prevailing theory in invariant NKT cell development is that they emerge 
from  double  positive  thymocytes.  Two  models  have  been  proposed  for  the 
development  of  iNKT  cells  -  the  committed  precursor  model  and  the  TCR 
instructive model.  
The committed precursor model is based on a single study done by Makino et al 
(70). In this study, they identified that the development of NKT cells occurred 
much earlier than the development of conventional T cells.  NKT cells started to 
express the V  chain at day 9.5 of gestation and this committed such cells to 
NKT development.      
 
The TCR instructive model is more widely accepted compared to the committed 
precursor  model.  In  mice  following  V   TCR  rearrangement  the  V 14- J  18 
chain will pair with V 8.2, V 7 or V 2. In human, only when both the V 24 and 
V 11 are expressed can invariant NKT cells undergo ‘instructive’ differentiation. 
They then undergo positive selection by the CD1d expressed on DP thymocytes 
rather  than  conventional  MHC  selection  upon  cortical  and  medullary 
thymocytes.  This leads to a branch of NKT lineage cell development that may 
be further attenuated through negative selection. NK1.1 expression can either 
appear in the thymus or in periphery (160).  
Figure 1.6. The development program of iNKT cells. Modified from (160).    
 
There  are  three  groups  of  invariant  NKT  cells  in  humans,  which  are 
characterized as CD4
+, CD8
+ and double negative (161).  The different subsets 
give rise to the variety of cytokines that NKT cells have been shown to produce 
(162).  One  important  parameter  that  segregates  with  the  cytokine  production    
 
pattern  is  the  expression  of  CD4  in  invariant  NKT  cells.  Many  studies  have 
shown that CD4
+ invariant NKT cells favour the secretion of Th2 type cytokines; 
whereas CD4
- invariant NKT cells mainly secrete Th1 type cytokines (163, 164). 
This  dichotomy  influences  the  role  played  by  invariant  NKT  cells  in  their 
environment. 
 
1.5.2 Function of invariant NKT cells 
The  ability  to  restrict  and  counter  pathogens  or  tumours  is  one  of  the  main 
features of the immune system. At the same time, efficient immune regulation is 
required to prevent excessive self-reactivity through the secretion of cytokines 
and  unrestricted  activation  of  the  immune  system.  Thus,  the  ability  of 
immunoregulatory cells to appropriately promote activation or suppression is a 
key feature of the integrated immune response.  
 
Invariant NKT cells are able to produce both Th1 (proinflammatory) and Th2 
(regulatory)  type  cytokines.  This  multi-cytokine  secretion  property  has  made 
iNKT  cells  one  of  the  most  important  cells  in  bridging  innate  and  adaptive 
immunity. The diverse cytokines produced by different subsets of invariant NKT 
cells make them prototypic immunoregulatory cells. Due to this ability, invariant 
NKT cells have been shown to play an important role in various diseases (Figure 
1.7). Clinical trials are ongoing with  -GC pulsed dendritic cells and adaptively 
transferred invariant NKT cells in patients with cancer (165-167). Studies have 
also  shown  that  invariant  NKT  cells  are  important  in  certain  autoimmune 
disorders,  especially  Multiple  Sclerosis  (MS),  Systemic  Lupus  Erythematosus 
(SLE), Systemic Sclerosis and Rheumatoid Arthritis (162, 168-170). Other than 
cancer and autoimmunity, NKT cells have also been demonstrated as playing an 
important role in anti-bacterial, viral and parasitic immune responses (114, 171-
174).    
 
 
Figure 1.7. Summary of iNKT cell functions. iNKT cells can either promote 
Th1 or Th2 responses depend on the signal strength receive from CD1d/lipid 
and TCR interaction 
 
More recently studies have found that not only the types of iNKT cells but also 
the binding affinity of CD1d and the glycolipids, contributes significantly to the 
types of cytokine released by iNKT cells (175-178).  -GC has been recognized 
as the “prototypic” ligand for CD1d binding, possibly mimicking the undefined 
natural ligand (109). Crystal structures have shown that the lipid component of 
 -GC fits into the CD1d binding groove by forming   helices (179). The two 
lipid chains of  -GalCer, a 26 carbon acyl chain and an 18 carbon sphingosine 
chain  (Fig  3)  fit  tightly  into  the  respective  A’  and  C’  pocket  of  CD1d. 
Extrapolating from the conformation and stability of  -GC and CD1d, it was 
predicted that the maximum carbon size that can be accommodated in the A’    
 
pocket is 26 carbon atoms with 18 carbon atoms in the C’ pocket. This allows  -
GC to become one of the affinity lipids described (110). 
 
Figure 1.8. Structure of  -GalCer 
CD1d interacts with  -GC at the intersection of the polar head and the two alkyl 
chains by forming three hydrogen bonds (110). The 2’-OH of the galactose ring 
forms a hydrogen bond with Asp151 in CD1d. The second hydrogen bond is 
formed  between  the  3-OH  on  the  sphingosine  chain  with  Asp  80  in  CD1d. 
Several studies have shown that this hydrogen bond is crucial for mouse iNKT 
recognition  of  the  complex  (180,  181).  The  last  hydrogen  bond  is  formed 
between 1’-O of the  -GC and Thr154 (110). The head group of  -GalCer is then 




Figure 1.9. Interaction of  -GC with CD1d. Adapted from (110) 
 
binds, is lined with the residues Trp131 (Trp133) and Val81 (Ile81).
The end of the C¢ channel is formed by Ile123 (Val125) and Phe118
(Phe120). As with the extension to the A¢ channel detailed above, this
end region of the C¢ channel is contributed by the vestiges of what is a
junction region with F¢ and T¢ in human CD1b (Fig. 3d).
Structural comparison of human CD1 molecules
Of the three human CD1 isoforms for which crystal structures have
been determined so far (human CD1a, CD1b and CD1d), human
CD1b has the largest available space to accommodate antigen in the
binding groove, with a volume of 2,200 A ˚ 3, compared with 1,400 A ˚ 3
for human CD1d and 1,300 A ˚ 3 for human CD1a18,20. The large
binding volume in human CD1b is created by an extensive network
containing three distinct channels (A¢,C ¢ and F¢) that open directly
onto the T cell recognition surface and are interconnected by a tunnel
(T¢) that runs along the bottom of the binding groove19 (Fig. 3e). The
human CD1d structure maintains the same ligand-binding network as
human CD1b, but its F¢ channel and T¢ tunnel are partially blocked.
The large side chains of residues Val98, Phe114 and Val116 occlude the
central portion of the T¢ tunnel (the equivalent residues in human
CD1b are Gly98, Leu114 and Gly116), but the segment that forms the
junction with the A¢ channel is preserved (Fig. 2a). This vestigial part
of T¢ can be considered to be subsumed in A¢ in human CD1d;
however, it is important in that it creates enough space to enable the
acyl chain of a-GalCer to ﬁt into the A¢ channel (as discussed above).
Similarly, the other end of the human CD1b tunnel T¢ is preserved in
human CD1d but can be considered as part of the C¢ channel
(discussed above). The F¢ channel is blocked in human CD1d by
the orientation of Phe84 (Fig. 2a), whereas the side chain conforma-
tion of Phe84 in human CD1b leaves this channel open to the TCR
recognition surface and allows binding of a detergent molecule18 or a
longer-chain lipid such as glucose monomycolate19. In human CD1b,
channel C¢ has a second opening to the surface of the a1-a2 domain
(beneath the a2 helix), but this is also closed off in human CD1d by
Trp131 (Cys131 for mouse CD1d)18,19. The net result of these
differences is a substantial reduction in the alkyl chain–binding
capacity of the human CD1d a1-a2 domain compared with that of
human CD1b. Human CD1d is therefore limited to binding lipids
with shorter alkyl chains.
Like human CD1d, human CD1b contains a central pole at the
junction of the A¢ and T¢ channels (formed by Phe70 and Val12). As
with binding of the acyl chain of a-GalCer to human CD1d, in the
human CD1b–glucose monomycolate structure19 the long meromy-
colate chain enters the A¢ channel, circles the pole and enters the T¢
tunnel (Fig. 3d). However, the glucose monomycolate circles the pole
in a clockwise direction (as viewed from above the binding groove), a
direction opposite to that for a-GalCer. The clockwise orientation
adopted in human CD1b seems to be necessary for the creation of a
smooth transition from the A¢ channel to the T¢ tunnel by the
meromycolate chain. As a-GalCer occupies only a residual portion
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Figure 3 Comparison of the structures of CD1 molecules and their lipid
antigens. (a) Structural alignment of human lipid-bound CD1d (gray) and
mouse CD1d (green). The bound a-GalCer is in orange. (b,c) Enlargements
of areas outlined in a in yellow (b) and blue (c). (b) Conservation of residues
in human and mouse CD1d that form hydrogen bonds with a-GalCer.
Hydrogen bond colors are as described for the backbones in a.( c) Residues
of human CD1d and mouse CD1d that result in altered function when
mutated in mouse CD1d and that are probably involved in direct TCR
interactions with the surface of CD1d. (d) Overlay of the structures of
antigens bound to human CD1d (a-GalCer; yellow-orange), human CD1b
(glucose monomycolate; green) and human CD1a (sulfatide; magenta),
presented without the protein backbone. (e) The ligand-binding groove
of human CD1b (gray line in d) The hydrophobic binding surface is drawn
as a gray mesh with carbon atoms from the acyl tails occupying the groove
drawn as Van der Waals spheres. Figure from ref. 19 (Copyright 2004.

























Figure 2 Antigen binding and recognition of a-GalCer in CD1d. (a) Side view
of bound a-GalCer. The hydrophobic antigen-binding groove, with pockets
labeled A¢ and C¢, is gray; a-GalCer is orange; residues of CD1d are blue.
(b) Top view of the TCR recognition surface formed by presentation of a-
GalCer in CD1d. Colors are as in a.( c) Hydrogen bonds between residues of
CD1d and a-GalCer. The galactose 2¢-OH hydrogen atom forms a hydrogen
bond with the Asp151 Cd2 atom, the 1¢-O forms a hydrogen bond with Cg1
of Thr154 and the 3-OH atom of the sphingosine forms a hydrogen bond
with Asp80 Cd2. Colors are as in a.( d) Proposed model of the interaction of
an iNKT TCR with the CD1d–a-GalCer complex. Figure adapted from ref.
56. Red triangle, position of the Va chain of the TCR; blue triangle, position
of the Vb chain of the TCR; green rectangle, region of the a1 helix where
mutations in mouse CD1d have altered recognition by the iNKT TCR.
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1.5.3 invariant NKT cells in health and disease   
 
                           
So far, iNKT cells have been demonstrated to play a role in bacterial, parasitic, 
fungal and viral infections (182). During the anti-microbial response, iNKT cells 
can be directly involved in microbial recognition, direct cytotoxicity, and cross 
talk  with  the  adaptive  immune  response;  or  they  can  modulate  the  innate 
response such as influencing NK cells (183).   
 
Glycosphingolipds are commonly found in Sphingomonas spp. and they can be 
efficiently recognized by iNKT cells. In contrast, extracellular bacteria such as 
Salmonella spp. and E.coli do not have glycolipids for iNKT cell recognition 
(184).  
 
Many studies have focused on the relationship of iNKT cells and viral infections. 
Such studies have found that in human subjects with viral infection, the number 
of  iNKT  cells  is  significantly  decreased  (185).  In  EBV  associated  X-linked 
lymphoproliferative  disease  in  patients  without  SAP  mutation  a  second  gene 
defect has been identified in the X-linked inhibitor of apoptosis protein (XIAP), 
that significantly reduces iNKT cell numbers with no change in T, B and NK 
numbers (186).  Very recently, iNKT-cell deficiency was also demonstrated in 
another primary immunodeficiency, Wiskott-Aldrich syndrome (WAS). Patients 
with mutation in the WAS protein also share an increased susceptibility to viral 
infection (187). In HIV-1 infected individuals, the number of circulating iNKT 
cells decreases and this may relate to the expression of the CCR5 co-receptor on 
iNKT cells making the CD4 iNKT cells are more susceptible to the virus than 
conventional CD4 T cells (188).    
    
 
               
The first glycolipids recognised ( -GC) by iNKT cells were identified through an 
anti-tumour screening programme (111, 189, 190). iNKT cells can achieve the 
primary  protective  role  in  tumour  responses  through  the  release  of  Th1  type 
cytokines  i.e.  IFN- .  When   -GC  is  added  to  certain  tumour  lines  including 
thymoma, melanoma, sarcoma and carcinomas, iNKT cells can mediate tumour 
rejection through CD1d recognition (191, 192). In vivo studies have found that 
adoptive therapy of NKT cells to NKT deficient mice can protect the mice from 
induced  sarcomas  (193).  Such  adoptive  therapy  may  facilitate  cooperative 
responses with dendritic cells for additional conventional T cell responses. In a 
B16 melanoma mouse model where mice were treated with syngeneic dendritic 
cells pulsed with  -GC, tumour regression was effectively demonstrated (194). 
Other  studies  have  also  revealed  that  iNKT  cells  are  necessary  for  tumour 
rejection in IL-12 therapeutic settings (136).  
 
Despite numerous studies in mice identifying a role for iNKT cells in cancer, 
what  is  the  evidence  in  humans?  Several  in  vitro  studies  have  revealed  that 
human  iNKT  cells  can  expand  and  differentiate  to  a  Th1  phenotype  when 
dendritic cells are pulsed with  -GC, subsequently inducing tumour lysis (195, 
196). In vivo studies have also found a link between iNKT cells and tumour 
status. A defect of functional Th1 NKT cells was found in progressive multiple 
myeloma patients in both peripheral blood and tumour tissue. Interestingly, the 
defect was not found in non-progressive myeloma or premalignant monoclonal 
gammopathy  patients  (197).  Such  studies  have  identified  a  loss  of  CD1d  on 
myeloma  cells  as  the  malignancy  progresses  (198),  with  resistance  to  iNKT 
cytotoxicity. Target cell killing could be reinstated after CD1d was restored on 
the  cell  surface  of  myeloma  cell  lines  (198).  Other  than  multiple  myeloma 
patients, prostate cancer patients were also found to be defective in Th1 NKT 
cells (199). In a cohort of 109 patients with solid tumours, a decrease in the 
number of iNKT cells compared to the healthy controls was identified (200). 
Many additional studies have revealed a coexistent defect in IFN-  production    
 
from  the  reduce  number  of  iNKT  cells  in  cancer  patients  (201,  202).  More 
recently, the Van der Vliet group suggested that the lower IFN-  production in 
Th1 iNKT cells might be due to their interaction with myeloid dendritic cells. 
They suggest it this based on their study showing that dendritic cells from cancer 
patients can suppress the iNKT cytokine production from healthy individuals 
(203). 
 
In contrast to these studies with deficiencies of iNKT cells, certain tumours have 
been associated with robust iNKT responses. Isolated iNKT cells from patients 
with  glioma  can  kill  glioma  target  cells  following  expansion  with   -GC  and 
mediate direct cytotoxicity (204). Interestingly, in colorectal cancer patients, a 
high number of iNKT cells were found infiltrating the tumour tissue (205), with 
those patients having a higher NKT infiltration demonstrating a higher overall 
disease free survival rate (205).  
 
                           
The  role  of  iNKT  cells  in  autoimmune  disease  is  controversial;  with  studies 
showing  that  iNKT  cells  can  either  have  a  protective  role  or  potentiate  the 
autoimmune  disorder.  Studies  have  been  undertaken  in  several  autoimmune 
disease models. A milder course of Con-A induced hepatitis was found in the 
absence of iNKT cells (206, 207). Interestingly, Th1 skewed iNKT cells were 
found in human type I diabetes (208, 209).   
The impact of exogenous  -GC in these disease models has similarly not been 
conclusive.  In  some  disease  models  i.e.  autoimmune  cholangitis,  the  iNKT 
activation makes the disease worse whilst others show remission i.e. EAE (210). 
Experimental autoimmune encephalomyelitis (EAE), a murine model of human 
multiple sclerosis, has undergone extensive research with iNKT manipulation. 
Immunization with  -GC and myelin antigen enhances the disease in B10 mice; 
whereas it prevents EAE development in the C57BL/6 mice (170). It has been 
suggested that the functional consequence of iNKT cells in autoimmune EAE    
 
model is highly dependent on the MHC haplotype and the conventional T cell 
effector response that is shaped by iNKT cells (170).  
 
1.5.4 Mechanism of invariant NKT cells in cancer 
 
                                                
As  suggested  above,  iNKT  cells  play  an  important  role  in  the  anti-tumour 
response, but how might they achieve this? 
Even though iNKT cells can release Th1 cytokines and promote tumour cell 
lysis, they may also orchestrate other cells in the anti-tumour response. The other 
effector cells such as NK, CD8
+ T and dendritic cells may be influenced by 
iNKT cells. The study of methylcholanthrene – induced tumour suppression by 
transferred iNKT cells in mice was found to be CD8
+ and NK cell dependent. 
The transferred iNKT cells are seen to induce perforin production in CD8
+ and 
NK cells (193). Several studies have shown that perforin and interferon-  are 
important for this tumour rejection, and this is initiated by iNKT cells in an IL-2 
and IFN-  dependent manner (211).  
 
The  ability  of  iNKT  cells  to  mature  and  induce  the  release  of  IL-12  is  also 
important in the anti-tumour responses (Figure 1.10). The production of IL-12 is 
a mechanism by which iNKT cells can activate and interact with DCs (212). The 
prototypic ligand  -GC induces the expression of the IL-12 receptor on activated 
iNKT cells. When DCs pulsed with  -GC are co-administered a robust IL-12 
dependent  Th1  cytokine  production  is  seen  with  enhanced  activation  of 
conventional CD4
+ and CD8
+ T cells (213).     
 
 
Figure 1.10. iNKT cells in anti-tumour responses 
 
                                                                   
The development of iNKT cells as a therapeutic strategy has evolved alongside 
the basic scientific discoveries and animal models. In one of the earliest murine 
models of B cell malignancy, co-delivery of  -GC and irradiated tumour pulsed 
dendritic cells led to improved activation of conventional CD4
+ and CD8
+ T cells 
with  successful  rejection  (214).  Other s tudies  using  pulsed   -GC  in  B16 
melanoma, J558 plasmacytoma and EL4 thymoma models were all shown to 
provide the anti-tumour responses to the host by cross presentation of tumour 
antigens through DC to conventional T cells (215, 216). This protection was 
tumour  specific  with  no  cross  protection,  consistent  with  a  antigen  restricted 
conventional T cell effector response (195). The adoptive transfer of iNKT cells 
was also shown to protect against melanoma lung metastases in a murine model 
(217).   
In human subjects, studies have also been undertaken to treat cancer patients 
with either  -GC alone or in combination of autologous dendritic cells. Studies    
 
on solid tumour patients showed that no toxicity was found when they were 
given  -GC in a 4 weekly cycle. Increasing Th1 cytokine levels were identified 
in those patients with higher circulating iNKT cells pre-treatment (218). In 2002, 
the first  -GC pulsed dendritic cell clinical trial was carried out in 4 metastatic 
cancer patients, with two infusions. The serum level of IFN-  was found to be 
significantly  increased  in  the  follow  up  study,  but  there  was  no  improved 
outcome (219, 220). A later study with  -GC pulsed mature DC was undertaken 
to treat five patients with advanced metastatic non-small cell lung cancer. An 
increase  in  the  iNKT  cell  number  was  found  even  after  6  months  of  the 
treatment; together with elevated levels of IL-12 and CMV specific CD8 T cell 
immunity  were  also  found  significantly  increased  (197).  This  suggested  that 
adoptive therapy was safe and could mediate bystander effects on existing T cell 
populations.  
However, despite the mouse models and clinical trials showing an increase in 
iNKT cell number and production of Th1 type cytokines, no human study has 
demonstrated a complete or partial remission of the tumour (195).  
 






















    
 
2.1 Methods and Materials for Chapter 3 
 
2.1.1 Antibodies and Reagents  
 
The  antibodies  for  identifying  the  iNKT  cells  used  in  this  project  were  as 
follows: anti-human V 24 (clone C15) FITC and PE (Immunotech, Marseille, 
France), anti-human V 11 (clone C21) PE and APC (Immunotech, Marseille, 
France), anti-human CD161 APC (Becton-Dickinson Pharmingen, California), 
anti-human  CD3  PerCP  (Becton-Dickinson  Biosciences,  San  Jose,  CA),  anti-
human  CD4  PE-Cy7  (Becton-Dickinson,  Pharmingin,  California),  anti-human 
CD8  APC-Cy7  (Becton-Dickinson  Biosciences,  Pharmingin,  California)  and 
anti-human 6B11 (BD Pharmingen, Pharmingin, California). 
The  FACS  lysing  solution  was  obtained  from  Becton-Dickinson  Biosciences. 
The   -galactosylceramide  was  made  by  School  of  Chemistry.  The   -
galactosylceramide analogues were made by the School of Chemistry, University 
of Southampton. Ficoll-Plaque Plus was purchased from GE Healthcare.  RPMI, 
Pen-Strep, NEAA and L-glutamine were from Cambrex, UK. IFN-  and IL-4 
ELISPOT  sets  were  purchased  from  eBioscience.  The  cytokines  IL-2,  IL-15, 
GM-CSF and IL4 were from purchased from Peprotech.  PHA was obtained 
from Sigma-Aldrich, US. Other reagents for specific experiments are mentioned 
alone with the text.  
2.1.2 Study population 
 
Buffy coats from healthy donors containing around 8 – 9 x 10
8 PBMCs were 
purchased from National Blood Service, UK. Recruitment of healthy volunteers 
was also carried out at the local laboratory. 
    
 
2.1.3 Developing a FACS panel for enumerating invariant NKT cells 
 
                        
47 samples from healthy individuals were used for developing and validating the 
panel for iNKT cells.  The volume of antibodies used was determined using a 
flow cytometry titration assay. The volumes of antibody used in the control were 
as follows: 
 
  Antibody volume 
V 24 FIT-C  15µl 
V 11 PE  15µl 
CD161 APC  20µl 
CD3 PerCP  10µl 
CD4 PE-Cy7  5µl 
CD8 APC-Cy7  5µl 
 
Table 2.1. Volume of antibody used in experimental samples 
 
For the iNKT TCR binding affinity, the following antibody combination was 
used.  
  Antibody volume 
6B11 FITC  20µl 
V 24 PE  15µl 
V 11 APC  5µl 
CD3 PerCP  10µl 
CD4 PE-Cy7  5µl 
CD8 APC-Cy7  5µl 
 
Table 2.2 Antibody concentrations for clonaltypic panel    
 
 
500µl of the whole blood sample or diluted buffy coat from each individual was 
used to identify the iNKT cells. All the antibodies were added to the 500µl whole 
blood sample. The samples were incubated in the dark for 15 minutes at room 
temperature, after adding all the antibodies. Two ml of the BD FACS lysing 
solution was then added to the sample and briefly vortexed. Samples were then 
incubated  for  a  further  15  minutes  to  lyse  the  red  cells  at  4°C.    After  this 
incubation,  they  were  spun  down  at  1500rpm  for  five  minutes  and  the 
supernatants were discarded.  Two ml of the FACS washing buffer was added to 
each tube to remove the excess antibody, and the samples were again centrifuged 
at 1500rpm for five minutes. A further two ml of FACS washing buffer was 
added to each sample and vortexed well. They were then left at 4
oC in the dark 
until prior to analysis. 
 
                                              
 
Due to the low number of iNKT cells present in the peripheral blood there is a 
greater  likelihood  of  non-specific  events/debris  interfering  with  accurate 
enumeration and therefore an appropriate approach was required to analyse the 
cell population in the peripheral blood. The approach shown in Figure 1 was 




Figure 11. Approach for identifying invariant NKT cells    
 
 
The antibody stained sample was run on the flow cytometer with a minimum of 
100,000 T cells collected for further analysis. The T cells were further positively 
selected upon the markers CD161 and V 24.  The V 24
+CD161
+ cells were then 
analysed  for  expression  of  V 11  expression.  Only  those  cells  with  both 
V 24V 11 expression through this strategy were true iNKT cells.  This analysis 
was validated in 18 samples and further applied to 29 samples.  
 
2.1.4 Proliferation assay of invariant NKT cells 
 
                             
Lymphocytes were isolated from 40ml of whole blood (or alternatively from 
250ml 80%PBS+ buffy coat) by Ficoll gradient.  15ml of the Ficoll solution was 
transferred by pipette into 50ml tubes. The tubes were tilted to a 45
oC angle, and 
the blood was carefully layered onto the top of the Ficoll solution.  The samples 
were centrifuged at 1600rpm for 25 minutes at room temperature, with the brake 
off.    The  interphase  was  carefully  removed  using  pasteur  pipettes  after 
centrifugation.  The  interphase  was  then  washed  three  times  with  PBS.  The 
lymphocytes were then suspended in one ml of RPMI. 2 x 10
5 PBMCs were used 
in every well for IFN-  and 5 x 10
5 PBMCs were used for the IL-13 and IL-17 
ELISPOT. 
 
The proliferation assay of iNKT cells was performed with  -GC for 7 days (221). 
5  x  10
6  PBMCs  were  resuspended  in  5ml  of  complete  RPMI1640  culture 
medium with 100IU/ml of recombinant human IL-2 and 100ng/ml of the  -GC. 
Proliferation of NKT cells was assessed at day 7 using the six-colour FACS 
panel. Proliferation index was calculated by comparing the total number of iNKT 
cells pre-proliferation to the total number of iNKT cells post proliferation.  
    
 
2.1.5 Cytokine profile of the analogues 
 
The  cytokine  profile  of  the  PBMCs  stimulated  with  different  analogues  was 
measured using IFN- , IL-13 and IL-17 ELISPOTs according to manufactures 
instructions.  
 
                                             
Cultured  ELISPOTs  were  done  with  cells  cultured  for  7  days  with  the 
appropriate analogue and pulsed for final 18 hours with the CD1d ligand. 
 
ELISPOTs were performed using a human IFN-  ELISPOT, IL-13 ELISPOT 
and  IL-17  ELISPOT  set  according  to  the  manufacturer’s  protocol.  ELISPOT 
plates  were  coated  with  PBS  diluted  anti-IFN-   (or  IL-13,  IL-17)  antibody 
overnight. The plates were then blocked with complete RPMI for 2 hours. The 
lymphocytes were then counted and incubated overnight at 2 x 10
5/well for IFN- 
  or 5 x 10
5/well for IL-13/ IL-17 at 37°C with a series concentrations of the 
appropriate ligand (either control or experimental) in triplicate. Wells were then 
washed with deionised water and PBS-Tween. Plates were then incubated with 
biotinylated anti-human IFN-  antibody or anti-human IL-13 or anti-human IL-
17  for  2  hours.  Plates  were  washed  four  times  with  PBS-Tween,  and  then 
incubated with streptavidin for 1 hour at room temperature. The plates were then 
washed again with PBS-Tween and PBS. The plates were incubated with the 
substrate solution and the spot development was monitored. The reaction was 
stopped by washing with deionised water. The plates were dried for 2 hours 
before analysis by ELISPOT analyser. 
 
2.1.6 FACS sorting of invariant NKT cells 
 
PBMC was isolated with Ficoll, followed by labeling antibodies V 24 FITC, 
V 11PE, CD161APC, CD3 PerCP, CD4 PE-Cy7 and CD8 APC-Cy7 for half an    
 
hour at 4°C. The labeled PBMCs were then washed with FACS wash twice and 
resuspended in PBMC, and run on the FACSAria. The invariant iNKT cells that 
were identified with the approach from figure 1 were further divided into CD4 
and nonCD4 subsets. The CD4 and non-CD4 components were separately sorted 
into  a  different  collection  tubes  with  complete  medium.    In  the  experiments 
performed  in  Chapter3,  a  set  number  of  1000  cells  were  collected  in  each 
fraction. 
2.1.7 Statistical Analysis 
The  statistical  analysis  in  the  thesis  was  performed  using  Graphpad  Prism  4 
software.  Statistical  Analysis  for  pair  comparison  in  Chapter  3  and  7  was 
performed  using  Paired  t  test,  as  data  analysis  by  prism  suggest  data  show 
Gaussian distribution. Correlation studies in Chapter 3 was analysed with linear 
regression to obtain R
2. Chapter 4, 5 where statistics are required for comparing 


















    
 
2.2 Methods and Materials for Chapter 4 
 
2.2.1 Isolation of antigen presenting cells 
 
Various  antigen  presenting  cells  were  positively  selected  using  magnetic 
separation with MACS beads (Miltenyi Biotec, Germany). Cells were incubated 
at room temperature for ten minutes with anti – CD19 microbeads for B cell 
depletion,  anti-CD14  microbeads  for  monocyte  depletion  and  anti-BDCA-1 
microbeads for myeloid dendritic cells depletion (20µl per 10
7 cells). The cells 
were  then  washed  with  RPMI  and  resuspended  in  100µl  MACS  buffer 
(phosphate buffered, 5mM EDTA and 0.5% BSA). At the same time, an LS 
separation column (Miltenyi Biotec, Germany) was set up by flow through with 
500ul of the MACS buffer. The cells were then washed and resuspended in 500µl 
of buffer. The cells were then applied to the LS separation column and the flow 
through  collected  according  to  manufacturer  instructions.  The  column  was 
washed three times with 500µl MACS buffer and the flow through collected. The 
purity of the flow through was then checked by cytometry (above 93% purity 
were obtained with the depletions). The remaining monocyte/B cells in PBMC 
were also assessed by cytometry (10.4% in total PBMC pre-depletion compared 
to below 0.5% post-depletion). 
 
2.2.2 iNKT proliferation with separate APC subsets 
 
PBMC  or  partially  depleted  PBMC  were  cultured  with  100ng/ml   -GC  and 
100IU of IL-2. In experiments when IL-15 was added, 20ng/ml of IL-15 was 
used. The PBMC was cultured for seven days before the proliferation index was 
determined by FACS. Proliferation index was calculated by comparing the total 
number of iNKT cells pre-proliferation to the total number of iNKT cells post 
proliferation.     
 
2.2.3 Titration of IL-15  
 
Cultured ELISPOTs were performed with a series of IL-15 concentrations for 
seven days. The concentration of IL-15 used for these experiments was 25ng/ml, 
20ng/ml, 15ng/ml, 10ng/ml, and 5ng/ml. IFN- , IL-13 and IL-17 were performed 
as described in Chapter 3.  
2.2.4 Study of effect of IL-15  
 
                              
                           
For the IL-15 induced IL-15R  experiments, 20ng/ml of IL-15 was added to the 
PBMC,  and  then  the  B  cells  and  monocytes  were  then  sorted.  For  intrinsic 
expression of IL-15, the B cells and monocytes were directly sorted from the 
PBMC  without  pre-culturing.  The  cells  were  pelleted  and  washed  once  with 
PBS, prior to lysis for 30 minutes (150mM, 5mM EDTA (Sigma, UK), 20mM 
TriHCL (Sigma, UK), 2mM Phenylmethylsulphonylfluoride (Sigma, UK), 2mM 
Iodoacetamide (sigma, UK) and 0.5% NP-40 (Sigma, UK)). The lysates were 
then centrifuged at maximum speed (13,000 rpm) for 5 minutes. The lysates 
were then mixed in 2x SDS-loading buffer (4% SDS (Sigma, UK), 0.125M Tris 
(Sigma,  UK),  20%  glycerol  (Sigma,  UK),  0.05%  Bromophenol  blue  (Sigma, 
UK), 5%  -merceaptoethanol (Sigma, UK)). Heated to 95°C for 5 minutes and 
spun down. 
 
                        
The cell lysates with the SDS-loading buffer were run on a 10% polyacrylamide 
gels (Invitrogen, UK). The gel was cast in 1mm gel cassettes and run in a X-Cell 
SureLock Mini Cell System (Invitrogen, UK). The gel was then transferred to a 
nitrocellulose membrane overnight at 12 Volts.    
 
Once the transfer was complete, the membrane was blocked with 5% milk in 
PBS at room temperature for an hour or 4°C overnight. The membrane was then 
added to PBS with a 1:2000 dilution of the IL-15R  detection antibody and 
incubated overnight at 4°C. The membrane was then washed 3 times in PBS-
0.1% Tween. The membrane was then further incubated in the 1:10,000 anti-goat 
HRP in PBS for an hour at room temperature. The membrane was then washed 3 
times in PBS and detected in ECL solution (Pierce). 
 
                                                                   
To look at the expression of IL-15R  and common  chain in iNKT cells, PBMC, 
after a seven day culture were labeled with V 24 FITC, CD122/CD132 PE, CD3 
PerCP, CD4 PE-Cy7 and CD8 APC-Cy7 for 15 minutes at room temperature. 











    
 
2.3 Methods and Materials for Chapter 5 
 
2.3.1 Preparation of Analogues 
 
The analogues were received from collaborators (Dr Bruno Linclau, University 
of Southampton and Dr. Serge Van Calenbergh, University of Ghent) and all 
dissolved  in  PBS  with  10%  DMSO.  The  analogues  were  then  aliquoted  and 
stored  at  -20°C. 
 
2.3.2 Cytokine study of the Analogues  
 
                                     
Cells from seven day cultures with various analogues were collected and washed. 
The cells were plated in a 96 U bottomed plate. The cells were then incubated 
with 100ng/ml of the appropriate analogues and 5 x 10
3 irradiated autologous 
feeder cells and 1uM/well Golgistop were added for 6 hours. 
Cells were then labeled with 15ul of 6B11 and 10ul of CD3 for 15 minutes at 
4
oC.  Cells  were  then  washed  twice,  fixed  and  permeabilised  with  the  BD 
permeabilisation and fixation kit before intracellular labeling with 5ul PE-Cy7 
mouse anti-human IFN- , 20ul FITC mouse anti-human IL-17 and 5ul APC rat 
anti-human  IL-4  for  20  minutes  at  4
oC.  After  a  final  wash  the  cells  were 
resuspended in FACS buffer and run on the FACScanto. 
 
                               
Supernatants from PBMC cultured with  -GC and analogues were sampled at 2-
16 hours at every two hours interval to identify the optimal time for cytokine 
sampling. The samples were then stored at -20°C for use in the multiplex assay.    
 
To perform the cytokine analysis, a human Th1/Th2 multiplex kit was used. 50µl 
of 1x Assay Buffer was added to each well of the filter plate to pre-wet the plate. 
25µl  of  Standard  Mixture  were  added  to  the  first  two  rows  of  the  plate  to 
generate a standard curve.  The samples were added to appropriate wells. 25µl of 
the Bead Mixtures were then added to each well, and 50µl of Biotin-Conjugate 
Mixture was added to the wells. After adding the mix to the plate, it was covered 
by adhesive film and incubated at room temperature for 2 hours on a 500rpm 
shaker with protection from the light. The film was removed after 2 hours and 
the  plate  was  washed  three  times  with  100µl  of  1xAssay  Buffer.  100µl  of 
1xAssay  Buffer  was  added  to  each  well  after  the  washes  with  50µl  of  the 
Streptavidin-PE solution. The plate was again covered and incubated at room 
temperature for 1 hour on the shaker. The plate finally washed three times with 
assay buffer and 200µl of the assay buffer was added to each well for mixing the 
samples and transfer to FACS tube.  
The samples were then run on the flow cytometer and each detected cytokine 
was identified by the size of its conjugation beads. The level of PE intensity 
indicated  the  level  of  the  cytokine  and  the  results  were  analysed  on  the 
FlowCytomix Pro2.3 Software.  
 
2.3.4 Anergy study of iNKT cells 
 
To investigate the level of anergy in iNKT cells PBMCs were labeled with PD1 
FITC (20µl), 6B11 PE, CD3 PerCP, CD4 PE-Cy7 and CD8 APC-Cy7 for 15 
minutes at room temperature pre and post a 7 day culture. The cells were then 
washed twice in FACS buffer and run on the FACSCanto. 
 
    
 
2.4 Methods and Materials for Chapter 6 
 
2.4.1 Specificity killing of iNKT cells 
 
                                             
The NKT cells lines were generated from 1 x 10
7 PBMCs, initially incubated in a 
T 25 flask with 100ng/ml  -GalCer and 100IU/ml IL2.  -GC pulsed autologous 
APCs were restimulated every 7 days. The NKT cells were sorted with MACS 
isolation after 2-3 rounds of restimulation and the lines maintained in IL-2. 
 
                                        
CD1d expression on the target tumour cells was analysed before each killing 
assay. The CD1d expression was analysed on Jurkat, K562 and U 937 cell lines 
with a CD1d PE antibody.  
The tumour cells were incubated with the CD1d PE antibody for 15 minutes at 
room  temperature.  The  cells  were  then  washed  twice  with  FACS  wash  and 
analysed on the FACSCanto.   
 
                                   
The killing assay in this project was established by measuring direct cell death 
using the DNA binding dye To-Pro-3 (Invitrogen, UK). Each assay counted 5000 
target cells that had been pulsed with 100ng/ml  -GC or analogues for 2 hours. 
The cells were then washed twice with complete RPMI1640. The NKT cells 
were added to the wells in appropriate effector: target ratios in a 96 well plate. 
The plate was then incubated at 37˚C for 4 hours. 2ul (1:100) of To-Pro-3 was 
added into each well and incubated on ice for 30 minutes. After the incubation, 
the plates were washed twice with FACS wash and analysed on the FACSCanto.     
 
2.4.2 Generation of a CD1d dimer 
 
                                                                     
                                            
The primers (Sigma, UK) used for generating the CD1d dimer were as follows: 
Signaling peptide –  2m:  
•  Forward: GGT GCT AGC  ATG GAA TGG AGT TGG ATA TTT CTC TTT CTC 
CTG TCA GGA ACT GCA GGT ATG ATC CAG CGT ACT CCA AAG 
•  Reverse: ACG AAG CTT AGC ACC TCC TCC AGA ACC TG 
CD1d:  
•  Forward: 5’- CGA AAG CTT GTC CCG CAA AGG CTT TTC C – 3’ 
•  Reverse:  5’ – ACG GGT ACC CAG GAC GCC CTG ATA GGA AG – 3’ 
Heavy Chain.  
•  Forward: CGT GGT ACC  GAG GTC CAG CTG CAG CAG TCT GG 
•  Reverse: 5’ – AGC CTC GAG TCA TTT ACC AGG AGA GTG GG – 3’ 
Those underlined sequences represent the restriction sites:: GCT AGC – NheI, 
AAG CTT – HindIII, GGT ACC – KpnI, CTC GAG - XhoI 
  
                                            
Individual PCR reactions were carried out to generate different fragments for 
subsequent ligation into the cloning vector. Human CD1d and signaling peptide 
were generated from from an image clone (Clone ID 39685). The mouse Heavy 
Chain  was  generated  from  a  pEE6.1  vector  containing  mouse  variable  and 
constant regions (a gift from Claude Chan, Tenovus, Southampton). The PCR 
approach utilised was as follows ; 5 minutes at 94°C,33 cycles of 30 seconds 
@94°C:45 seconds 60°C and 2 minutes @72°C. A 7 minute 72°C final extension 
was then performed. 
PCR products were purified using a QIAquick PCR purification kit (QIAGEN), 
and performed according to the manufacturer’s protocol. For DNA binding, the    
 
mixture was then transferred to a QIAquick spin column, centrifuged for 30-60s 
and the flow through was discarded. 0.75ml of PE buffer was added to wash the 
column, prior to a 30-60s centrifugation step. 30µl of elution buffer was added to 
the  centre  of  the  column  membrane.  The  flow  through  was  collected  and 
retained. 
 
                                             
All PCR products were cloned individually into pGMT vector. 5µl of the PCR 
product were mixed with 2µl of the pGMT vector, 1µl DNA ligase and 2µl of T4 
ligase buffer. The reactions were ligated at 16°C overnight. 
2 µl of each ligation preparation were transferred to a tube containing competent 
E.coli.  The  tubes  were  left  on  ice  for  30  minutes.  The  tubes  were  then  heat 
shocked at 42
oC for 30 seconds. They were left on ice for a further 2 minutes 
after heat shocking. Then, 250µl of SOC medium was added to each tube. The 
tubes were left at 37
oC in a shaking incubator for one hour. After incubation, the 
tubes were centrifuged for 20 seconds to spin down the bacteria. The liquid was 
tipped  out  of  each  tube  and  the  bacteria  were  resuspended  in  the  remaining 
medium  
A blue/white screening was performed for pGMT cloning with 50µl of X-gal and 
50µl   -galactosidase  spread  on  ampicillin-LB  agar  plates.  200µl  of  the 
transformed culture was plated and incubated at 37°C overnight. White colonies 
were picked and grown on ampicillin LB medium at 37°C overnight.  
After  overnight  incubation,  the  bacterial  culture  was  tipped  into  a  1.5ml 
eppendorf tube and the remaining cultures kept for future use. The eppendorf 
tubes were spun for 1 minute at 13000rpm and the medium was removed. The 
bacterial cells were resuspended in 250µl of buffer P1 (resuspension buffer) and 
250µl of buffer P2 (lysis buffer). 350µl of P3 was then added and mixed by tube 
inversion.  The  culture  tubes  were  then  centrifuged  for  15  minutes  at 
13000rpm.The supernatant was added to the QIAspin column, centrifuged for 1 
minute. And 0.5ml of the binding buffer (PE) added for 1 minute. The column    
 
was washed using 0.75ml PE and centrifuged for 1 minute. 50µl of elution buffer 
was added to elute the DNA; the DNA was collected by centrifugation for 1 
minute. 
To  screen  the  colonies,  5µl  of  the  purified  DNA  was  digested  with  the 
appropriate enzymes in a total volume of 20µl. The digested plasmids were then 
run on a 1% agarose gel to check for the presence of an insert. 
The  DNAs  with  the  correct  insert  were  sent  for  sequencing  by  GeneService 
(Oxford, UK). 
 
                              
The DNA containing the correct sequence was cut with the appropriate enzyme 
to release signaling peptide- 2m, CD1d and heavy chain. The three fragments 
were  cloned  into  the  pcDNA3.1  by  multiple-restriction  enzyme  ligation.  The 
cloning was performed by three step ligation. First, the signaling peptide- 2m 
sequence was inserted into the plasmid, followed by CD1d and heavy chain. 
Double digestion was performed after every new insertion to check the correct 
insert has been placed.  
The final product was sent for confirmatory sequencing.  A Maxiprep was then 
performed  following  the  sequencing  confirmation  of  our  correct  vector.  The 
overnight culture in 250ml LB-amp was centrifuged and the bacterial pellet was 
resuspended in 10ml of P1 buffer. 10ml of buffer P2 was added into the mixture 
and left at room temperature for 5 minutes. 10ml of P3 were added to the culture 
and this was inverted 4-6 times. The lysate was then poured into a QIAfilter 
Cartridge and left for 10 minutes. The QIAGEN – tip 500 was equilibrated by 
adding 10ml QBT buffer and left to flow through. After 10 minutes, the cap of 
the  QIAfilter  Cartridge  was  removed,  and  the  plunger  was  inserted  into  the 
QIAfilter Maxi Cartridge. The flow through from Maxi Cartridge was collected 
into the equilibrated QIAGEN tip. The QIAGEN – tip was then washed with 2 x 
30ml QC. 15ml of QF were used for eluting DNA and the DNA was collected in 
a Beckman tube. 10.5ml isopropanol was added to the eluted DNA, in order to    
 
precipitate it, mixed and centrifuged at 15000g for 30 minutes. The supernatant 
was  decanted  and  the  pellet  washed  in  70%  ethanol  and  dried  at  room 
temperature for 30 minutes, prior to redissolving in 200µl of elution buffer. 
 
                                 
                                                     
The cells line for expressing the CD1d dimer construct is a murine myeloma cell 
line J 558L which is heavy chain deficient but capable of producing Ig  chain (a 
gift from Professor Aymen Al-Shamkhani). The cells were grown on serum free 
medium and 2µl of pcDNA3.1 containing construct was transfected to 1 x 10
7 
cells by nucleofector (Lonza Cologne AG, Cologne, Germany). Cells with the 
transfected DNA were grown in the presences of 0.5mg/ml of G418. 
 
The supernatant produced by transfected J558L cells was collected after 2 weeks 
incubation.  The  culture  supernatant  was  then  applied  to  protein  G  sepharose 
column and washed with 0.1M glycine buffer until there was no detection of 
protein on the flow through, by nanodrop. The CD1d dimer was then eluted by 
adding 0.1M glycine buffer and a series of 500µl elutions collected.  
 
                              
The purified protein was then used as the protein target of a western blot with a 
primary  rabbit  anti-human   2m  antibody  and  secondary  anti-rabbit  HRP 
antibody. 
The CD1d dimer construct was also validated by FACS analysis by intracellular 
staining of non-transfected and transfected J558L cells with an anti CD1d-PE 
labeled antibody.  
    
 
                                                
The competitive ELISA assay followed the protocol developed by Shiratsuchi et 
al as discussed in Chapter 6. To calculate the Kd of the conditional ligand a 96 
well Nunv MaxiSorp plate was coated overnight with 100µl of 1:500 mouse 
monoclonal antibody (a gift from Dr. Natalia Savelyeva). The plates were then 
washed three times with PBS-Tween and a titration series of the conditional lipid 
(Biotinyl  PE)  was  added  to  8µl/ml  of  CD1d  dimer.  The  half  maximal 
concentration was calculated to give the Kd. For competitive ELISAs a similar 
approach was taken with a titration series of analogues added to a CD1d dimer 
conditional  ligand  mix  of  2µl/ml  CD1d:  0.8µl/ml  of  Biotinyl  PE.  This  was 
incubated overnight at 37°C to facilitate the competition between the reporter 
Biotinyl PE and index analogues. The plates were washed three times with PBS-
Tween and the HRP-labeled avidin was added to detect the residual binding of 
the reporter. The Ki of each analogue was then calculated using the formula Ki = 
IC50 / (1 + [B-PE] / Kd), where IC50 is the concentration of index analogue that 
reduces maximal signal by 50%, [B-PE] the concentration of reporter ligand and 









    
 
2.5 Methods and Materials for Chapter 7 
 
2.5.1 Details of patient samples 
 
37 CVID patient samples and 4 X linked agammaglobulinaemia samples, 20 ml 
of  lithium  heparin  blood,  were  sent  from  our  clinical  collaborator  (Professor 
Bodo Grimbacher) at the Royal Free Hospital, London. The methods used for the 
enumeration and functional studies of these patients were identical to those used 








































Studies  in  recent  years  have  shown  that  the  number  of  iNKT  cells  can  vary 
enormously in healthy individuals (163, 168, 222, 223). Most studies report that 
the number of iNKT cells in the peripheral blood among healthy individuals, 
ranges from 0.01 -1% of total T cells, with a mean of around 0.1% (224).  This 
three-log range for a conserved T cell subset is unique to the iNKT lineage and 
poorly understood. 
 
3.1.1 Approaches for identifying iNKT cells 
 
Traditionally,  this  cell  type  in  humans  was  identified  using  two-color  flow 
cytometry with antibodies directed against the conserved T cell receptor V 24 
and V 11 (222). The generation of CD1d/ -GC tetramers have provided a more 
specific  way  to  identify  the  iNKT  cells  in  both  humans  and  mice  (225).  
However, in comparison to monoclonal antibodies, the tetramer staining can lead 
to a higher background staining, especially in the presence of monocytes (222, 
226). Recently a clonotypic monoclonal (6B11) antibody has been established as 
a useful tool for identifying iNKT cells. This antibody was generated against the 
conserved CDR3 V 24 chain of iNKT cells (227). In comparison to the previous 
technique, the advantage of using the 6B11 is that it can identify iNKT cells with 
a single antibody rather than a combination of two and that it is specific for a 
TCR sequence signature.  However it again shows a higher background staining 
as compared to the dual antibody approach. 
 
 
    
 
3.1.2 Factors influencing the number of iNKT cells 
 
Currently, little is known as to the factors that contribute to the differences in 
iNKT  cell  numbers  amongst  the  heterogeneous  human  population.  Several 
candidate genes have been identified that are influential in their development. 
SH2D1A  is  one  of  the  genes  that  is  thought  to  have  an  impact  in  iNKT 
development.  SH2D1A  encodes  for  the  signaling  lymphocytic  activation 
molecule (SLAM)-associated protein (SAP), whose absence is responsible for X-
linked lymphoproliferative disease (XLP). In SAP deficient patients, their B, T 
and  NK  cell  numbers  are  within  normal  range,  whilst  their  iNKT  cells  are 
deficient (151, 228).  Reciprocal experiments in mice with engineered knockouts 
of SAP confirm this selective requirement for iNKT cell development. Studies 
have  also  shown  that  the  activation  of  PKC   by  Fyn  is  essential  for  the 
generation of NKT cells (229, 230). It is now known that the SAP-Fyn- PKC  
pathway is essential for the NKT cells development.  
Peripheral factors may also shape the iNKT repertoire as it is known that low 
levels of iNKT cells are present in cancer patients, as well as individuals with 
viral infections (231, 232). 
 
3.1.3 iNKT cells – a number’s game? 
 
Invariant NKT cells are also believed to influence certain autoimmune diseases. 
Some studies have shown that the number of iNKT cells is significantly reduced 
in patients with Multiple Sclerosis (MS), Systemic Lupus Erythematosus (SLE), 
Systemic Sclerosis and Rheumatoid Arthritis (162, 168, 169). 
 
During human immunodeficiency virus (HIV) infection, the number of iNKT 
cells dramatically decreases in the host (233). In some instances, a complete 
depletion of iNKT cells was seen (188, 233). A restoration of circulating iNKT 
cells number has been described after highly active antiretroviral therapy (234). 
In hepatitis B and hepatitis C infected individuals, the number of iNKT cells    
 
resident  in  the  liver  is  much  higher  than  those  in  healthy  subjects  (235). 
Interestingly, no increase was observed in the circulating iNKT cells compared 
to healthy controls (236). The absolute number of iNKT cells in the liver of some 
Hepatitis C subjects is ten times higher than that in their peripheral blood (236). 
A single case study reports a girl with iNKT cell deficiency who died of varicella 
infection  following  vaccination,  with  have  no  other  immunodeficiency 
discernable (174). 
 
Despite  these  factors,  it  is  still  not  fully  understood  what  accounts  for  the 
variable  number  of  iNKT  cells  seen  across  healthy  individuals.  Outstanding 
questions also concern the relationship between iNKT cells and conventional T 
cells.  Is  there  perhaps  a  signature  to  define  individuals  with  high  iNKT  cell 
numbers  compared  to  those  with  low  iNKT  cells?  And  finally  is  there  a 













    
 
3.2 Aims of this study 
 
The aims of this study were to  
•  Develop  methods  that  can  be  used  for  accurately  enumerating  and 
examining the function of iNKT cell populations in healthy controls and 
cancer patients. 
 
•  Develop an experimental platform to systematically analyse a portfolio of 
novel glycolipids compounds that have been designed to improve CD1d 














    
 
3.3 Results  
 
3.3.1 Development of an iNKT panel 
The FACS panel for identifying iNKT cells was developed by using whole blood 
sample labeling with six antibodies (V 24 FITC, V 11 PE, CD161 APC, CD3 
PerCP,  CD4  PE-Cy7  and  CD8  APC-Cy7).  The  iNKT  cells  were  initially 
identified using a sequential step gating strategy.  Figure 3-1 is a representation 
of this approach for identifying the iNKT cells. 
 
Figure  3.1  Steps  in  identifying  invariant  NKT  cells.  (a)  General  view  of 
leucocytes in flow cytometry forward scatter/side scatter dot plot. A gate 
was set for Lymphocytes which represents 18% of the whole population. (b) 
T cells were identified from the Lymphocyte gate which represented 56% of 
the Lymphocyte population. (c) Possible invariant NKT cells were identified 
by using V 24 and CD161 antibody on the T cell gate. V 24
+CD161
+ cells 
contribute about 88% of the V 24
+ T cells. (d) Invariant NKT cells were 
identified  from  possible  invariant  NKT  cells  by  using  V 24  and  V 11 
antibodies.  87%  of  the  possible  invariant  NKT  cells  were  true  invariant 
NKT cells as defined as CD3
+V 24
+V 11
+.  All of these were CD161 positive. 
(e) The CD4 and CD8 distribution of invariant NKT cells. (f) The CD4 and 
CD8 distribution of total T cells.    
 
Examination of Figure 3-1 reveals that iNKT cells represent 1.2% of T cells for 
this healthy individual. Qualitatively it can be seen that most of the iNKT cells 
are CD161 positive and express a higher density of V 24 compared to those 
V 24 positive non iNKT cells (MFI of 2773 compared to 1194, p < 0.002) The 
majority  of  the  iNKT  cells  are  double  negative  (DN)  for  CD4  and  CD8  co-
receptors.  This  qualitative  and  quantitative  assessment  provides  an  accurate 
identification  of  iNKT  cells  in  whole  blood  and  prevents  some  of  the  non-
specific factors that can influence the enumeration of rare populations in whole 
blood. 
3.3.1 Conventional T and invariant NKT cells 
 
From  the  panel  established  above,  we  further  analyzed  and  compared  the 
phenotypic properties of conventional and iNKT cells. 
As  iNKT  cells  are  a  subset  of  the  T  cell  lineage  we  compared  the  CD3 
expression between iNKT cells and conventional T cells. 
 
 
Figure 3.2 CD3 expression on conventional T cells and iNKT cells. MFI of 
CD3  comparison  between  conventional  T  cells  and  iNKT  cells  across  43 
individual.    
 
From the Figure 3-2, it can be seen that conventional T cells have a much higher 
expression of CD3 compared to iNKT cells (MFI 5453 compared to 2890, p< 
0.0001,  n=43).  This  is  intriguing  when  the  previous  result  of  an  increased 
expression of V 24 is noted in iNKT cells compared to conventional T cells. 
Populations of iNKT cells and non-iNKT V 24 T cells were selected for further 
investigation (Fig 3.3). 
 
 
Figure 3.3 V 24 expression on iNKT cells and non-iNKT V 24 cells.     
 
A homogenous peak for the density of V 24 expression is observed in the iNKT 
cell  population.  In  contrast  to  this,  heterogeneous  peaks  of  V 24  expression 
were observed in the non-iNKT V 24 T cell populations.  
 
Figure 3.4 Analysis of V 24 expression on iNKT cells and non-iNKT V 24 
cells across 47 healthy individuals. MFI expression of V 24 was compared 
between  the  conventional  V 24  T  cells  population  and  iNKT  cells 
population. The V 24  MFI is much higher in iNKT cells compared to their 
conventional counter part. 
Figure  3.4  illustrates  that  across  the  heterogeneous  population,  conventional 
V 24 T cells showed a much lower receptor expression compare to the iNKT 
cells despite them having a higher level of CD3 receptor expression.   
CD161 is considered as a maturation marker of iNKT cells with only mature and 
resting  iNKT  cells  expressing  CD161.  The  majority  of  iNKT  cells  in  adults 
express CD161 and Figure 3.5 shows that there was no significant difference 
between the two populations of iNKT cells for CD3 expression.    
 
 
Figure  3.5  CD3  expression  in  CD161  positive  and  negative  iNKT  cells. 
Comparison  of  CD3  MFI  in  the  CD161  negative  and  positive  iNKT 
population. No difference was found in the two populations.  
 
3.3.2 Quantitative analysis of invariant NKT cells 
 
The quantitation and phenotypic evaluation of iNKT cells was then performed on 
47  adult  controls.  We  observed  that  the  number  of  iNKT  cells  varied 
considerably from individual to individual as previously reported (Figure 3-6).    
 
 
 Figure 3.6 The number of variant iNKT cells in the 47 healthy volunteers. 
Absolute numbers relate to a denominator of 100,000 T cells. 
The  range  of  iNKT  cells  extended  over  four  logs,  from  1  to  1100  cells  per 
100,000 T cells. A skewed distribution was seen in the number of iNKT cells in 
the  control  population.  Most  individuals  (30/47)  had  an  iNKT  cell  number 
between 0-200, with a mean of around 0.1% of the T cells. Approximately 15% 
(7/47) of all individuals have more than 500 iNKT cells per 100,000 T cells. We 
have subsequently dissected the population into individuals with high iNKT cells 
(>0.5% iNKT cells), medium iNKT cells (0.2-0.5% iNKT cells) and those with 
low iNKT cells (<0.2% iNKT cells).  
We wanted to establish if iNKT cell numbers were stable over a long period of 
time for an individual. Seven individuals were followed up for up to three years, 
and  no  significant  changes  were  identified  in  each  of  these  healthy  controls 
(Figure 3.7). Our results suggested that the iNKT number was a stable parameter 
for healthy controls.     
 
 
Figure 3.7 Longitudinal changes in iNKT cell number overtime.  
 
3.3.3 Qualitative analysis of invariant NKT cells 
 
As  suggested  in  previous  studies,  the  phenotypic  evaluation  of  iNKT  cells 
identifies functional subsets of these cells. Clonal T cell studies have identified 
that CD4
+ cells mainly promote Th2 like responses whilst CD4
- subsets promote 
Th1  like  responses,  through  IFN-   secretion.  We  extended  these  analyses  by 
evaluating the CD4 expression amongst the different groups of individuals 
(low compared to medium-high iNKT group) in contrast to previous studies of 
clonal sub populations from the same individual.    
 
 
Figure 3.8 CD4 expression on iNKT cells between the low iNKT donor and 
the medium-high iNKT donor groups. Percentage of CD4 iNKT cells were 
calculated and analyzed in the low iNKT (<200) and medium-high iNKT 
population ( >200). 
 
As can be seen in Figure 3.7, there is a significant difference in the percentage of 
iNKT cells expressing CD4 between the 2 groups. The mean percentage of CD4 
iNKT cells is notably higher in low iNKT donors (~50% of their iNKT cells) 
compared to the controls with medium-high levels of iNKT cells (~25% of their 
iNKT cells) (p < 0.0074). This suggested that the number of iNKT cells may 
correlate with the functional repertoire of these cells for cytokine production in 
individuals and across healthy populations.  
We then further analysed the group to see if the differential CD4 expression seen 
in  the  iNKT  cells  was  comparable  to  that  seen  in  the  conventional  T  cell 
population.    
 
 
Figure 3.9 Conventional T cell CD4:CD8 ratio in low and high donors 
 
Surprisingly there was also a strong association of iNKT number with the ratio of 
CD4:CD8 lineage choice in conventional T cells. The control individuals with a 
lower number of iNKT cells showed a much higher ratio of CD4
+ to CD8
+ T 
cells  within  their  conventional  T  cell  lineage  compared  to  the  controls  with 
medium-high  iNKT  cells  (CD4:  CD8  ratio  of  2.5  compared  to  1.3  in  the 
conventional lineage, P<0.001). To put this another way, those individuals whose 
T cell selection had resulted in a diverse conventional TCR population with a 
CD4:CD8 ratio of <1.5 appeared to co-select a higher proportion of iNKT cells. 
For those individuals who had a low number of iNKT cells (with a CD4 bias), 
their conventional T cell repertoire is also CD4 biased (as is seen in most normal 
individuals).  We  wished  to  explore  this  intriguing  finding  further  to  assess 
whether those with low iNKT numbers had a smaller pool of V 24 or V 11 T 
cells to recruit from. 
 
 
    
 
3.3.4 Immunophenotyping TCR V 24 and V 11 bearing conventional T and 
iNKT cells 
 
Due to the wide variation in the number of iNKT cells in normal individuals we 
further  analyzed  the  T  cells  that  expressed  the  individual  V 24  and  V 11 
receptors (Figure 3.10).  
 
Figure 3.10 The total numbers of V 24 and V 11 in the control population 
 
The  results  showed  that  the  total  number  of  V 24  and  V 11  T  cells  varied 
considerably (range 417 to 1695 for V 11 and 234 to 1867 for V 24 per 100,000 
T cells) in healthy individuals. The total number of T cells expressing V 11 was 
greater than that for V 24. Importantly, the mean number of V 24 cells was no 
different in those individuals with low NKT cells compared to most of those with 





Figure 3.11 Relationship between the total number of V 24 and invariant 
NKT cells 
To further examine the relationship between iNKT enumeration and the total 
number of V 24 and V 11 T cells we looked for a correlation between the two. 
     
 
 Figure 3.12 Relationship between the total number of V 11 and invariant 
NKT cells 
             
  
    
    
    
    
     
     
     
     
     
     
                                        
             
  
    
    
    
    
     
     
     
     
     
     
                                        














































Number of iNKT cells    
 
No significant correlations were found between the number of iNKT cells with 
the total number of V 24 and V 11 T cells (Figure 3-11 and 3-12). This suggests 
that the number of V 24 or V 11 cells cannot be used to predict the total number 
of iNKT cells.  
Since the number of iNKT cells did not directly correlate with the number of 
V 24 and V 11 T cells, we examined the percentage usage of these distinct TCR 
families in the iNKT cells of the controls (Table 3.1). 
 
Sample  Total  iNKT 
cells  per 
100,000  T 
cells 
Total  V 24 
per  100,000 
T cells 
Percentage 
of  total 
V 24  in 
iNKT cells 
Total 
V 11  per 
100000  T 
cells 
Percentag
e  of  total 
V 11  in 
iNKT 
cells 
Control1  163  234  69.7  601  27.1 
Control2  19  249  7.6  706  2.7 
Control3  1  257  0.39  561  0.2 
Control4  198  275  72  463  42.8 
Control5  161  313  51.4  707  22.8 
Control6  22  316  7.0  960  2.3 
Control7  123  376  32.7  673  18.3 
Control8  53  398  13.3  710  7.5 
Control9  1  182  0.55  999  0.1 
Control10  245  445  55.1  765  32 
Control11  19  188  10.1  324  5.9    
 
Control12  345  660  52.3  790  43.7 
Control13  646  937  68.9  1444  44.7 
Control14  35  975  3.6  291  12 
Control15  39  1809  2.2  472  8.3 
Control16  45  614  7.3  556  8.1 
Control17  23  423  5.4  733  3.1 
Control18  3  351  0.9  675  0.4 
Control19  476  660  72.1  1255  37.9 
Control20  37  447  8.3  968  3.8 
Control21  192  471  40.8  587  32.7 
Control22  275  774  35.5  975  28.2 
Control23  99  445  22.2  721  13.7 
Control24  25  341  7.33  568  4.4 
Control25  659  975  67.6  1132  58.2 
Control26  221  630  35.1  1326  16.7 
Control27  44  409  10.8  567  7.8 
Control28  128  362  35.4  774  16.5 
Control29  406  1003  40.5  1281  31.7 
Control30  213  349  61  417  51.1 
Control31  283  425  66.6  1543  18.3 
Control32  43  366  11.7  519  8.3    
 
Control33  4  577  0.7  963  0.4 
Control34  57  391  14.6  442  12.9 
Control35  7  389  1.8  509  1.4 
Control36  106  897  11.8  761  13.9 
Control37  4  423  1.0  619  0.7 
Control38  87  415  20.9  697  12.5 
Control39  669  784  85.3  1139  58.7 
Control40  692  862  80.3  1247  55.5 
Control41  1329  1431  92.9  1531  86.8 
Control42  1110  1417  78.3  1695  65.5 
Control43  379  631  60.1  813  46.6 
Control44  646  1200  53.8  1742  37.1 
Control45  235  789  29.8  1003  23.4 
Control46  89  602  14.8  697  12.8 
Control47  32  341  9.4  568  5.6 
 
Table 3.1 Enumeration of iNKT, V 24 and V 11 T cells in healthy control 
cohort 
 
It  was  observed  that  most  of  the  samples  (13/17)  with  >200  iNKT  cells  per 
100,000 T cells incorporated more than 50% of their total V 24 chain usage 
within the NKT cells in peripheral blood (four exceptions had a percentage of 
around 30-40%). For some of these individuals over 90% of V 24 T cells were    
 
iNKT cells. In agreement with this, those individuals who were found to have 
low iNKT cells (<200 per 100,000 T cells) had less than 25% of their total V 24 
usage within the iNKT cells.  
The percentage of total V 11 usage in iNKT cells was different to that seen with 
V 24. These percentages fluctuated from person to person (0.1-80%), but could 
still be broadly divided. In those with >200 iNKT cells per 100,000, only 6/17 
had more than 50% of their total V 11 chain usage within iNKT cells. Those 
individuals with low iNKT cells (<100 per 100,000 T cells) had less than 15% of 
their  total  V 11  usage  within  in  iNKT  cells.    This  suggested  that  the  V 24 
restriction element for iNKT selection was more important for iNKT selection 
choices.  
Further evaluations of the immunophenotype of V 24 and V 11 T cells were 
undertaken. The V 24 and V 11 T cells were divided into CD4
+ and non-CD4
+ 
subsets to observe their relationship to the total number of iNKT cells.  
Interestingly,  a  striking  positive  correlation  was  identified  between  the  total 
numbers  of  non  CD4
+ V  24  positive  T  cells  and  iNKT  cells  within  each 
individual (Figure 3.13b). This association was unique to the non CD4
+ V 24 
positive T cells and not shared with CD4
+ V 24 positive T cells, non CD4
+ V 11 
positive T cells or CD4
+ V 11 positive T cells (Figure 3.12a). This implied that 
both the V 24 receptor and CD4 co receptor were influential in determining the 
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Figure 3.13 (A) Relationship of CD4
+ V 24 positive T cells, non CD4 V 11 
positive T cells or CD4
+ V 11 positive T cells with iNKT cell number (B) 
Relationship of non CD4 V 24 T cells and number of iNKT cells 
 
In most of the samples with a count of >100 iNKT cells, the V 24 expression 
tended  to  favor  non-CD4
+  rather  than  CD4
+  cells  (i.e.  the  V 24  T  cells  are 
typically double negative iNKT). In agreement with this, in those samples with 
<100  iNKT  cells  count;  the  immunophenotype  of  V 24  favoured  CD4
+ 
expression. From Figure 3.13, we can extrapolate that the total number of iNKT 
cells increases as the total number of non CD4
+ V 24 increases and that the low 
NKT individuals can be predicted from the CD4
+/non CD4
+ ratio within their 
polyclonal V 24 positive T cells. A ratio of CD4
+/non CD4
+ V 24 T cells >2 
distinguishes all low NKT individuals from those with >100 NKT per 100,000 T 
cells in peripheral blood. 
It therefore appears that majority of healthy individuals (63%) have <200 iNKT 
per 100,000 T cells and that this co associates with such individuals having a 
B    
 
CD4 to CD8 ratio of ~2.5 across their conventional T cell populations. Their 
V 24  subsets  are  composed  of  a  polyclonal  V x  repertoire  that  are 
predominantly CD4
+ whilst their iNKT cells make up approximately 25% of the 
subset  and  are  themselves  CD4  biased.  For  those  with  high  iNKT  numbers, 
typically>500 per 100,000, this situation is reversed with a CD4 to CD8 ratio of 
<1.5 across their T cell populations, iNKT cells accounting for over 85% of 
V 24 T cells with a non CD4
+ bias. Given this tight association between number 
and  phenotype,  and  previous  linkage  to  functional  outcomes,  we  further 
evaluated our population for inherent programming of function. 
 
3.3.5 Functional differences in healthy individuals 
 
We began our functional assessment by first revisiting the phenotyping of our 
cohort with an antibody that was clonotypic for the invariant V 24 J 18 region. 
We wondered whether the TCR profile of high donors was distinctive from that 
of the low donors and whether this was influential in shaping the co receptor 





Figure 3-14(a) Analysis of 6B11 expression by FACS. The 6B11 antibody 
was used in combination with V 24 and V 11 antibodies.  (b) Analysis of 
6B11 expression on 9 low donors and 5 high donors 
This  examination  suggested  that  another  feature  of  iNKT  cells  that  was 
distinctive between low and high donors may operate at the T cell receptor level. 
The different MFI of the clonotypic antibody for the invariant TCR across the 2 









     
 
groups was suggestive of a differing average affinity of the TCR between the 2 
groups. This observation may be important for both their thymic selection and 
subsequent antigen responsiveness and function. 
 
To investigate this further we first established whether there was a difference 
between  low  and  high  donors  in  their  capacity  to  proliferate  and  sustain  an 
expansion following activation with  -GC.  We performed a 7-day proliferation 
assay using 10
6 PBMC and recorded the result as the fold change in number, per 
100,000 T cells compared to day 0 (Figure 3.15). 
 
Figure 3.15 Proliferation of iNKT cells in 7-day culture in low and medium-
high controls. The number of iNKT cell were enumerate pre-proliferation 
and enumerate again post-proliferation using flow cytometry. 
 
These experiments showed that both control groups mounted robust proliferative 
responses with comparable stimulation indices of 40-50 fold. 
In light of the previous descriptions of a cytokine bias associated with distinct 
iNKT  subpopulations  we  evaluated  the  cytokine  signatures  of  the  iNKT 
populations within our distinctive control group populations. Ex vivo cultured 
ELISpot assays were set up to measure the Th1, Th2 and Th17 representative 
cytokines released at day 7, following activation of 1 x10
6 PBMC with 100ng/ml     
 
of   -GC,  amongst  the  2  groups  of  healthy  individuals. The  evaluations  from 
three representatives high and low donors are shown below (Figure 3.16).  
 
 
Figure 3.16 Cultured ELISPOT in high and low donors. 4 x 10
5 cultured 
PBMC were taken to perform the ELISPOT, each pulsed with 1 x 10
5  -GC 
pulsed irradiated PBMC. 
 
In the high donor group, the majority of the cytokines produced by iNKT cells 
were IFN-  with no or little Th2 cytokines (i.e. IL-13). This marked Th1>Th2 
bias  in  the  high  donors  is  likely  a  representation  of  the  skewed  DN  iNKT 
populations present in such individuals In contrast, a significant level of Th2     
 
cytokine production was observed in the low donor group with a less marked 
Th1>Th2  skew.  However,  it  is  worth  noting  that  Th1  cytokine  is  still  the 
dominant cytokine produced in the low donor group, but is unclear as to which 
iNKT subpopulation is producing each cytokine in these individuals. Due to the 
different starting numbers of iNKT between these 2 groups no direct comparison 
of cytokine production per donor could be assessed. We therefore developed a 
sorting experiment to control for cell number entry and determine whether there 
were  inherent  differences  between  iNKT  cell  subpopulations  across  different 
control  donor  groups.  To  achieve  this  we  FACS  sorted 1000  cells  of  double 
negative  or  CD4
+  iNKT  cells  from  high  and  low  donors  following  a  7-day 
cultured  ELISpot  (Figure  3.17).  These  cells  were  then  co-cultured  with  10
5 
irradiated autologous PBMC pulsed with 100ng/ml of  -GalCer overnight prior 
to determination of their cytokine production. 





Figure  3.17  1000  sorted  iNKT  cells  both  from  double  negative  and  CD4 
populations  of  high  and  low  donors  were  used  to  perform  the  cultured 
ELISPOT, pulsed with 10
5 PBMC with 100ng/ml  -GC.
  
 
From Figure 3.17 it can be seen that IFN-  production is comparable between 
CD4
+  and  non-CD4
+  iNKT  cells  in  both  low  and  high  donors  but  is 
approximately  4-5  fold  higher  from  iNKT  of  the  low  donors.  This  inherent 
behavior  of  the  iNKT  cells  from  the  low  donors  is  not  predicted  from  the     
 
proliferation studies. The Th2 type cytokine i.e. IL-13 is only released by the 
CD4+ iNKT cells, consistent with previous reports on cell lines. The production 
is surprisingly similar across the high and low donors although it should be noted 
that  some  high  donors  do  not  possess  a  CD4  iNKT  population  and  would 
therefore be deficient for this function. For IL-17, both donors and iNKT cell 
populations  produce  this  cytokine.  The  non-CD4  iNKT  cell  populations 
predominantly release IL-17 and it is interesting to note that the iNKT cells from 


























• INKT cells in humans are stable and have a distribution that can extend over 4 
logs, with all iNKT populations having a distinctively higher expression of V 24 
and lower expression of CD3 compared to conventional T cells 
• The CD4 and non CD4 co receptor phenotype of iNKT cells is associated with 
the  number  of  iNKT  cells  in  controls,  with  a  CD4  dominant  profile  in  low 
controls and a non CD4 dominant profile in high controls  
• The high and low status of iNKT controls is directly or indirectly related to the 
CD4/CD8 ratio in conventional T cells selection, such that low controls have a 
ratio of >2.5:1 and high controls ~1.5:1 (P< 0.0001). 
• The selection of iNKT cells is influenced by the use of CD4 by developing 
V 24 T cells such that where there is predominance of conventional V 24 CD4
+ 
T cells, few iNKT cells are present. Conversely as iNKT numbers increase the 
DN signature of these cells dominates the V 24 lineage with few conventional 
V 24 CD4
+ T cells present. 
• iNKT cells from high donors appear to have a different TCR signature to low 
donor iNKT cells (MFI intensity to a clonotypic (6B11) antibody).  
•Functional analyses of iNKT cells in all controls shows restriction of TH2 type 
cytokines to the CD4 subset, whilst IFN  is comparable across both CD4 and 
non-CD4 subsets and IL-17 is predominantly from the non-CD4 subset.  
•  Whilst  iNKT  cells  in  low  and  high  donors  have  comparable  proliferation 
profiles there appears to be a significant increase in IFN  and IL-17 production 




     
 
3.4 Discussion and conclusion 
 
Previous  studies  have  shown  that  the  number  of  iNKT  cells  differs  greatly 
between different individuals (122). However, little is known about what give 
rises to these variations. This study has shown that this variability is not just 
related to the overall usage of V 24 or V 11 but is predictable by the usage of 
CD4 in V 24 T cells. Furthermore a relationship exists between the number of 
iNKT cells and (i) the CD4: non CD4 ratio of invariant V 24V 11 NKT cells, 
(ii) the partitioning of cytokine function to these subsets across low and high 
donors and (iii) the CD4:CD8 ratio of all conventional T cells.  This complex 
arrangement is not easily explained and may relate to many factors that shape 
both the development of iNKT cells and conventional T cells both in the thymus 
and in the periphery.  
Within  the  TCR  instructive  model,  iNKT  cells  first  undergo  TCR  
rearrangement before TCR  (237). The expression of the invariant V 24V 11 
TCR and its commitment to the iNKT lineage is not determined until the DP 
stage.  The  potential  iNKT  cells  expressing  V 24  (and  V 11)  in  the  double 
positive stage may then react with the CD1d expressed by a double positive 
developing thymocyte within the thymic cortex (66). If the TCR binding is too 
strong, the pre-iNKT cells will die from negative selection. If the pre-iNKT cells 
do not bind to any CD1d on double positive thymocytes, they will then die from 
neglect. Only those that bind with a moderate affinity will survive and mature to 
become  an  iNKT c ell.    This  receptor  affinity  model  has  been  previously 
proposed to account for the final DN bias of NKT cells where it has been argued 
that  the  TCR  affinity  is  sufficient  for  positive  selection  whilst  co  receptor 
signaling leads to negative selection. Concurrent with this idea are the studies 
that  use  mouse  strains  that  ectopically  express  MHC  class  II  on  the  CD1d 
positive thymic cortex, leading to a suppression of iNKT cell development in 
these mice (229, 238, 239). 
Another interesting result in this project is that in those individuals with low 
iNKT cells, the immunophenotype of V 24 conventional T cells favoured CD4+     
 
expression.  How  might  this  fit  with  the  TCR  instructive  model?  As  V 24 
positive T cells are not absent in these individuals (instead associating with other 
V  chains and often utilizing the CD4 co-receptor), this suggests that classical T 
cell  selection  may  be  favoured  and  CD1d  selection  disfavoured  in  these 
individuals.  This could occur if most double positive cells with an expression of 
V 24 and V 11 die from negative selection upon CD1d and CD4 engagement, 
with residual V 24 T cells, perhaps with a lower affinity for CD1d and MHC 
class II, left for conventional T cell selection with a CD4 coreceptor bias. In 
recent years, many studies have been performed on V  spectratyping, but only 
very  few  studies  have  analysed  V   spectratyping.  A  study  of  TCR  
spectratyping showed that most of the expressed V 24 will predominantly be 
expressed  with  V 11,  and  that  the  dominant  phenotype  for  V 24  T  cells  is 
double negative(240). The results in my thesis show that this is not always the 
case. In fact, 29 out of 47 healthy individuals (61.7%) have shown predominance 
of  CD4  usage  in  total  V 24  T  cells,  most  often  in  low  iNKT  controls.  See 
appendix table 1. 
It is tempting to speculate that high iNKT controls, where CD4 dominance is not 
seen in iNKT cells, may preferentially bypass negative selection perhaps through 
utilization  of  a  different V  24:V 11  CDR  region  configuration  that  would 
normally  be  negatively  selected  in  low  controls  where  CD4  may  play  an 
additional role. Indeed the iNKT cells of low donors have a heterogeneous 6B11 
signature that may be consistent with a wider spectrum of invariant TCRs being 
representative  of  low  iNKT  donors  that  have  passed  through  strict  negative 
selection in the presence and absence of CD4.  
The  function  of  iNKT  cells  is  highly  related  to  their  phenotype  (163,  224). 
Previous  studies  have  shown  that  the  double  negative  subset  predominantly 
releases the Th1 type cytokine and the Th2 type cytokine is secreted by the CD4 
subset.  I  show  in  my  work  that  there  is  not  only  a  relationship  between  the 
subsets and cytokine release, but that this is influenced by the status of the donor 
for subset partitioning as well as a quantitative differences between such subsets 
across low and high control groups.  At a population level this results in high     
 
donors preferentially producing the Th1 type cytokines, whereas low donors are 
capable of producing both Th1 and Th2 cytokines. Finally we have established 
that  iNKT  cells  in  low  donors  are  more  responsive  for  cytokine  production 
compared  to  the  iNKT  cells  in  high  donors.  We  would  postulate  that  this 
functional attribute is linked to the selection process that distinguishes high and 
low  donors  at  the  multiple  levels  we  have  described.  Further  studies  should 
address the affinity of the invariant TCRs of low and high controls to establish 
whether any differences here may account for the quantitative and qualitative 
differences that we have identified in the control populations. 
 



























INKT cells are able to produce Th1, Th2 and Th17 types cytokines. They have 
been  recognized  as  one  of  the  most  important  cells  in  bridging  innate  and 
adaptive immunity (241).  The key to an effective immune response is often the 
initial cytokine milieu that can subsequently polarise a T cell response (242). The 
diverse  cytokines  produced  by  these  cells  make  them  the  ideal  candidate  to 
operate as important immunoregulatory cells.  
As  with  other  immune  cells,  we  postulated  that  iNKT  cells  were  highly 
influenced  by  their  local  environment,  in  particular,  the  types  of  antigen 
presenting cells and cytokines present. 
 
4.1.1 Invariant NKT cells and antigen presenting cells 
 
INKT cells respond to glycolipid bound CD1d presented by antigen presenting 
cells,  to  enable  activation  and  proliferation.  Studies  have  suggested  that  the 
effector  cytokines  produced  by  iNKT  cells  may  differ  according  to  the 
characteristics of the lipids and presentation pathways utilised. The loading of 
the prototypic ligand  -GC requires endocytosis by a lipid carrier protein, such 
as  ApoE,  entering  the  endosomes  for  subsequent  processing  (243).  The 
subsequent  processing  is  highly  dependent  on  the  pH  and  presence  of  lipid 
transferring proteins (244). Thus, glycolipids like  -GC will preferentially load 
to  phagocytic  CD1d  antigen  presenting  cells  such  as  dendritic  cells  and 
macrophages. In contrast, a  -GC analogue OCH, can be directly loaded on the 
cell surface leading to the preferential production of Th2 type cytokines (245).  
This glycolipid with a shortened acyl and sphingosine chain can be easily loaded 
on cell surface CD1d of non-phagocytic antigen presenting cells such as B cells 
(244).  A further notable difference between such phagocytic and non phagocytic     
 
CD1d positive antigen presenting cells is their own cytokine production and level 
of co-stimulatory molecules (244).  
The  dendritic  cell  has  been  recognized  as  one  of  the  most  potent  antigen 
presenting cells. Studies have shown that both human and mouse dendritic cells 
can efficiently present  -GC to iNKT in vitro and in vivo (213, 242, 246, 247).  
In vitro studies of human iNKT cells have shown that both immature and mature 
dendritic cells were able to induce proliferation and cytokine production of iNKT 
cells. These studies demonstrated that at a low effector:target cell ratio, mature 
dendritic cells induced greater proliferation and IFN-  production. No differences 
were  observed  between  monocytes,  immature  and  mature  dendritic  cells  at  a 
higher effector:target cell ratio (246).  However, a more recent study showed that 
the cytokine production by the iNKT cells is not always preferential to IFN-  
through  dendritic  cells.  The  study  by  Iwabuchi  et  al.  suggested  that  the  pre-
treatment of mature dendritic cells is as important as the antigen presenting cells 
themselves. They suggested when pre-treating dendritic cells with IL-4, a high 
level of IFN-  production was achieved by iNKT cells; in contrast, when pre-
treating dendritic cells with IFN- , a higher level of IL-4 was produced (242).  
A high level of CD1d is expressed on B cells, in particular marginal zone B cells 
(248).  A study by Batista et al. demonstrated how the B cell receptor could 
recognise  a  specific  CD1d  antigen  in  vitro.  They  identified  that  the  B  cell 
receptor binds to lipids with a very low affinity that is sufficient for receptor 
mediated endocytosis (249). They also suggested that after initial recognition by 
the B cell receptor, iNKT cells are required to further help B cell proliferation 
and specific antibody production (249). 
 
4.1.2 iNKT cells and cytokines 
 
Early  murine  studies  found  that  cytokines  were  extremely  important  for  the 
development  of  iNKT  cells,  several  important  cytokines/receptor  have  been     
 
identified  in  receptor  knockout  mice.  Table  4.1  gives  a  summary  of  the  key 
cytokines that influence the development of iNKT cells (250). 
 
 












IL-2R         Not known  Not known  Reduction 
IL-7 (252)  Reduction  Reduction  Reduction 
IL-15 (252, 253)  Normal  Normal  Reduction 
IL-15R   (252, 
254) 
Normal  Normal  Reduction 
IFN R (255)  Normal  Normal  Normal 
IL-12R  (256)  Not known  Not known  Normal 
IL-4R  (256)  Not known  Not known  Normal 
CD45 (257)  Not known  Not known  Reduction 
CD137 (258)  Not known  Not known  Reduction 
GMCSFR  (259)  Not known  Not known  Reduction 
Table 4.1 Summary of Cytokines effect on iNKT cells 
As shown above, most of the cytokines and their receptors do not affect the early 
development of iNKT cells. The only cytokine is known to significantly affect 
the early development of iNKT cells is IL-7. Most of the other cytokines have 
their  influence  in  later  stages  of  iNKT  development  and  maturation.  This 
maturation can be influenced both in the thymic and extrathymic compartments.      
 
To  date,  three  cytokines  have  been  found  to  play  an  important  role  in  the 
function  of  iNKT  cells  (260-262).    In  early  studies,  IL-7  was  the  cytokine 
thought to play a major role in iNKT cell proliferation and cytokine production, 
both in humans and mice (262). It was suggested that IL-7 drove a Th2 type 
biased  iNKT  cytokine  profile,  whereas  IL-12  would  drive  a  Th1  type  biased 
cytokine  production.    In  vitro  studies  have  also  found  there  is  significant 
















     
 
4.2 Aims of this study 
 
•  Investigate the effect of different APC’s on iNKT cell proliferation and 
cytokine production 
 
•  Investigate the effect of the cytokine milieu on iNKT cell proliferation 




















4.3.1. Cytokine and APC effects on iNKT cells of high and low donors 
 
Previous research has suggested that both cytokines and the nature of the antigen 
presenting cell can influence iNKT cell function. However, the combined effects 
of both antigen presenting cells and cytokines upon ex vivo polyclonal iNKT 
cells have not been systematically studied. In this component of my thesis, I have 
examined  this  aspect  by  systematically  depleting  various  CD1d  expressing 
antigen presenting cells including B cells, monocyte and myeloid dendritic cells. 
During  this  study,  plasmacytoid  dendritic  cells  were  not  examined  because 
previous studies have suggested the plasmacytoid dendritic cells have no CD1d 
expression on their cells surface (263). As discussed in the previous chapter, 
controls may be considered as low or high donors with distinctive characteristics. 
Therefore, we continue to divide the controls into two groups when investigating 
iNKT cell proliferation and cytokine production.  
As seen in Figure 4.1, the nature of the antigen presenting cell does have an 
influence on iNKT cell proliferation. For high donors there appears to be ‘APC 
redundancy’ as all depletions (mDC, B cells or monocytes) retain a proliferation 
index that is similar to the undepleted PBMC setting. In contrast the low donors 
(i.e. majority of healthy controls) show comparable levels of proliferation in the 
absence of B cells or mDC but are absolutely dependent upon monocytes for 
their activation.      
 
 
Figure 4.1. Proliferation of iNKT cells in high and low donors with selected 
antigen  presenting  cells.  The  antigen  presenting  cells  were  selectively 
depleted  and  cultured  with  iNKT  cells  for  seven  days.  The  proliferation 
index was calculated by comparing the number of iNKT cells pre and post 
culture. 
This approach was also extended to cytokine production by PBMC under the 
above conditions (Figure 4.2). These results support the proliferation studies with 
monocyte depleted cultures having no ability to support cytokine secretion from 
iNKT cells of low donors. The production of IFN- , IL-13 and IL17 was not that 
different across the other depletion settings in both high and low donors. 
 
 
A     
 
 
Figure 4.2. Cytokine responses of high and low donors following CD1d +ve 
subset depletion. (A) Cytokine analysis in high donor. (B) Cytokine analysis 
in low donor.  
 
To extend these observations the monocyte population was then returned to the 
monocyte  depleted  cultures,  and  the  proliferation  was  reassessed.  Figure  4.3 
shows that this restored the normal proliferation capacity. 
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As CD1d is highly expressed in most B cells, and was sufficient to support iNKT 
cell proliferation in high donors we artificially increased the input number of 
iNKT cells in the culture of the low donors to see if this restored responsiveness.  
Figure 4.4 shows that even when the iNKT cell numbers are artificially increased 
to that of a high donor they remain inactive in the presence of only B cells.  
 
 
Figure 4.4. iNKT proliferation in low donors following an increase in iNKT 
cell number input. The first bar represent no artificial increase in iNKT 
cells (230 cells in culture), second bar represents a ten fold and the last a 
100x increase of the normal number. 
 
Previous studies have suggested that IL-2, IL-7 and IL-15 are important for the 
proliferation of iNKT cells. IL-2 and IL-15 are believed to be more important for 
the  extrathymic  maturation  and  proliferation  of  iNKT  cells.  As  all  the 
proliferation  experiments  involve  the  addition  of  IL-2,  IL-15  was  chosen  for 
further examination as an influence on promoting INKT cell proliferation. 
Figure 4.5 shows the effect of IL-15 in both high and low iNKT controls with 
depletion  of  selected  antigen  presenting  cells.  No  significant  changes  were 
observed in comparison to Figure 4.1, suggesting that the simple production of 
IL15 from monocytes was not an explanation for the differences in reactivity 
between the low donor iNKT cells and the type of effective APC.     
 
Of additional note was that the provision of this cytokine did not particularly 
enhance the proliferation of iNKT cells in the controls with high or low iNKT 
cells.  
 
Figure 4.5. Proliferation of iNKT cells with IL-15 in high and low controls. 
 
4.3.2. Effect of cytokines on qualitative iNKT cell responses.  
 
Following on from the observation that IL-15, in the presence of IL-2, did neither 
promote iNKT proliferation of both donor groups or correct proliferation in the 
absence of monocytes we looked at the iNKT cytokine responses that might be 
influenced by these additional cytokines.  With the addition of IL-2, a small 
increase in total cytokine production was observed (Figure 4.6). IFN- , IL-17 
and  IL-13  showed  an  overall  increase  but  this  did  not  achieve  statistical 
significance. 





Figure 4.6 Influence of IL-2 on cytokine secretion of low and high donors.  
(A) Cytokine analysis in low donors. (B) Cytokine analysis in high donors. 
Representative of 4 selected donors. 
 
Following addition of IL-15 a notable difference occurred between the cultures 
of both high and low donors when PBMC where used as the APC (Figure 4.7). A 
reduction in IL-13 production by the iNKT cells was observed in high and low 
donor iNKT cell cultures in the presence of IL-15.  The sharp decrease of IL-13 
production was accompanied with an increase of IFN-  in both IL-15 cultures. 
No significant differences were observed in IL-17 production in both high and 
low donor iNKT cell controls. 
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Figure 4.7. Analysis of iNKT cytokine responses in the presence and absence 
of IL-15. (A) Cytokine analysis in low donors (B) Cytokine analysis in high 
donors. Representative of 4 selected donors. 
 
We further investigated this observation to assess whether the IL-15 effect was 
dose dependent (Figure 4.8). A titration series was undertaken on a low donor 
A 
B     
 
and a clear relationship was established between the amount of IL-15 and the 
degree of IL-13 reduction following antigen specific activation of iNKT cells. 
 
 
Figure 4.8. Effect of titrated exogenous IL-15 upon IL-13 production from 
iNKT cells. 
 
IL-15 is able to influence the qualitative response of iNKT cells towards a Th1 
profile but is unable to further increase IL-2 supported proliferation or B cell 
activation of iNKT cells from low donors. 
 
4.3.3. The effect of monocytes and IL-15 on the cytokine production of iNKT 
cells of high donors. 
 
As  described  previously,  monocytes  are  critical  for  the  proliferation  (and 
cytokine production) of iNKT cells from low donors, but were not indispensible 
for the proliferation of iNKT cells from high donors. To extend our evaluation of 
the influence of monocytes as APC’s upon iNKT cell functions, we evaluated     
 
cytokine responses in high iNKT donors in the presence and absence of these 
cells. We were also interested in how IL-15 influenced the cytokine skewing, 
reduced  IL-13,  of  iNKT  and  therefore  combined  cytokine  addition  and  cell 
depletion to see if the mechanism of these observations could be established. 
 
 
Figure 4.9. The effect of monocyte depletion and IL-15 addition on iNKT 
cells of high donors  
 
In association with Figure 4.7b it can be seen that a maximal IFN-  response is 
seen with PBMC and IL-15 (~1100/10
6 SFC), reducing slightly in the absence of 
IL-15 (~900 SFC).  The depletion of monocytes from PBMC (in the absence of 
IL-15),  whilst  not  influencing  the  previous  proliferation  studies,  effects  the 
cytokine  responsiveness,  reducing  the  IFN-   response  further  (650  SFC). 
Surprisingly  the  addition  of  IL-15  to  monocyte  depleted  PBMC  leads  to  the 
greatest reduction of IFN- , suggesting an inhibitory effect in the absence of 
monocytes.  For  IL-13  it  can  be  seen  that  the  previous  reduction  upon  IL-15 
addition (Figure 4.7b) is dependent upon the presence of monocytes as it is not 
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monocytes are not indispensible for supporting proliferation they are necessary 
for a maximal IFN-  response and IL-13 reduction in the presence of IL-15.  
It is known that the  -receptor for IL-15 (CD122) is common with that of the 
high affinity IL-2-R (CD25, CD122, CD132). IL-15 is distinctive in being able to 
mediate cis and trans presentation, and it is notable that the IL-15  -receptor is 
expressed  on  iNKT  cells.  The  alpha-receptor  is  unique  for  IL-15,  and  it  is 
expressed on certain antigen presenting cells. Thus, a further investigation was 
performed  to  establish  whether  IL-15  receptor     was  differentially  expressed 
between B cells and monocytes.  
 
 - IL-15R   42 KDa 
 - beta actin  
1  2  3  4 
 
 
Figure 4.10. Western blot of IL-15R-  expression on monocytes and B cells. 
Lane 1 monocyte with no IL-15, Lane 2 monocyte with IL-15, Lane 3 B cells 
with no IL-15, Lane 4 B cells with IL-15  
 
From the western blot (Figure 4.10), it can observed that B cells and monocytes 
with  no  addition  of  IL-15  show  no  or  very  low  levels  of  IL-15  Receptor    
expression. In contrast, following the addition of IL-15, an upregulation of IL-
15R   was  observed  in  monocytes  but  not  B  cells.  This  further  supports  the 
observation that the nature of the CD1d positive APC is crucial in shaping iNKT 
responses  and  suggests  that  the  results  shown  earlier  relate  to  an  important 
interaction between IL-15 acting on monocytes to shape the nature of the iNKT 
response.      
 
Finally the expression of the individual IL-15R subunits on iNKT cells were 
examined, to assess if they were both present and/or differentially distributed 
between the CD4 and DN subsets For CD132, the common   chain, both CD4 
and DN cells demonstrated similar levels of expression (Figure 4.11). Similarly 
the expression of the CD122 did not differ between the iNKT subsets (Figure 
4.12). 
 
Figure 4.11. CD132 expression on iNKT cell subsets 
Red represent CD132 negative control cells, blue represents CD4+ve iNKT 
cells and yellow represents DN iNKT cells.     
 
 
Figure 4.12 CD122 expression on iNKT cell subsets. 
Red represents CD122 negative control cells, blue represents CD4+ve iNKT 










     
 
4.3.4 Summary of antigen presenting cells and cytokine effect to iNKT  
 
• Monocytes and B cells are distinct APCs for iNKT responses  
•  Individuals  with  low  iNKT  cells  have  an  absolute  dependence  of  upon 
monocytes for supporting iNKT proliferation and cytokine production.  
 
• CD1d positive B cells are unable to support activation of iNKT cells from low 
donors 
 
•Individuals  with  high  iNKT  cells  have  APC  redundancy  in  supporting 
proliferation but require monocytes for maximal IFN-   responses 
• IL-15 can skew the cytokine diversity of iNKT responses towards a Th1 bias, 
through the reduction of IL-13. This effect is more notable in low iNKT donors 
where the Th2 cytokine producing CD4 subset is numerous. 
 
• The IL-15 mediated effects upon the CD4 positive iNKT cells are mediated 
through monocytes. 
 
• All iNKT cells express the   and   IL-15R subunits, whilst monocytes and not 
B cells express the IL-15R   subunit. This may allow IL-15 mediated signalling 




     
 
4.4 Discussion and conclusion 
 
During this study, we have identified that in low donors, monocytes are crucial 
for the proliferation of iNKT cells. In contrast, B cells and myeloid dendritic 
cells are redundant APC’s for supporting proliferative and cytokine responses.  
This  selective  APC  usage,  despite  CD1d  is  expressing  on  B  cells,  was  not 
expected.  
 
Surprisingly, the same effect was not seen on the iNKT cells of high donors. In 
this  setting,  depletion  of  any  one  subset  did  not  abrogate  iNKT  proliferative 
responses,  suggesting  that  for  this  function  all  3  APC  populations  mediate 
sufficient presentation.  However monocytes were shown to be important in the 
context of maximal Th1 cytokine production from iNKT cells and in permitting 
IL-15 induced cytokine skewing of IL-13. 
 
The interesting finding that IL-15 can diminish the Th2 type cytokine production 
in the presence of monocytes for all donors, implies a mechanism of shaping 
effector  iNKT  responses  along  the  lines  classically  described  for  signal  3 
(cytokine  influence  upon  Th1:Th2  outcome)  in  conventional  T  cells.  We 
carefully distinguished the effect of monocyte depletion from myeloid dendritic 
cell depletion, as it is known that CD14 is also weakly expressed on the myeloid 
dendritic cells (264). Previous studies have also shown that myeloid dendritic 
cells are key players in the iNKT cells response and can lead to a bias in cytokine 
production (203, 265). We therefore compared CD14 depletion with BDCA-1 
depletion (depletion of myeloid dendritic cells) to examine the effect of selective 
mDC depletion. The results suggested that depletion of myeloid dendritic cells 
leads to a minor effect and that the CD14 depletion was principally operating 
through monocytes.  
 
Unlike other cytokines such as IL-2 and IL-7, IL-15 can be presented in a cis and 
trans configuration (266). The trans-presentation is achieved by the high affinity 
of  IL-15  to  IL-15R   and  further  association  with  the  IL-15R   (CD122)  and     
 
common   chain (CD132) subunits on the effector cell (266). This is typically 
achieved through the binding of intracellular IL-15 to IL-15R  within an APC.  
We introduced exogenous IL-15 to our system and it was observed that it was 
able to stabilize the IL-15R  binding. A speculative model of exogenous IL-15 
activation of iNKT cells through trans-presentation is shown below.  
 Figure 4.13. A model of IL-15 presentation to iNKT cells 
A monocyte may express intracellular IL-15, IL-15R  or an IL-15:IL-15 R  
complex (Steps 1,2). Cis presentation may be facilitated by stabilisation of 
IL-15R  with exogenous IL15, followed by release of this complex (4). This 
soluble complex may then bind to an effector cell to activate the Jak/Stat 
pathway (5,6). Trans presentation may be undertaken if the cells expressing 
the  CD122  and  CD132  receptors  are  in  approximation  to  the  monocyte 
expressed IL-15R :IL-15.  In these scenarios the presentation of IL-15R  in 
the resident APC is critical for the trans (direct) or cis (indirect) activation. 
     
 
In  our  study,  we  showed  that  monocytes  but  not  B  cells  were  capable  of 
stabilizing the IL-15R  subunit following the addition of IL-15. We propose that 
for low and high iNKT donors monocytes utilise this mechanism to support the 
maximal proliferation and Th1 cytokine responses of effector iNKT cells.  For 
low donors this is critical for their particular iNKT repertoire and requires both 
monocytes (IL-15R  source) and IL-15 (exogenous or intracellular) to support 
their proliferation. Through an effect upon the CD4 subset of iNKT cells this can 
also  mediate  a  reduction  in  IL-13  production.  For  high  donors  there  is  no 
absolute  dependence  upon  the  monocyte-IL-15  pathway  as  other  cells  may 
substitute. However for maximal Th1 responses both monocytes and IL15 are 







































Upon activation, iNKT cells can secrete Th1, Th2 and Th17 cytokines and this 
property facilitates their importance in immune-regulation. Importantly, iNKT 
cells can efficiently produce IFN-  and promote anti-tumour responses in murine 
models. For example, some studies have shown that iNKT cells, under  -GC 
activation, can promote anti-tumour responses to melanoma. This anti-tumour 
response was mainly due to the enhanced production of IFN-  in such systems 
(267). At the same time, iNKT cells may produce Th2 type cytokines, such as 
IL-4 and IL-13 and promote regulatory responses. IL-13 secreted by iNKT cells 
was previously found to suppress tumour rejection (268). Therefore the balance 
between  Th1  and  Th2  iNKT  responses  for  tumour  control  may  be  critical. 
However  in  other  models  such  Th2  cytokine  secretion  may  be  useful  in 
autoimmunity as the secretion of IL-4 by iNKT cells can protect the NOD mouse 
from the development of Type I diabetes (269).  
How do iNKT cells select the types of cytokines to release? In the previous 
chapters, I have investigated the significance of antigen presenting cells as well 
as the conditional cytokines that influence the cytokines produced by iNKT cells. 
Other studies have focused on the affinity of the glycolipid to CD1d as a major 
contributing factor that influences the types of cytokine released. These studies 
have suggested that by altering the length or structure of the  -GC analogue, 
different cytokines may be selectively induced (270)(57, 59). This has been most 
readily seen in the OCH variant of   -GC where the acyl and sphingosine chains 




     
 
5.1.1  -GC modification 
 
                                          
Although   -GC  has  been  recognized  as  the  “prototypic”  ligand  for  CD1d 
binding, is  -GC optimal as a clinical translational therapeutic candidate? The 
cytokine production induced by  -GC is in a relative Th1 and Th2 equilibrium. A 
good therapeutic candidate for tumour activity would have a predominant Th1 
cytokine production; whilst, a good Th2 candidate ligand could show potential in 
an autoimmune disease setting.  
 
                                           
 
It has been increasingly recognized that there may be the potential for iNKT cell 
ligand  use  in  clinical  vaccination  strategies  as  adjuvants  or  as  standalone 
immunomodulators. Currently, most of the glycolipid modifications are based 
upon influencing the CD1d-ligand-iNKT cell interaction through reference to the 
crystal structure.  
 
From the crystal structure it is understood that the sphingosine chain of  -GC is 
bound to the F’ pocket in mouse/C’ pocket in human whereas the acyl chain is 
associated with the A’ pocket. The galactose head group of  -GC is not bound to 
the CD1d but emerges from the groove for recognition by the  -chain of the T 
cell receptor (109, 110, 177, 271, 272). Furthermore, the 3-hydroxy group on the 
sphingosine chain together with the O-glycosidic link further stabilises the lipid-
CD1d complex. The 3-hydroxy group on sphingosine chain has also been proven 
to  be  essential  for  mouse  iNKT  cell  recognition,  as  it  forms  an  important 
hydrogen bond with Asp80. In addition, the Thr154 position in mouse forms an 
additional hydrogen bond with the O-glycosidic link. The 2’-OH of the galactose 
head  is  also  crucial,  making  a  hydrogen  bond  with  the  Asp151  in  human  / 
Asp153 in mouse (109, 110, 177, 271, 272). The importance of this hydrogen     
 
bound network is to stabilise the galactosyl head for a productive CD1d-lipid-
iNKT cell interaction (7). 
 
                                          
In the therapeutic setting, many groups are actively searching for ideal analogues 
of  -GC to meet different objectives. The different approaches include changes 
to the length of the lipid as well as alterations to the saturation of the lipid (7). 
These different approaches have led to differential effects in terms of changing 
the stability, binding affinity as well as the cellular loading compartment of the 
complex (245, 270, 273, 274).  
 
One of the earliest approaches to  -GC modification was to shorten both the 
sphingosine and acyl chains. One such ligand was the  -GC truncated analogue 
OCH. The OCH analogue has a 2 carbon truncation on the acyl chain and 9 
carbon  truncation  on  the  sphingosine  chain  compared  to   -GC  (270).  The 
truncated  -GC, OCH was shown to release a high level of IL-4, with a marked 
reduction of IFN-  compared with  -GC. This finding suggested that by altering 
the length of  -GC, analogues could be designed to produce desired cytokine 
outcomes. Indeed, the crystal structure of  -GC bound with CD1d predicted that 
the carbon chains of  -GC might be the optimal length to stabilise the CD1d-
lipid  complex  (110).  Later  studies  comparing  the  binding  affinity  of  varying 
truncations  of   -GC  further  strengthened  these  predictions  (243).  Indeed, 
shortening the chain length of lipid binding to CD1d regardless of the either A’ 
or F’ pocket, increases the rate of lipid-CD1d dissociation, and suggests that the 
optimal length for CD1d-ligand binding is an 18 carbon length sphingosine chain 
and a 26 carbon length acyl chain (243). These studies showed that incomplete 
filling of the C’ pocket could lower the CD1d stability as well as the binding 
affinity of TCR to CD1d-lipid complex (243). 
 
Besides  the  length  of  lipid  chains,  the  structure  of  the  lipid  chains  can  also 
influence the binding to CD1d, and hence the cytokine release. In an experiment 
looking for selective anti-tumour responses by administering  -GC analogues     
 
with removal of the hydroxyl group to mice with melanoma, a greater degree of 
tumour  regression  compared  to   -GC  was  shown  (34).  Introduction  of  an 
aromatic group to the fatty acid chain of the  -GC also enhanced the stability of 
CD1d- lipid complex, and led to a selective Th1 type cytokine profile (275). A 
more  recent  study  showed  that  by  replacing  the  amide  group  with  a  triazole 
group, an enhanced Th2 type profile was seen. This suggested that by changing 
the amide moiety of  -GC, a different immune response could be obtained (276).  
Recently,  the  Cerundolo  group  has  introduced  a  new  group  of  iNKT-CD1d 
ligands.  This  group  of  lipids  do  not  have  a  glycosidic  link  between  the 
hydrophilic head and ceramide and one such compound, threitolceramide, had 
some interesting functional properties (7). This group showed that this synthetic 
compound activated iNKT cells efficiently, influencing other cells including DC 
maturation as well as T cell priming. The threitolceramide-CD1d complex had a 
relatively  lower  binding  affinity  compared  to  the   -GC-CD1d  complex.  The 
group  suggested  that  the  new  ligand  gave  the  particular  advantage  of  sub 
maximal activation through by passing target cell killing (i.e. APC), allowong 
continued NKT activation (277). 
                                        
 
As discussed above, studies in recent years have found that modification of the 
 -GC lipid chains could polarize the cytokine secretion of iNKT cells (176, 267). 
The translational implication of this being that it may be possible to alter  -GC to 
achieve the ideal cytokine response for the specific treatment of tumours and/or 
autoimmunity  (197).  Currently  4  approaches  have  been  adopted  in  the 
modification of  -GC: sphingosine core modification, fatty acid modification, 
amide modification and sugar modification (276). However, current data shows 
that the clinical effects of these analogues are moderate and the mode of action is 
not fully understood. 
 
Another criticism of existing analogue identification systems is that most of the 
functional  and  cytokine  release  data  are  analysed  in  a  murine  system.  Early     
 
studies suggested that mouse and human CD1d structures are highly conserved. 
Indeed, human iNKT TCR   and   chains show a high sequence homology to 
mouse  iNKT     and     chains  (278).  Furthermore,  human  iNKT  cells  can 
recognise  and  cross-react  with  mouse  CD1d-   -GC  complexes  with  similar 
affinity  and  vice  versa  for  mouse  iNKT  cells  (279).  However,  some  studies 
indicate  that  the  non-conserved  region  of  CD1d  can  lead  to  a  difference  of 
recognition  in  iNKT  cells.  A  recent  study  showed  that  a  modified  analogue 
preferable to Th2 type cytokine production showed a high Th2 type cytokine 
release in human, but failed to produce detectable amount of cytokines in murine 
systems. Not only did the analogue not lead to the cytokine production in mouse 
NKT cells, it also failed to be recognised by NKT cells within the CD1d complex 
(280). Studies have also identified important differences in the position of the 
galactose ring (281) which cause inter-species differences in antigenicity (282). 
Thus, the cytokine profile for a particular analogue in a mouse system is not 
necessary the same as the cytokine profile in humans. 
 
Furthermore,  current  analogues  that  promote  a  robust  Th1  cytokine  response 
often  result  in  maximal  activation  of  iNKT  cells.  However,  studies  have 
suggested that the maximum activation of iNKT cells might not be as useful in 
therapeutic  setting  as  the  overstimulation  of  iNKT  cells  can  cause  activation 
induced cell death, in particular of the antigen presenting cells (243, 277). It has 
also been shown that the uncontrolled activation of iNKT cells can lead to an 
anergic state of iNKT cells (283, 284).  Therefore engineered compounds that 
might  dissect  some  of  these  features  may  be  advantageous  over  exciting 
compound analogues. 
 
5.1.2 Proposed  -GC modification in this project 
 
Within this project, we have investigated alternative  -GC analogues, which may 
favour a Th1 immune response in humans. The modification of  -GC is based on 
current  understanding  of  the  stimulatory  model  for  cytokine  selectivity. 
Compared  to  other  modified   -GC  analogues,  the  approach  in  this  project     
 
involved modification of different side chains and domains including the polar 
domain, apolar chain and the galactose unit, which allows more opportunities to 
identify the ideal ligand for enhanced iNKT activity.  
Furthermore, we have additionally investigated the activation threshold of iNKT 
cells stimulated by these ligands through the use of the postulated anergy marker 
programme death-1 (PD-1). In naïve T cells, PD1 is express at a very low level. 
Upregulation of PD1 expression occurs when T cells activated by professional 
antigen presenting cells. PDL1 is the ligand for PD1, being expressed in B cells, 
monocytes, dendritic cells
1. The interaction of PD1 and PD-L1 has been found to 
an importantly role in the development of central and peripheral tolerance
2,  3. 
Recently, PD1 has been considered as an important therapeutic target for many 
diseases  including  cancer,  autoimmunity  and  transplant  rejection  where 
interference with tolerance is beneficial 
4. PD1 targeting cancer therapy has been 
the most promising with successful inhibition of metastasis in a myeloma mouse 
models 
5,  6. Currently, monoclonal antibodies specific to PD1 are undergoing 
phase I clinical trials in human in combination with cancer vaccine studies 
7.    
 It  was  first  suggested  in  2008  by  Kang  et  al.  that  PD1  is  essential  for  the 
instruction and persistence of anergy in iNKT cells (285).  PD1 is present at 
minimal  levels  on  iNKT  cells  pre-activation,  with  an  upregulation  upon 
activation. No down-regulation of PD1 was observed when there was persistence 
of anergy, but this could be reversed by addition of a PD1L antagonist (285) 
(286-288).   
 
                                  
 
From the crystal structure of CD1d, it was observed that the acyl chain fits the A’ 
pocket in an anticlockwise direction, whilst the sphingosine chain fits into the C’ 
pocket with a straighter conformation. As the most stable confirmation for the 
hydrocarbon  chain  is  an  antiperiplanar  structure,  which  has  an  angle  of  180 
degrees, this means that upon binding, the hydrocarbon chain is forced to adopt a 
less stable conformation. As seen in the CD1d-  -GC crystal structure, there are     
 
many “bends” observed when the two hydrocarbon chains are accommodated 
into the CD1d cavities. In discussion with our collaborators at the Department of 
Chemistry, University of Southampton (Dr Bruno Linclau) it was observed that 
some of these bends are close to a gauche conformation (60 degree dihedral 
angle). Gauche conformations are less stable than anti conformations because of 
steric repulsion. In collaboration with our chemists a series of modifications were 
devised that could stabilise the gauche conformation, hypothetically leading to a 
positive impact in the binding affinity. 
 
Previous studies demonstrated that the gauche confirmation could be stabilised 
by  CF2,  S  and  anti-vicinal  difluoride  modifications  (289).  This  led  to  the 
synthesis of 32A (Figure 5.1).  
 
The  second  type  of  analogues  studied  contains  modifications  that  alter  the 
hydrogen bonding between the GalCer and CD1d (and the TCR). The amide 
group was modified in compound 31B, whilst in 43B the sphingosine group was 
modified. Compound 44B is a hybrid of 31B and 43B (subsequently referred to 
as 31, 32, 43 and 44). 
 
Figure 5.1 Structure of glycolipid analogues with acyl and sphingosine chain 
modifications 
     
 
A second collaborative chemist (Dr Serge Van Calenbergh) at the University of 
Ghent, Belgium also designed a series of analogues principally based upon the 
galactose head. Few studies had focused on this group at the start of project, as it 
was  not  directly  involved  in  CD1d-lipid  binding.  In  contrast,  this  group  is 
important for the interaction with the iNKT cell TCR. This group of modified 
compounds (Table 5.1) was also profiled to compare iNKT responses that are 
















     
 
5.2 Aims of this study 
 
•  To analyse the functional impact of the different analogues upon ex vivo 
and cultured human iNKT cells and derivative clones. 
 
•  Study  the  effect  of  the  modified  ligands  in  heterogeneous  human 
population  samples,  at  the  level  of  proliferation,  cytokine  production, 
activation and anergy compared to the prototypic Th1 and Th2 ligands  -
GC and OCH respectively.  
 
•  Compare the functional differences between human and mouse studies 













     
 
5.3 Compound evaluation results 
 
To  analyse  the  effects  of  different  analogues  upon  iNKT  cells,  several 
parameters  were  evaluated.  Studies  of  iNKT  cells  included  proliferation 
comparisons for each analogue as well as the ability of analogues to produce 
cytokines as assessed by ELISPOT, intracellular cytokine analysis and multiplex 
approaches. Furthermore, the killing ability of the analogues was also analysed. 
 
Table 1 summarises the structural modification of analogues used in this chapter: 
 
 
a)  University  of  Southampton  modification  modification  (Dr  Bruno 
Linclau): 
 






























































































Table 5.1 – Summary of modified ligands used during this study 
Those principally modified for CD1d binding from University of Southampton (A) and mainly iNKT 
TCR interaction from University of Ghent (B) are shown.  
 
5.3.1. iNKT proliferation with analogues 
 
The target ‘ideal’ analogue was initially defined as that which could increase 
IFN-  and be able to expand iNKT cells compared to  -GC. Figure 5.2 shows the 
proliferation  profile  of  some  of  the  analogues,  including  the  two  prototypic 
analogues  ( -GC  and  OCH)  compared  with  those  possessing  acyl  and 
sphingosine chain modifications. 
     
 
 
Figure 5.2. Proliferation profile pre and post activation with  -GC, OCH 
and acyl/sphingosine chain analogues. 
 
Figure  5.2  shows  that  the  inducible  proliferation  of  iNKT  cells  with  the 
compounds 43 and 44 is reduced compared to the proliferation potential from the 
acyl chain modified compounds. As introduced from the previous chapter, we 
asked  if  the  ligands  act  differentially  upon  the  iNKT  cells  of  high  and  low 
control groups.  
 
Figure 5.3 shows that the proliferation of iNKT cells in a selection of high donor 
(>500 iNKT cells per 10
5T cells) and low donors (<100 iNKT cells per 10
5T 
cells).     
 
 
Figure 5.3 Proliferation of iNKT cells in different donors (left: low donor, 
right:  high  donor)  with  different  analogues.  Pre  proliferation  number 
compared to post proliferation number.  
 
Surprisingly, compounds 43 and 44 were able to induce proliferation in the high 
donors but not the low donors, suggesting that the analogue displayed specificity 
between these two groups of healthy controls. This suggested that the ligands 
were able to bind to CD1d but that this was insufficient to activate the iNKT cell 
repertoire of low donors. Due to the predominance of low donors amongst the 
population we undertook most of our subsequent experiments on low donors to 
allow the results to represent a homogeneous population.  However it should be 
noted that the differences in initial iNKT portfolio may impact upon such ligand 
screening activities, as suggested by the data in Figure 5.2. 
 
The  analogues  were  subsequently  grouped  according  to  their  closely  related 
structure for further comparison to  -GC and OCH. The groups included; (i) 
alterations in the interaction with CD1d (Acyl chain modification (31 and 32), 
Sphingosine  modification  (43  and  44));  (2)  alterations  predominantly  in  C3 
position  (315  and  322);  galacosyl  head  alterations  with  amine  or  urea 
substitutions. The proliferation responses for the complete set of analogues is 
shown in Figure 5.4, each run with  -GC (gold standard for strong ligand) and 






























































































Figure  5.4  Proliferation  index  of  Acyl,  Sphingosine  and  6’  Galactose 
modified compounds. The compounds 422, 430, 432 and 434 are all amide 
substitution (next to  -GC) whilst 424, 440, 432 and 442 are urea modified 
(next to OCH). 
 
No  significant  differences  were  found  between  the  acyl  chain  modified 
compounds and  -GC. In contrast, mark reductions of iNKT cell proliferation 
were observed with the sphingosine modifications, falling below that seen with 
OCH. Interestingly the compounds 422 and 424, which had an amide (422) or 
urea (424) substitution at the C’6 position, showed contrasting results with the 
422 showing the greatest proliferation ability of all ligands tested.  For most of 
the  other  ligands  tested  the  amide  modification  had  a  comparatively  higher 
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5.3.2 Cytokine production by iNKT cells following analogue activation 
 
To  extend  the  study  of  the  different  analogues  on  iNKT  cell  function,  we 
analysed the cytokine production from iNKTs following a 7 day expansion and 
overnight activation. We analysed IFN- , IL-13 and IL-17 production from a 
minimum of 4 healthy controls for each analogue. 
Figure  5.5  shows  that  analogue  31  has  a  similar  IFN-   and  IL-13  profile 
compared to  -GC. Whilst unremarkable in the proliferation assays, compound 
32 shows a distinctive cytokine profile to both  -GC and OCH with an increased 
IL-13 signature. Interestingly, both analogues showed good IL-17 productivity 
compared to the two prototypic analogues, with a three-fold increase in IL-17. 
 
Figure  5.5.  Cytokine  production  by  acyl  chain  modified  compounds 
ELISPOT of IFN-gamma, IL-13 and IL-17 cytokine production by PBMC 
with specific ligand. 
 
Figure  5.6  is  the  multi-cytokine  profile  of  the  sphingosine  chain  modified 
compounds. When it is remembered that both analogues, 43 and 44, showed a 
very poor proliferation response, the excellent cytokine production observed is 
all the more unexpected. Both analogues were able to increase the Th1, Th2 and 
Th17 cytokines compared to their respective gold standard.  This suggests that 
these  ligands  can  bind  to  CD1d  but  are  able  to  dissociate  proliferation  from 
cytokine responsiveness when activating iNKT cells of low donors.     
 
 
Figure 5.6. Cytokine production by sphingosine chain modified compounds. 
ELISPOT of IFN-gamma, IL-13 and IL-17 cytokine production by PBMC 
with specific ligand. 
 





     
 
 
Figure 5.7 Cytokine production by TCR modification analogues. ELISPOT 
of IFN-gamma, IL-13 and IL-17 cytokine production by PBMC with specific 
ligand. 
 
It is first interesting to note that the compounds that gave a poor proliferative 
response, 434,442 and 323, were all able to support cytokine secretion that was 
similar to the prototypic ligands. Indeed despite the wide array of substitutions in 
the  galactosyl  head  it  is  clear  that  all  still  permit  a  productive  iNKT  TCR 
interaction  at  the  level  of  cytokine  production.  When  all  the  compounds  are 
reviewed, most are similar to  -GC apart from 424 and 430, which demonstrate a 
significant increase in IL-17 production. 
Most modifications did not extensively alter the IFN-  production by iNKT cells. 
Surprisingly,  the  sphingosine  modifications  (43  and  44)  enhanced  IFN-  
production despite showing poor proliferative capacity. Besides the ligands 43 
and  44,  compound  430  was  the  only  other  modified  compound  that  also 
significantly increased IFN-  production. 
One  compound,  32,  showed  a  comparable  IFN-   production  to  OCH  and  an 
enhanced IL-13 response. This might suggest that this is an enhanced compound 
for  Th2  type  responses  that  have  been  proposed  to  be  potentially  useful  in 
autoimmune settings.  
Interestingly, most of the compounds were shown to be good IL-17 producers 
compared  to  the  prototypic  ligands.  Only  one  compound  was  found  to  have 
lower  IL-17  compared  to   -GC,  analogue  438.  The  greatest  IL-17  producing 
compounds were found in acyl and sphingosine modified compounds, as well as 
ligands 424 and 440.     
 
In terms of IL-13 production, most of the analogues have a very similar pattern 
compare to  -GC, and produce a much lower level of IL-13 compared to the Th2 
gold standard ligand OCH. Three compounds showed a comparable level of IL-
13 production compared to OCH, compound 32, mentioned previously, together 
with 43 and 44. A summary of these results in seen in Table 5.2.  
 
A) 
  Proliferation  IFN-    IL-13  IL-17  Comment 
31  ++  ++  +  +++  Similar  to   -
GC,  with  an 
increased  IL-
17 production 
32  ++  +  ++  +++  Similar  to 
OCH,  with  an 
increased  IL-
17 production 
43  +  +++  ++  +++  Poor 
proliferator, 
good all round 
cytokine 
producer 
44  +  ++  ++  +++  Poor 
proliferator 
and  all  round 
cytokine 
producer 
 -GC  ++  ++  +  ++  Gold  standard 
Th1 ligand 
OCH  +  +  ++  ++  Gold  standard 
Th2 ligand     
 
Comment  No  high 
proliferator 
    Minimum 
two  fold 
increase  in 
IL-17 
production 
by  new 
ligands 





















Increase  in 
Proliferation 
424-




















































































to   -GC 
323- 
Similar to   
-GC,  but 
with 
reduced 
proliferation      
 
Similar to   





Comment  No  ligand 
increase 
proliferation 
No  ligand 
reduces 
IFN-  
No  ligand 
enhances  
IL-13 
Maximum  4 
fold  increase  
in IL-17 
 
Table 5.2 – Summary of ligands modified for CD1d binding (A) and predominantly TCR interaction 
(B)  
Although the ELISPOT analysis gave a good indication of the cytokine profile 
for each analogue, it did not indicate which cytokines were directly produced by 
iNKT  cells  or  whether  the  same  cell  could  produce  combinations  of  these 
cytokines.  To  accomplish  this,  a  further  analysis  was  carried  out  utilising 
intracellular analysis. This analysis gives the results for the cytokines released 
specifically by the iNKT cells as well as identifying single/multiple cytokine 
producing iNKT cells subsets. Figure 5.8 demonstrates the approach taken to this 
using the clonotypic antibody to identify the iNKT cells post activation followed 
by triple staining for IL-4, IL-17 and IFN-  . This clearly shows that iNKT cells 
gated in the first plot are able to produce the various cytokines, and that they 









Figure 5.8. FACS analysis of intracellular IL-17, IL-4 and IFN-  production 
in iNKT cells post analogue activation. The upper panel shows the cytokine 
production  by  total  T  cells,  and  the  lower  panel  shows  the  cytokine 
production  by iNKT cells. 
 
Utilising  this  set  of  data  we  derived  the  ratio  of  Th1/Th2  (Figure  5.9)  and 
Th1/Th17 (Figure 5.10) responses that were specific to the activated iNKT cells.  
 
     
 
 
Figure 5.9 Th1/Th2 ratio for intracellular cytokines for all analogues 
 
 
Figure 5.10 Th1/Th17 ratio for intracellular cytokines for all analogues.   
     
 
Comparing  the  IFN-     and  IL-4  production  by  the  iNKT  cells,  it  is  easily 
observed  that  at  least  10  compounds  achieve  a  similar  or  improved  IFN-    
production comparing to  -GC. Only three compounds showed an IL-4>IFN-   
profile, suggesting that most compounds are directed to Th1 bias from iNKT 
cells. 
 
The IFN-   /IL-17 ratio gave a more dynamic distribution. Roughly, around half 
of the compounds showed an IFN-   > IL-17 profile; and the other half showed 
the reverse ratio but with a smaller effect.  
 
We then extended these analyses to identify whether individual iNKT cells were 
able  to  produce  single/double  or  multiple  cytokines  utilising  Boolean  gating. 
This is based on the choosing a defined population and using a combination of 
commands including “and”, “or” and “not” to define the respective populations. 
Figure 5.11 displays this data for each analogue illustrating the percentage of 








Figure  5.11  Boolean  gating  analysis  of  iNKT  intracellular  cytokine 
responses following analogue activation. 
 
From the intracellular cytokine analysis, it can be easily seen that most of the 
iNKT cells (more than half of the iNKT population) are activated by most of the 
ligands. The acyl and sphingosine analogues were comparable to  -GC in both 
the proportion of activated cells and the relative distribution of cells producing 
single  or  combined  cytokines.  The  second  group  of  compounds  were  more 
variable in their responses. Analogues 432 and 442 were notable for having a 
substantially  reduced  or  increased  cytokine  signature  compared  to   -GC. 
Compound 442 was also distinctive in that a larger percentage of cells were 
producing 2 cytokines, predominantly IFN-   and IL-17 when looked at in detail. 
This  was  consistent  with  the  ELISPOT  results  summarised  in  Table  5.2.    It 
should be noted that the intracellular analysis was done after a seven day culture, 
and  the  potential  of  some  ligands  to  induce  anergy  is  a  potential  variable  in 
evaluation of this dataset.  
 
Finally,  we  analysed  the  cytokines  with  multiplex  analysis.  Compared  to 
ELISPOT and intracellular analyses, the multiplex analysis was undertaken after 
an 18 hours activation of ex vivo cells, compared to the other two approaches 
which are undertaken after a seven days culture. The 18 hour ex vivo multiplex     
 
assay was only undertaken with the acyl chain and sphingosine chain modified 
compounds. 
  
We initially undertook the assay to select the optimal time for the measurement 
of our key effector Th1/Th2 cytokines. These preliminary studies over 2, 4, 6 and 
16 hours established that the cytokines could be defined into 2 different groups. 
Cytokines primarily produced by iNKT cells (including IFN- , IL-2, IL-4, IL-10 
and TNF- ) which were maximal at 6 hours and cytokines that may be produced 
by other cell types (including IL-5, IL-6, IL-8, IL-1ß and IL-12) which were 
maximal at 16 hours. Figure 12 summaries these multiplex cytokine results. 
 




Figure  5.12  Acyl  chain  and  sphingosine  chain  modified  compounds  for 
multi-cytokine analysis after short term culture. 
From  the  multiplex  cytokine  analysis,  all  the  four  analogues  produced 
comparable levels of IFN-  . Compound 31 showed a higher IL-4 and IL-2 level 
compared the other ligands at 6 hours. No IL-4 was detected from compounds 43 
and 44 at this early time point, in contrast to that seen after a cultured ELISPOT. 
In terms of the breadth of cytokines produced, compound 32 showed the broadest 
range. This led to high levels of IL-6, IL-8, IL-1b and IL-12 production at the 16 
hour time point as well as IFN- , IL-2, IL-4 and TNF-  at 6 hours.      
 
 
5.3.3 Ligands and iNKT cells – Anergy or not? 
 
From the previous extensive cytokine study, it is suggested that some of the 
iNKT cells do not produce cytokines. This may be due to a variety of reasons 
including  factors  relating  to  CD1d  binding,  TCR  activation  or  possibly  the 
effects of the previous 7 day culture and the induction of anergy in the expanded 
iNKT  cells.  Figure  5.13  shows  the  percentage  of  unresponsive  cells  after 




Figure 5.13 Percentage of unresponsive iNKT cells for cytokine production 
after seven days culture. 
 
As discussed previously, PD1 is thought to be a marker of iNKT cells that have 
undergone activation induced anergy. We investigated the PD1 expression on 
iNKT cells after 7 days culture for each of the ligands to establish if this was 
related  to  their  subsequent  cytokine  responsiveness.  Figure  5.14  is  a 
representative  example  of  the  difference  between  PD-1  expression  following 







Figure  5.14.Representative  PD1  expression  of  iNKT  cells  after  7  days 
culture with  -GC or 442 
 
The PD1 expression of iNKT cells after 7 days culture was quantified using the 
mean flourcense intensity of PD1 for the whole iNKT cell population. Figure 
5.15 shows the different PD1 MFI of the iNKT cells follwing ligands activation. 
 
 




Figure 5.15 Analysis of PD1 expression in all analogues after seven days 
culture. 
 
The trend for the percentage of unresponsive cells and higher PD1 expressors is 
generally in keeping with the 7 day culture experiments, especially for those 
ligands  at  the  extreme  end.  Analogue  442  which  had  the  lowest  number  of 
unresponsive iNKT cells (18%) showed the lowest expression of PD1. Likewise, 
analogue 432 with the highest number of unresponsive iNKT cells (81%) showed 
the highest expression level of PD1. These results suggest that the analogues may 
also differ in the manner in which they induce anergy and that this must also be 
considered  in  the  interpretation  of  functional  data  and  the  design  of  optimal 







     
 
5.3.4 Summary of ligand properties 
 
The complete functional data of proliferation, cultured Th1/Th2 ELISPOT and 
intracellular cytokine activation is shown in Table 5.3 below. 






GC  1  1  1  38 
OCH  <50%  <1  ND  ND 
31     1  1.49  55 
32     1  1.24  54 
43  <25%  +  3.88  50 
44  <25%  +  0.5  48 
315     1  3.07  31 
323  <25%  1  1.28  22 
422     +  0.75  70 
424     +  1.82  30 
430     +  0.71  57 
440     +  1.91  30 
432     +  3.19  19 
438     1  1.59  64 
434  <25%  1  5.47  54 
442  <25%  1  14.79  82 
Table  5.3  –  Summary  of  modified  iNKT  ligands  for  proliferation,  activation  and  Th1/Th2 
responses.  = similar or higher proliferation index compared to  -GC, + = higher Th1/Th2 cytokine 
production  in  ELISPOT  assay.  Those  ligands  with  an  equal  or  greater  response  to   -GC  are 
highlighted in gold.      
 
5.4 Discussion and conclusion 
 
Several  compounds  including  43,  424,  440  and  432  seemed  to  have  a 
reproducible  difference  in  Th1  responsiveness  compared  to   -GC,  in  both 
ELISPOT and intracellular cytokine assays. Compound 442 showed the highest 
Th1/Th2 ratio through intracellular responsiveness, but only an average Th1/Th2 
ratio by ELISPOT. These differences may relate to the technical approaches used 
as the amount of cytokine produced may fall above or below the sensitivity of 
the assay employed i.e. many cells producing a small amount of cytokine may 
not form a discernable spot. The two compounds (31 and 32) with acyl chain 
modifications  showed  very  similar  activities  compared  to   -GC  in  terms  of 
proliferation. By ELISPOT analysis compound 32 displayed a Th2 bias which 
was similar to that observed in previous mouse experiments (290). Additional in 
vivo murine studies, though our collaborators at the University of Ghent, have 
also  revealed  that  some  of  the  6’  -derived  galactose  modified  compounds, 
including 430 and 424, have a Th1 biased cytokine profile (291-293). This was 
also  the  case  for  analogue  43  in  the  murine  in  vivo  systems  (33).  These 
comparative  assessments  highlight  the  need  to  have  testing  systems  that  can 
correlate animal studies across to man, even when using relatively conserved 
immune systems such as CD1d and iNKT cells. 
 
The  potential  of  iNKT  cells  to  become  anergised  by  overstimulation  is  an 
important area that may limit the potential current ligands to become therapeutic 
options. We have addressed this as part of our screening programme to assess the 
differential  ligand  effects  upon  both  the  percentage  of  activated,  cytokine 
producing  cells  and  the  expression  of  PD1  after  7  days  of  activation 
prestimulation  to  restimulation.   -GC  which  has  been  described  as  inducing 
anergy through its potent activation activated 48% of cells and had a mean PD-1 
MFI of ~1200.  Only a few compounds activated more than 60% of the iNKT 
cells,  including  422,  438,  442.  Concordant  with  this,  ligand  442  induced  the 
lowest level of PD-1 expression, having the highest number of responsive cells. 
Compound 432 has the least percentage of responsive iNKT cells and the highest     
 
PD-1 expression. Although this association was not seen across all compounds it 
may be appropriate to consider low PD1 staining post activation as a marker of 
anergy resistance, which would be important if iNKT ligands are to be repeatedly 
administered in a therapeutic setting.  
 
Previous studies have also suggested that other than the cytokines produced by 
iNKT cells, iNKT cells also highly influence other cell types in particular antigen 
presenting cells, i.e. dendritic cells and B cells (294-297) through cytotoxicity. It 
has been suggested that overstimulation of iNKT cells by high affinity ligands 
may  lead  to  inappropriate  APC  cell  death  (271).  If  this  could  be  selectively 
modified a longer period of antigen presentation may be permitted which could 
be beneficial in adjuvant settings. Some of the ligands tested in our screen appear 
to possess different functional properties compared to  -GC and this aspect of a 
screening programme would be a useful addition to future studies.  
 
In conclusion, the screening programme has established a range of enhanced, 
reduced,  dissociated  functions  on  human  iNKT  cells  that  suggest  that  the 
modification  of   -GC  for  specific  iNKT  manipulation  may  be  a  useful 
undertaking. We have identified compounds that meet the original intention of 
enhancing the Th1 response of these cells as well as establishing others markers 
associated  with  activation,  IL17  responsiveness  and  proliferation/cytokine 
dissociation.    It  is  clear  that  a  range  of  different  approaches  need  to  be 
undertaken in the evaluation of new compounds that are intended to manipulate 
to human immune system and that these must be profiled in animal models and 
ex vivo human settings to fully explore their potential functions.  Future studies 
may  now  be  directed  at  examining  structural  features  that  may  underlie  the 
functional divergences seen with these compounds as well as mechanistic work 
that  begins  to  better  understand  how  different  effector  responses  may  be 


























As discussed previously, CD1 molecules represent of the most conserved family 
of  molecules  across  mammalian  species.  Among  the  five  family  members  in 
humans, CD1d has received the most attention for a number of reasons. Firstly, 
compared to other CD1 molecules, the ligands bound to CD1d have been well 
defined (189, 245, 267, 270, 298). Secondly, the unique population of iNKT cells 
is conserved in both humans and mice, both reacting to a conserved ligand-CD1d 
complex  (128).  Thirdly,  iNKT  cells  have  a  specific  TCR   -chain  (V 24  in 
humans; V 14 in mice) and conserved V  chain across the species, which allows 
comparative structural studies to be undertaken. Lastly, the discovery of this cell 
type’s  multi  functional  properties  has  encouraged  the  development  of  CD1d 
ligands  that  may  have  a  therapeutic  impact  in  both  tumour  and  autoimmune 
disease settings (299, 300).  
Although  the  significant  contribution  of  CD1d  to  immune  responses  is  well 
recognised,  the  number  of  ligands  that  been  identified  for  iNKT  activation 
remains  limited.  Indeed,  most  of  the  ligands  currently  used  for  studying  the 
biological properties of iNKT cells are synthetic ligands (300, 301). Very few 
ligands have been identified from pathological tissues and during disease settings 
(302). With regard to iNKT self-ligands, iGb3 was proposed to be the natural 
ligand for iNKT cells in mouse (303), but this was not thought to be relevant for 
humans (304).  
A better understanding of CD1d and iNKT cells has been achieved through the 
development of tools such as CD1d tetramers, clonotypic antibodies and TCR 
antibodies that may robustly identify these rare subsets (305). 
At the level of functional cellular studies there has been a particular reliance 
upon clonal iNKT cell evaluations. In murine studies many paradigms have been 
established using iNKT hybridomas and then applied to broader in vivo systems 
of mice and man. As seen in the previous chapter, different ligands were shown 
to  mediate  different  iNKT  functions  and  we  wished  to  evaluate  whether  this     
 
related to the original affinity model that led to their design. Therefore we began 
to develop additional tools to study of these behaviors including a recombinant 
CD1d dimer for glycolipid_CD1d affinity measurements and a series of ligand 
specific iNKT clones to examine CD1d ligand cross reactivity. 
 
6.1.1 Current tools for the study of Lipid – CD1d interactions 
 
A few examples of the current tools used to study CD1d-lipid binding include: 
fluorescent lipid probes (306), Isoelectric-Focusing Electrophoresis (IFE) (307), 
and Surface Plasmon Resonance (SRP) (308). 
The fluorescent lipid probes utilise a system that directly measures the binding of 
a  fluorescently  labeled  lipid  directly  to  a  CD1d  molecule.  These  studies  use 
single chain soluble CD1 proteins and bespoke glycolipids with a NBD group, 
which provides the fluorescence detection. Such studies suggest that binding is 
influenced by the construction of each individual probe and pH sensitivity of the 
lipid probes (306).  
Isoelectric-focusing electrophoresis utilises an approach where different shifts in 
gel position reflect loaded and empty complexes. The enumeration of the density 
of these recovered complexes representing the binding strength of the different 
CD1d-lipid complexes (307). 
Surface  Plasmon  Resonance  is  one  of  the  earliest  techniques  to  analyse  and 
measure the binding of CD1d and lipid. In this system soluble CD1d complexes 
are fixed to a sensor chip through a streptavidin biotin approach. To measure on 
and off rates, different lipid ligands can be passed over the complexes and the 
conformational changes associated with ligand association and dissociation can 
be measured. This has become the commonest way to measure the on/off rates of 
different ligands and their associated affinities (308). 
Most of these assays involves tagging the lipids or CD1d with an indicator i.e. 
individual lipid probe or immobilizer i.e. biotin. This allows robust readouts but     
 
does not provide convenience for high throughput screening. Also by modifying 
each  index  lipid,  unexpected  effects  may  partition  to  that  compound 
subsequently influencing its affinity (305). 
Recently, a new tool has been commercially developed (BD Biosciences) for the 
investigation of CD1d-lipid interactions. This is a CD1d dimer, consisting of a 
recombinant soluble CD1d molecule that is fused to an IgG1 backbone. This 
IgG1-CD1d fusion protein can then be expressed in a mouse plasmacytoma cell 
line that is heavy chain deleted to produce a bivalent IgG1-CD1d fusion protein 
that in the presence of  2m forms a functional CD1d structure for glycolipid 
binding Index lipids can then loaded to the dimer and used for further studies 
(309). 
Shiratsuchi et al. have recently developed this concept and modified the original 
construct to produce a single chain soluble IgG1-CD1d dimer where  2m has 
been incorporated into the heavy chain fusion protein through a flexible linker. 
The  latter  tool  was  shown  to  provide  an  enhanced  stability  compared  to  the 
former.  We choose to develop such a reagent to examine the affinity of some of 
our ligands for CD1d. 
 
6.1.1.1 Approaches for generating CD1d dimmers/tetramers  
 
Previous studies have produced the CD1d monomer in a Drosophila system; 
where contamination of foreign lipid may occur leading to a very stable complex 
that does allow the efficient exchange and loading of lipids of interest (108). This 
has  led  to  most  recombinant  approaches  to  CD1d  dimers  and  tetramers  now 
being undertaken in bacterial systems when the individual heavy and light chains 
of CD1d are prepared prior to loading of the index lipid. 
The first tetramer generation techniques were developed about a decade ago, and 
these  have  contributed  significantly  to  our  understanding  of  iNKT  biology. 
However, the current approaches to the generation of CD1d tetramer are still     
 
difficult. The process is complex involving numerous stages such as transient 
gene expression by bacteria, stable gene expression by bacteria (310), expression 
in insect cells (311), expression in mammalian cells (163), and protein refolding 
(312,  313)  all  of  which  pose  their  own  difficulties.  However  most  of  these 
approaches yield a successful generation of CD1d complexes.  Innovations to 
these  processes  continue  to  occur,  with  recent  protocols  producing  CD1d  in 
lentiviral systems where the yield was shown to be much higher (314).  
Traditionally, dimer production was performed in the original Drosophila system 
(308, 310, 315). The dimer was produced by stable co-transfection of both the 
CD1d  and   2m  containing  plasmids.  Currently,  most  dimer  production  is 
undertaken in bacterial expression systems with an IgG1-Cd1d fusion protein.  
We decided to adopt the methodology developed by Shiratsuchi et al. with minor 











     
 
6.2 RESULTS  
 
6.2.1 Constructing the CD1d dimer 
 
We initially introduced a few modifications during the construction of our CD1d 
dimer compared to that developed by the Shiratsuchi group. Table 6.1 below 
shows  the  main  differences  between  the  Shiratsuchi  dimer  and  our  in-house 
dimer 
 
Shiratsuchi dimer  In house dimer 
Initial Cloned 
into pcDNA3 









Plasmid containing Ig region 
 
Plasmid without Ig region 
 
Cloned signaling peptide,  2m and 
CD1d into plasmid with two steps PCR 
Cloned signaling peptide,  2m, CD1d 
and IgG1 heavy chain with multiple 
restriction enzyme approach 
 
Linker present in the plasmid for CD1d 
and Ig region 
 
Add on linker to the plasmid for the 
CD1d and Ig region 
Table 6.1 – Approaches to CD1d dimer construction 
Following  the  completion  of  the  above  approaches  the  new  inserts  were 
examined by a combination of restriction enzyme digests (Figure 6.1).     
 
 
Figure 6.1 Digestion of final construct product and dimer mapz.  
Lane 1 is digested with Nhe1 and HindIII for  2m release, lane 2 is with 
KpnI  and  HindIII  for  CD1d  release  and  lane  3  with  XhoI  and  Kpn  for 
heavy chain release 
 
The  CD1d  single  chain  construct  was  sequenced  and  this  confirmed  that  the 
signaling peptide (red),  2m (purple), linker (green), CD1d heavy chain (orange) 
IgG heavy chain variable region and constant regions (blue) were all correct 
(Figure 6.2).  
 
GCT AGC ATG GAA TGG AGT TGG ATA TTT CTC TTT CTC CTG TCA 
GGA ACT GCA GGT ATG ATC CAG CGT ACT CCA AAG ATT CAG GTT 
TAC TCA CGT CAT CCA GCA GAG AAT GGA AAG TCA AAT TTC CTG 
AAT TGC TAT GTG TCT GGG TTT CAT CCA TCC GAC ATT GAA GTT 
GAC TTA CTG AAG AAT GGA GAG AGA ATT GAA AAA GTG GAG CAT 
TCA GAC TTG TCT TTC AGC AAG GAC TGG TCT TTC TAT CTC TTG 
TAC TAC ACT GAA TTC ACC CCC ACT GAA AAA GAT GAG TAT GCC 
TGC CGT GTG AAC CAT GTG ACT TTG TCA CAG CCC AAG ATA GTT 
AAG TGG GAT CGA GAC ATG GGA GGA GGT TCT GGA GGT TCA GGT 
TCT GGA GGA GGT GCT  AAG CTT  GTC CCG CAA AGG CTT TTC CCC 
CTC CGC TGC CTC CAG ATC TCG TCC TTC GCC AAT AGC AGC TGG 
1  2  3     
 
ACG CGC ACC GAC GGC TTG GCG TGG CTG GGG GAG CTG CAG ACG 
CAC AGC TGG AGC AAC GAC TCG GAC ACC GTC CGC TCT CTG AAG 
CCT TGG TCC CAG GGC ACG TTC AGC GAC CAG CAG TGG GAG ACG 
CTG CAG CAT ATA TTT CGG GTT TAT CGA AGC AGC TTC ACC AGG 
GAC GTG AAG GAA TTC GCC AAA ATG CTA CGC TTA TCC TAT CCC 
TTG GAG CTC CAG GTG TCC GCT GGC TGT GAG GTG CAC CCT GGG 
AAC GCC TCA AAT AAC TTC TTC CAT GTA GCA TTT CAA GGA AAA 
GAT ATC CTG AGT TTC CAA GGA ACT TCT TGG GAG CCA ACC CAA 
GAG GCC CCA CTT TGG GTA AAC TTG GCC ATT CAA GTG CTC AAC 
CAG GAC AAG TGG ACG AGG GAA ACA GTG CAG TGG CTC CTT AAT 
GGC ACC TGC CCC CAA TTT GTC AGT GGC CTC CTT GAG TCA GGG 
AAG TCG GAA CTG AAG AAG CAA GTG AAG CCC AAG GCC TGG CTG 
TCC CGT GGC CCC AGT CCT GGC CCT GGC CGT CTG CTG CTG GTG 
TGC CAT GTC TCA GGA TTC TAC CCA AAG CCT GTA TGG GTG AAG 
TGG ATG CGG GGT GAG CAG GAG CAG CAG GGC ACT CAG CCA GGG 
GAC ATC CTG CCC AAT GCT GAC GAG ACA TGG TAT CTC CGA GCA 
ACC CTG GAT GTG GTG GCT GGG GAG GCA GCT GGC CTG TCC TGT 
CGG GTG AAG CAC AGC AGT CTA GAG GGC CAG GAC ATC GTC CTC 
TAC TGG GGT GGG AGC TAC ACC TCC ATG GGC TTG ATT GCC TTG 
GCA GTC CTG GCG TGC TTG CTG TTC CTC CTC ATT GTG GGC TTT 
ACC TCC CGG TTT AAG AGG CAA ACT TCC TAT CAG GGC GTC CTG 
GGT ACC ACT AGT GTG CCC AGG GAT TGT GGT TGT AAG CCT TGC 
ATA TGT ACA GTC CCA GAA GTA TCA TCT GTC TTC ATC TTC CCC 
CCA AAG CCC AAG GAT GTG CTC ACC ATT ACT CTG ACT CCT AAG 
GTC ACG TGT GTT GTG GTA GAC ATC AGC AAG GAT GAT CCC GAG 
GTC CAG TTC AGC TGG TTT GTA GAT GAT GTG GAG GTG CAC ACA 
GCT CAG ACG CAA CCC CGG GAG GAG CAG TTC AAC AGC ACT TTC 
CGC TCA GTC AGT GAA CTT CCC ATC ATG CAC CAG GAC TGG CTC 
AAT GGC AAG GAG TTC AAA TGC AGG GTC AAC AGT GCA GCT TTC 
CCT GCC CCC ATC GAG AAA ACC ATC TCC AAA ACC AAA GGC AGA 
CCG AAG GCT CCA CAG GTG TAC ACC ATT CCA CCT CCC AAG GAG 
CAG ATG GCC AAG GAT AAA GTC AGT CTG ACC TGC ATG ATA ACA     
 
GAC TTC TTC CCT GAA GAC ATT ACT GTG GAG TGG CAG TGG AAT 
GGG CAG CCA GCG GAG AAC TAC AAG AAC ACT CAG CCC ATC ATG 
GAC ACA GAT GGC TCT TAC TTC GTC TAC AGC AAG CTC AAT GTG 
CAG AAG AGC AAC TGG GAG GCA GGA AAT ACT TTC ACC TGC TCT 
GTG TTA CAT GAG GGC CTG CAC AAC CAC CAT ACT GAG AAG AGC 
CTC TCC CAC TCT CCT GGT AAA TGA  CTC GAG 
Figure 6.2. Sequence of the final single chain CD1d dimer construct 
 
To furnish the single chain construct with a light chain for correct folding the 
construct was transfected into the J558L plasmacytoma cell line, with a GFP 
vector to check for the efficiency of transfection. Figure 6.3 shows the overlay of 
untransfected J558L (Blue) and transfected J558L cells (Red) demonstrating an 
85% transfection efficiency, with a viability of the cells of more than 80%. 
 
 
Figure  6.3.  Transfection  efficiency  of  GFP  and  single  chain  construct 
following co-transfection 
 
GFP     
 
To check the cells for successful CD1d single chain construct expression and 




Figure 6.4 CD1d expression in non-transfected and transfected J558L cells 
 
The secreted protein was then purified (IgG affinity column) and an SDS-page 
gel  of  the  purified  protein  undertaken  with  blotting  for  the  linked  anti- 2m 
(Figure 6.5)  
 
 
Figure 6.5  2m western blot of CD1d dimer construct following supernatant 
purification. Lane 1  - IgG affinity column elution, Lane 2 – affinity column 
flow through, Lane 3 – size marker lane 
CD1d 
PE 




50 KDa     
 
The secreted protein was reactive with  2m and of the appropriate molecular 
weight. A schematic diagram of the single chain dimeric tool is shown in Figure 









Figure 6.6 Schematic diagram for the single chain CD1d dimer 
 
6.2.2 Recognition of INKT cells  
 
To assess if the CD1d fusion dimer was functional, we first looked at its ability 
to recognize polyclonal iNKT cells. The dimer was loaded with  -GC overnight 
and used to stain iNKT cells. Figure 6.7 shows the identification of a small iNKT 










Figure 6.7 FACS staining of human PBMC with a loaded (A) and unloaded 
(B) CD1d dimer. 
 
6.2.3 CD1d dimer binding to iNKT cells  
 
To  assess  the  binding  of  different  lipids  to  CD1d,  we  used  the  established 
competition ELISEA assay described by the Shiratsuchi group (305). We set up 
the competition assay with a fluorescent lipid indicator, namely 18:1 Biotinyl PE 
(B-PE) (Figure 6.8). The 18:1 Biotinyl PE lipid has been shown previously to 
bind to CD1b, CD1c and CD1d (317). 
 




A  B 
CD3 
CD1d 
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We established the assay with our acyl and sphingosine chain modified ligands 
that had been originally designed to influence CD1d binding. Figure 6.9 shows 
the  initial  Kd  assessment  for  the  reporter  18:1  Biotinyl  PE  lipid  following  a 
titration to saturation binding of the empty dimer. The calculated Kd of 18:1 
BiotinylPE  from  this  was  1.54  (0.5  –  2.588)  which  is  similar  to  that  of  the 
original publication (1.68). 
 
Figure 6.9 Titration of the labeled 18:1Biotinly-PE lipid to evaluate its Kd. 
The  (squares)  represent  experimental  data  points,  the  uninterrupted  line 
represent  the  best  fit  curve,  and  the  dotted  lines  the  95%  confidence 
intervals for the Kd value. 
 
Figure 6.10 shows the ELISA results for the acyl chain and sphingosine chain 
modification  analogues  in  this  heterologous  competition  assay.  Here  the 
18:1Biotinly  PE  CD1d  complex  is  initially  loaded  and  an  increasing 
concentration of the index lipid added overnight to compete with the reported 
ligand. The Ki can then be calculated for the unlabelled ligand using the formula 
Ki = IC50 / (1 + [B-PE] / Kd). Here the Kd represents that of B-PE calculated 
previously, the concentration of B-PE used in the preloaded complex and IC50     
 
the concentration of the structurally distinct analogues that reduce B-PE binding 
by 50%.  
 
Figure  6.10  Heterologous  competition  ELISA  results  for  the  4  acyl  and 
sphingosine modified compounds.  
 
The Ki results for the 5 compounds, including  -GC are as follows:  
   -GC  31  32  43  44 
Ki Value  0.04 (µM)  0.06(µM)  0.02(µM)  0.016(µM)  0.016(µM) 
 
The Ki value for  -GC obtained from our assay is similar to the value (0.07µM) 
suggested by Shiratsuchi et al.  It is notable that the compounds 31 and 32 are 
most  similar  to   -GC,  both  in  these  affinity  measurements  and  functional 
parameters. Compared to  -GC, Compounds 43 and 44 show a slightly improved 
affinity with an identical Ki of 0.016µM. 
     
 
6.2.4 Generation of iNKT clones 
 
We followed up our observations relating to the ligand specific differences in 
proliferative and cytokine responses by generating iNKT clones to the individual 
analogues and assessing their cytotoxicity and cross reactivity profiles.  
Jurkat and U937 cells both express CD1d and were selected as target cells whilst 
K562  cells,  which  do  not  express  CD1d,  were  selected  as  negative  controls 
(Figure 6.11).  
 
 
Figure 6.11. CD1d expression of Jurkat (red), U937 (blue) and K562 cells 
(green). 
 
A flow based killing assay was established using  -GC pulsed target cells, and an 
NKT cell clone generated with  -GC (gift from Professor Stephan Gadola).  
Figure  6.12  is  representative  of  the  cytotoxicity  observed  in  the  experiments 
where a cell permeable dye (To-Pro-3) that emits fluoresce in the APC channel is 
taken up by target cells when they have been recognized by ligand specific iNKT 
clone.  The  assay  measures  the  percentage  of  To-Pro3  positive  target  cells 
following co culture at the respective E:T ratios Figure 6.13 shows the killing 
CD1d     
 
ability of NKT cells against Jurkat, U937 and K562 cells in this ‘homologous 
ligand’ set up. 
 
Figure 6.12 Representative example of CD1d mediated cytotoxicity of  -GC 
pulsed target cells and iNKT cells clones at different E:T ratios (Left 0.1:1 
and right 5:1) 
The cytotoxicity was proportional to the level of expression of CD1d expressed 









Figure  6.13  iNKT  cytotoxicity  of   -GC  pulsed  target  cells  with  differing 
levels of CD1d expression      
 
As  expected,  no  specific  killing  was  observed  with  the  CD1d  negative  NK 
sensitive cell line K562 or in the absence of exogenous lipid ligand.  
We then evaluated the ability of the same  -GC iNKT clone to kill compound 
31-pulsed U937 target cells. Figure 6.14 shows the unexpected finding of an 
absence of killing of the pulsed target, despite the previously noted ability of 









Figure 6.14  -GC derived iNKT clone killing of a glycoplid analogue (31) 
pulsed target cell 
 
The absence of killing suggests that the  -GC iNKT line may have glycolipid 
ligand specificity and that despite the invariant nature of the TCR single antigen 
recognition may be inducible in iNKT cells. We subsequently generated NKT 
cell lines against the different analogues being successful for compounds g  -
GC, 31, 43 and 44. Figure 6.15 shows two examples (31 and 43) of the iNKT 
cell line phenotypes. All the iNKT cell clones retained their characteristic V 24 
and V 11 expression but in contrast to the previous polyclonal experiment these 
activated lines lost their expression of CD161. 
 




Figure 6.15 Phenotype of the iNKT cells clones 
Figure 6.16 shows a ‘criss cross’ cytotoxicity assay for the first ligand specific 
clones that were generated against compound 43. A number of observations can 
be made including the specificity of the clone for its index ligand and the poor 
cross  reaction  to  the   –GC  pulsed  target.  This  implied  that  there  was  little 







Figure 6.16 Cytotoxicity by compound 43 generated iNKT clones against 
homologous and heterologous targets.      
 
Similar experiments were then undertaken for the other ligand pairs and these are 




Figure 6.17 Summary of ‘criss cross cytotoxicity assays for ligand specific 
iNKT clones at a 10:1 E:T ratio.  
 
A similar level of ligand specificity was observed for all of the derived iNKT 
clones  across  the  different  compounds  tested.  This  suggests  that  antigen 
specificity may be a property that iNKT cells share with conventional T cells 








•We have successfully generated a new tool for the assessment of iNKT cells and 
affinity evaluations of novel CD1d lipids. 
•The compounds 31 and 32 have similar Ki to  -GC whilst 43 and 44 showed a 
slight improved affinity. 
•The differences in affinity between the compounds would not appear to explain 
the many difference observed between these lipids which were all able to induce 
proliferative, cytokine and cytotoxic iNKT cells responses.  
•iNKT  cells  may  be  derived  to  specific  glycoplids  that  do  not  show  cross 
reactivity to other Cd1d binding lipids. This specificity of ligand recognition is 
intriguing given the invariant nature of the V  chain and suggest subtle changes 












     
 
6.3 Discussion and Conclusion 
 
During  this  part  of  my  research,  we  successfully  generated  tools  to  help  us 
evaluate the binding characteristics of our novel compounds. The  2m-CD1d-
IgG dimer afforded us the opportunity to compare the Ki of the new compounds 
with  that  of   -GC  and  review  whether  the  original  improved  affinities  were 
evident and/or related to the diverse functional responses previously reported. 
The results suggest that the compounds do show some differences compared to 
the prototypic  -GC but these do not neatly align themselves with the diverse 
functional responses recorded. This method is an efficient approach for screening 
the affinity of new compounds for CD1d binding and might be adapted for those 
altered for TCR interactions in the future.  
The dimer did allow recognition of rare iNKT cells in PBMC but the unloaded 
dimer showed some background staining that would need to be addressed before 
this  is  used  for  robust  iNKT  enumeration.  This  staining  may  represent  non 
specific binding of the fusion protein to Fc receptors on monocytes or B cells and 
this may be improved with the addition of a Fc blocking antibody for further 
studies. 
 
In our CD1d binding study, most lipids showed a Ki that was in the same range 
as   -GC,  and  similar  to  that  of  the  original  Shiratsuchi  group  (305,  307). 
However  our  binding  assay  does  not  truly  represent  the  in  vivo  loading  of 
glycoplids  as  these  occur  in  the  late  endosome  which  is  more  acidic  (318). 
Indeed, previous studies have shown that optimal CD1d binding occurs in at 
around pH 5-6 (319).   
 
In addition to using this tool for evaluating the binding properties of the lipid to 
CD1d, it may be also used in the context of an artificial antigen presenting cells 
in a cell free system (305). Such systems are all ready in place for expanding 
peptide specific cytotoxic T cells for therapeutic indications.      
 
This work has suggested that even though iNKT cells can be considered as innate 
cells, they can exhibit certain ligand specificities similar to conventional T cells. 
The degree of cross reactivity between our ligand specific clones was minimal 
apart from ligands 43 and 44. It is not clear what the underlining reason for this 
may be; although both 43 and 44 share an alteration in the 4-OH position on the 
sphingosine chain. A previous study has suggested that even though the 4-OH 
position is not directly involved does in the binding to CD1d, it might affect the 
3-OH  recognition  (292).  The  proliferation  indices  of  different  analogues  also 
suggested that different ligands might selectively expand iNKT cells when 43/44 
were compared to 31/32. The differential effects of compounds 43 and 44 on the 
iNKT  cells  of  low  and  high  donors  also  support  the  previous  notion  that  a 
distinctive  functional  difference  exists  between  the  iNKT  cells  of  such 
individuals.  
 
In  conclusion  in  would  appear  that  the  original  assumption  that  altering  the 
binding affinity of  -GC analogues would increase the Th1/Th2 cytokine ratio is 
too  simplified.  We  have  shown  that  the  chemical  modifications  do  not 
significantly alter binding affinities whilst markedly altering functional profiles. 
These different effects compared to  -GC can be influenced at the level of the 
type  of  donor  (high  vs.  low),  cytokine  environment  (IL-2  vs.  IL15),  effector 
readout  (proliferation  vs.  cytokines),  specificity  and  murine/human  model. 
Further analogue development programs will need to take a multidisciplinary 
approach that extends beyond current structure function relationships to aid the 


























Common  variable  immunodeficiency  (CVID)  is  the  commonest  primary 
antibody  deficiency,  representing  a  heterogeneous  group  of  primary  defects 
(320).  CVID  is  also  commonly  known  as  acquired  hypogammaglobulinema, 
adult-onset hypogammaglobulinemia, or dysgammaglobulinemia (321). Patients 
generally  have  a  marked  reduction  in  serum  immunoglobulin  G  (IgG)  and 
immunoglobulin  A  (IgA),  sometimes  accompanied  with  a  reduction  in 
immunoglobulin M (IgM). They typically present with recurrent sinopulmonary 
infections  and  impaired  antibody  responses  to  vaccination  (322).  A  bimodal 
distribution has been described for the age of first presentation of CVID. A few 
patients present in childhood, but the majority present after the age of 20. The 
onset of CVID in males is relatively earlier compared to females, with a mean 
age of 23 compared to 28 years old (323). 
One  quarter  of  the  CVID  patients  also  present  with  associated  autoimmune 
disorders,  including  autoimmune  thrombocytopenia,  haemolytic  anaemia  and 
thyroiditis  (320).  Lymphadenopathy  and  organomegaly,  particularly 
splenomegaly, is also noted in a similar proportion. 
The  clinical  features  of  recurrent  infection,  antibody  deficiency  autoimmune 
events  and  lymphoproliferation  suggest  an  underlying  fundamental  immune 
dysregulation in this disorder. Recent research has established some single gene 
defects that offer different genotypic explanations for the phenotypic spectrum 
seen in this disorder. 
 
7.1.1 Genetic defect in CVID 
 
There are four major genetic defects that have been identified in CVID over the 
last decade. These four are the inducible T-cell costimulator (ICOS) (324, 325), 
transmembrane activator and calcium modulating cyclophylin ligand interactor     
 
(TACI)  (326-328),  the  B-cell  activating  factor  of  the  tumour  necrosis  factor 
family receptor (BAFFR) (329), and the CD19 (330).  
  
             
ICOS  was  the  first  genetic  defect  to  be  associated  with  CVID.  Nine  CVID 
individuals from four unrelated families were identified to have identical a large 
genomic deletion of the T cell activation molecule, ICOS (324, 325). 
ICOS belongs to a family of Ig-like co stimulatory receptors on T cells, sharing 
some  homology  with  CD28,  CTLA-1  and  PD1  (331).  In  humans,  ICOS  is 
located on chromosome 2q33-34, only 300kb away from CTLA-4 and CD28 
(332).  Unlike  CD28,  ICOS  and  the  other  members  of  this  family  are  not 
constitutively expressed on T cells (333). Activation of both the T-cell receptor 
and CD28 leads to a rapid induction of ICOS expression on the surface of T 
cells. Cytokines such as IL-12, IL-23 and IL-4 may also influence the expression 
of ICOS on activated T cells (334, 335). The influence of ICOS is evident for a 
range of T cell activity including T-cell differentiation, cell survival, cytokine 
production and the support of antibody production. These multiple activities are 
secondary to increases in the cytokines IL-4, IL-5, IL-6, IL-10, TNF-  and IFN-  
(333). ICOS mediates this cytokine signalling through its interaction with the 
growth factor receptor-bound protein 2 (Grb2), which is required for the initial T 
cell IL-2 production (333, 336).  
ICOS  is  primarily  expressed  in  the  thymus  and  secondary  lymphoid  tissues 
where  it  supports  T  cell  development  and  CD4  T  cell  help  following  initial 
antigen presentation (337). 
Although the initial genetic defect appeared to relate to a geographical region it 
has been estimated that this autosomal recessive condition may occur in up to 2% 
of CVID patients (325, 338). The phenotype of such patients includes a lack of 
circulating CD27+ switched memory B and a susceptibility to neoplastic disease 
and  autoimmunity  in  the  absence  of  ICOS  expression  post  T  cell  activation 
(320).      
 
             
CD19 deficient CVID patients were first identified in 2006 (330). Four patients 
from  two  unrelated  families  were  identified  to  have  homozygous  frameshift 
mutations in the cytoplasmic domain of CD19. A follow up study from another 
group identified a further 2 patients with a defect in CD19. This was a compound 
heterozygous disorder a splicing defect on one allele and a deletion on the other 
(339). 
CD19 in an early B cell membrane surface molecule, and it remains on B cells 
until they differentiate into plasma cells. CD19 forms a signalling complex with 
CD81, CD21 and CD225 on mature B cells (330) and is essential for stabilising 
and amplifying the signal derived from BCR ligation (340).  
Very  few  CVID  patients  have  been  subsequently  identified  to  have  CD19 
deficiency.  The  phenotype  of  such  patients  is  that  of  having  normal  B  cells 
numbers with a decrease in class-switched memory B cells and normal T cell 
function. 
 
                                           
Mutations  in  TNFRSF13B  (TACI)  and  TNFRSF13C  (BAFF-R)  are  found  in 
CVID  patients.  As  both  TACI  and  BAFF-R  are  tumour  necrosis  factor 
superfamily members, they share three common features. They both belong to 
the Type III transmembrane family, both contain cysteine-rich domains and their 
expression is restricted to lymphocytes (341).  TACI and BAFF-R, together with 
their ligands BAFF and APRIL, are the key signalling members to regulate the 
differentiation,  homeostasis  and  function  of  B  cells  (341).  Both  TACI  and 
BAFFR  ligands  are  widely  expressed  in  professional  antigen  presenting  cells 
such as macrophages, monocytes and dendritic cells (342, 343).  
TACI gene is one of the commonest mutations found in CVID patients. About 10 
- 15% of the CVID patients were found to have heterozygous TACI mutations. 
TACI expression is highly related to the maturation of the B cell population. 
TACI expression is observed on marginal zone B cells and CD27+ memory B     
 
cells, with an upregulation being evident after B cell stimulation (341, 344-346). 
TACI has a high affinity binding to both APRIL and BAFF (341) and can signal 
via both NF B and NFAT/AP1 pathways (341, 347).In TACI knockout mice, a 
lupus-like autoimmune disorder with lymphocyte infiltration of liver and kidney 
develops  in  the  absence  of  hypogammaglobulinaemia  (348).  In  addition,  this 
study  has  also  found  that  anti-murine  TACI  antibodies  could  inhibit  the 
proliferation of B cells (348). Further studies have suggested that the interaction 
between TACI and APRIL is the key cross talk for IgA induction. They showed 
that in APRIL deficient mice, there was a deficiency in IgA production (349) and 
that TACI was a positive regulator for terminal B cell differentiation (348). 
CVID  patients  with  TACI  mutations  normally  have  single  amino  acid 
substitutions,  which  introduce  premature  stop  codons  and  frameshifts  (350). 
Such patients typically have low IgG immunoglobulin, but normal range of IgM 
with autoimmunity and splenomegaly (351). 
Very few CVID patients have been identified to have BAFFR mutations. Unlike 
TACI, BAFFR only binds to one ligand and it is widely expressed on all the 
peripheral B cells (344). It is understood that the interaction between BAFFR and 
its ligand is the key for the survival of peripheral B cell subsets, particularly 
those  at  a  transitional  stage.  B  cell  lymphopenia  and  immunodeficiency  are 
observed in both BAFF and BAFFR deficient mouse model (352, 353).  
Up to date, only one individual with CVID has been reported to have BAFF-R 
deficient; with a 24 base pair deletion of the gene (320). Both class-switched and 
non-switched  memory  cells  were  reduced  in  the  patient  with  an  increase  in 
transitional B cells (320).  
7.1.2 CVID and T cells 
 
It  is  well  established  that  CVID  is  a  disorder  characterised  by  antibody 
deficiency,  but  with  features  that  that  suggest  T  cell  dysregulation.  Indeed 
effective thymopoiesis of naïve T cells and a lower activation and proliferation     
 
of memory T cells has been demonstrated in CVID leading to a higher rate of 
apoptosis and abnormal cytokine production (increase in IFN- ) (354).  
One of the major T cells defective in CVID is in the CD4+ naïve T cells and a 
CVID  classification  has  been  proposed  relating  to  this  abnormality  (355).  A 
correlation was identified between CD4+ naïve T cells levels and the incidence 
of splenomegaly (356) as well as the amount of IgG and IgA in the serum (355). 
Most  of  these  patients  were  subsequently  shown  to  fall  into  another 
classification, Warnatz Ia, based upon the presence of memory B cells (357). 
Furthermore recent studies using TRECs to evaluate thymic output have shown 
that only the patients in the Ia group have a lower level of TRECs, whereas 
normal levels of TRECs were found in groups Ib and II (357).  
Within the CD8+ T cell subset, further alterations have been identified including 
an increased number of CTL, a predominant effector-memory phenotype and a 
high level of serum IL-7 (354). This has led to a Th1 polarisation in many (354) 
and a higher turnover rate compared to healthy controls (356).  
Finally recent studies have indicated that Tregs may also be deficient in CVID 
patients  (358).  Tregs  from  those  with  autoimmunity  showed  decreased 
suppressor  function  and  downregulation  Treg  proteins  including  FoxP3, 
Granzyme A, pSTAT5 and GITR (358).  Again this cohort co segregated to that 
of the Ia patient group (359).  
  
7.1.3 iNKT cells and antibody production 
 
                               
The classical T cell dependent, B cell activation pathway was described over two 
decades ago (360).  Recently, several studies have established that iNKT cells, 
just  like  conventional  T  cells,  can  also  support  B  activation  and  antibody 
antibody production (249, 361-363).     
 
In such studies an important helper function of iNKT cells was demonstrated in 
the  primary  and  secondary  antibody  responses,  where  increased  antibody 
concentrations  were  observed  when   -GC  was  co-delivered  with  the  protein 
antigen (362). A study by Tonti et al. showed that activated iNKT cells, once 
they express CD40L, can enhance the responses on other B cells that express 
CD40, and that this is not limited by antigen specific CD1d recognition (363). 
Other studies have established that iNKT cells can directly interact with B cells 
(249, 361). In the first study, the interaction of iNKT cells with B cells led to the 
release of lipid specific antibody via a classical cognate interaction (361). The 
second study showed that iNKT cells could interact with the CD1d on B cells 
whilst the lipid was endocytosed by surface IgM. Very high titres of specific of 
IgM and early class switching were then observed in this model (249). These 
studies suggest that iNKT cells may play a direct or indirect role in supporting 
antibody production in mouse models (363).  
 
                                            
iNKT cell deficiency has been identified in two types of antibody deficiency – 
severe combined immune deficiency (SCID) and X-linked lymphoproliferative 
syndrome (XLP) (137, 150).  
XLP was the first antibody-deficiency associated disorder shown to manifest a 
specific iNKT defect. In the first study of XLP patients, no iNKT cells were 
detected through either CD1d tetramer or the invariant TCR receptor antibody 
approaches. All these patients were shown to have a defect in SAP, which is the 
adaptor protein that is critical for SLAM function (150). In XLP patients where 
the genetic defect is BIRC4 (and not SAP) contrast, the patients displayed a 
normal range of iNKT cells (ranging from 0.01% - 2%) (364). Following these 
descriptions a murine knock out of SAP was made which confirmed the absence 
of iNKT cells and importance of SAP in their development (364).  
 




•To  investigate  the  presence  of  iNKT  cells  in  a  large  population  of  CVID 
patients  with  no  known  mutations,  controls  and  a  disease  control  group  of 
patients with a specific B cell defect (X linked agammaglobulinaemia) 
•To evaluate the function of iNKT cells in CVID 


















7.3.1 iNKT cell frequency in CVID patients 
 
CVID patients and healthy controls were analysed by six-colour flow cytometer 








V 24  non 
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A series of 37 CVID patients and 50 healthy controls were analysed over one 
year period. Compared to the healthy control, no detectable iNKT cells were 
found in many CVID patients, as seen in Figure 7.1. It is notable that V 24 cells 
are present in the CVID patients but not iNKT cells. This lack of iNKT cells was 
supported by the lack of CD161 positive V 24 positive T cells.  
We then compared the number of iNKT cells in the 37 CVID patients and 50 
healthy controls (Figure 7.2). 
  
 Figure 7.2 Number of iNKT cells in CVID patients and healthy controls 
A marked reduction in iNKT cells was observed in the CVID patients compared 
to the healthy controls, with a mean value of 31 compared to 200 (p < 0.0002). 
However some CVID patients did appear to have a normal number of iNKT 
cells, suggesting heterogeneity with regard to this T cell subset abnormality. 
Two further properties of iNKT cells were reviewed including the expression of 
the CD4 co-receptor and maturation marker CD161. The ratio of CD4:DN iNKT 
cells differed between the groups (P<0.05) suggesting that CD4 iNKT with a Th2 
and Th1 cytokine capacity were present whilst CD161 expression was reduced in 
the  iNKT  cells  of  CVID  patients.  As  mentioned  earlier  this  may  be  due  to     
 
activation  or  immaturity  as  both  may  reduce  expression  of  this  CD161.
 
Figure 7.3. iNKT cell phenotype of CVID patients and healthy controls 
 
7.3.2 Function of iNKT cells in CVID patient 
 
iNKT  cells  were  detected  in  all  healthy  controls  with  our  approach  allowing 
accurate detection ~5 iNKT cells per 10
5 T cells. (0.0005%). To exclude the 
presence of iNKT cells below this number in CVID patients we undertook iNKT 
proliferation studies to assess if such low numbers could be expanded to our 
detection levels and to calculate the expansion potential of those patients where 
these cells were detectable. A representative plot of the proliferation experiments 
of a healthy control is seen in Figure 7.4, following a 7 day culture with  GC.  
 
Pre-proliferation  Post-proliferation     
 
Figure  7.4  Proliferation  profile  of  iNKT  cells  in  a  representative  healthy 
control. 
In  the  case  of  CVID  patients,  only  8  individuals  (21%)  showed  measurable 
proliferation (Figure 7.5). This was in accordance with the ex vivo enumeration 
where only 8 individuals had greater than 80 iNKT cells detectable. Of the 16 
controls all expanded, with a mean proliferation index of 50. Thus iNKT cells are 
truly deficient in the majority of CVID patients. From these initial functional 
studies  2  groups  of  CVID  patients  could  be  discerned.  The  first  group  had 
detectable iNKT cells and these could expand whilst the second group had low or 
absent iNKT cells that did not proliferate like healthy controls.      
 
 
Figure 7.5. Proliferation of iNKT cells  
(a) FACS plot for iNKT cells proliferation before and after (b) Two groups 
of patients were identified based on their proliferation ability 
 
However even those that demonstrated proliferation had a range, 5-1000, that 
was different to healthy control. Thus CVID patients could be divided into two     
 
groups based on the proliferation essay, namely Group 1 (8/37) who possessed 
proliferative activity and Group 2 (29/37) that did not. 
We then examined those CVID patients who possessed detectable iNKT cells for 
their  cytokine  responses  following  activation.  We  measured  3  cytokines  in  3 
representative patients from Group 1 (Figure 7.6).   
  
 
           
     
 
       
Figure 7.6. Cytokine production by iNKT cells of 3 Group1 CVID patients 
compared to controls 
From Figure 7.6, it can see that the patients did preserve a certain level of multi-
cytokine activity and they showed a marked increase in the IFN-  production 
compared to healthy controls. It is notable that all the tested patients showed a 
low  level  of  IL-17  production  in  whilst  IL-13  was  not  different  between  the 
patients and controls.  
7.3.3 Is the deficiency unique to CVID 
To understand and evaluate if the deficiency in iNKT cells is unique to CVID 
patients,  we  choose  to  look  at  the  iNKT  cells  in  another  type  of 
immunodeficiency, X-linked agammaglobulinemia (XLA). Both diseases have 
similar clinical presentations and both patient groups receive the same treatment 
(replacement immunoglobulin). In contrast to CVID, XLA patients have a well 
described deficiency of Brutons tyrosine kinase (BTK) which leads to a B cell 
specific  disorder.  We  first  looked  at  the  iNKT  cell  number  in  a  cohort  of  4 
patients with this primary immunodeficiency (Figure 7.7). 
 












Healthy control  CVID patient 
XLA patient 
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Figure  7.7.  Enumeration  of  INKT  cells  in  XLA  patients.  (a)  FACS 
comparison of healthy control, CVID patient and XLA patient. (b) number 
of iNKT cells per 100,000 T cells in XLA patient and healthy control 
 
XLA patients appeared to have a comparable number of iNKT cells compared 
with the healthy controls. We further evaluated the functionality of these iNKT 
cells by proliferation assay (Figure 7.8).     
 
 
Figure 7.8 Proliferation of iNKT cells. 
(A) Representative proliferation of iNKT cells in a healthy control and (B) 
XLA patient (C) Fold increase of iNKT cells in healthy controls and XLA 
patients 
 
    
 
 
Figure 7.8 Proliferation of iNKT cells. 
(a) Representative proliferation of iNKT cells in a healthy control and (b) 
XLA patient (c) Fold increase of iNKT cells in healthy controls and XLA 
patients 
     
 
The proliferation of iNKT cells in this disorder is similar to that of the healthy 
controls.  Therefore  the  iNKT  deficiency  of  CVID  is  not  related  to  the 
replacement  therapy  and  is  distinctive  to  the  extended  T  cell 
immunodysregulation of this antibody disorder. 
 
7.3.4 Do iNKT cells associate with B cell subgroups in CVID? 
 
Finally the number of iNKT cells was further used to analyse if there is any 
clinical or phenotypic association with other markers used to subdivide CVID. 
We  reviewed  the  B  cell  analysis,  which  had  been  undertaken  to  assess  the 
number of naïve and memory B cells through the markers IgD, CD27, CD10, 
CD38 and CD21. 
No  associations  were  found  for  non-switched  memory  B  cells,  transitional  B 
cells, or plasmablasts. However when the number of class switched B cells were 
reviewed  a  correlation  was  observed  between  iNKT  number  and  CD27
+IgD
- 
status (Figure 7.9).  
 
 
Figure  7.9  Association  of  iNKT  cells  with  percentage  of  class-switched 
memory B cells     
 
There is a significant reduction in the percentage of CD27
+IgD
- B cells in the 
CVID patients with less than 0.1% iNKT cells compared to those with more than 
0.1% iNKT cells (mean of 0.2% CD27+IgD- B cells compared to 1.2%). The 
association of class switched B cells with clinical status had previously been 
proposed to identify those at greater risk of autoimmune and lymphoproliferative 
complications in CVID. To assess if differences in iNKT number associate with 
class  switched  B  cells  in  healthy  controls  we  reviewed  the  number  of  class 
switched B cells in 5 donors with >200 iNKT/10
5 T cells and 5 with <200/10
5 T 
cells (Figure 7.10). 
 
 
Figure  7.10  Association  of  iNKT  cells  with  CD27IgD-  B  cells  in  healthy 
controls 
 
In the group of 10 healthy controls, the percentage of CD27
+IgD
- did not differ 
significantly between the 2 groups. This suggests that the difference in the CVID 
setting is disease specific and that iNKT number is a surrogate for class switched 
B cell memory status in such individuals.     
 
7.3.3 Summary  
 
•The number of iNKT cells is significantly reduced in CVID patients compared 
to healthy controls. Almost 50% of the patients have no detectable iNKT cells 
present in their peripheral blood. 
 
•The majority of CVID patients (78%) failed to proliferate following of  -GC 
activation. This suggests the iNKT cells are truly absent in these patients.  
 
•Those CVID patients with >80 iNKT cells retain multi-cytokine capacity but 
with a diminished IL-17 responsiveness and to increased IFN-  production to 
CD1d ligands. 
 
•An association between iNKT cell number and class switched B cell memory 
number is seen, the latter of which is known to be a surrogate for more severe 








     
 
7.4 Discussion and conclusion 
 
It has been more than 50 years since the first case of CVID was reported (365). 
Although  different  cellular  defect  and  genetic  defects  has  been  defined,  the 
mechanism of the disease is far from understood (320). In this study, we have 
identified another cell deficiency that is present in the majority of CVID patients 
but not in the related disorder XLA (366).  
Around 40% of the patients were shown to have a complete defect in the number 
of iNKT cells and a further 40% were shown to have a defect in NKT cells 
function. Therefore iNKT deficiency is present in over three quarters of all CVID 
patients tested in this large cohort.  
Previous studies have identified that CVID patients can be grouped according to 
the  number  of  class-switching  memory  cells  they  have.  Low  class-switch 
memory  cells  being  seen  in  group  I  CVID  patients,  whilst  group  II  CVID 
patients were normal. In our study, we found that those with normal iNKT cells 
were most similar to group II CVID patients, whilst group I CVID patients had a 
deficiency of iNKT cells and class switched B cells.  
It is tempting to speculate that these observations are related given the B cell 
help that iNKT cells are thought to provide. As discussed above iNKT cells, can 
act  in  a  number  of  ways  to  help  B  cell  proliferation  and  sustain  antibody 
production.  Figure  7.11  illustrates  how  iNKT  cells  may  promote  antibody 
responses through cognate and non-cognate interactions.  
     
 
 
Figure 7.11 iNKT cells may provide “help” to B cells in a number of ways. 
iNKT  cells  can  provide  help  to  B  cells  in  both  cognate  and  non-cognate 
pathway. iNKT provide cognate help to B cells via Dendritic cells and the 
activation  of  naïve  T  cells,  which  efficiently  up-regulate  co-stimulatory 
molecules in dendritic cells and further lead to memory B cell development 
and  antibody  production.  In  non-cognate  system,  iNKT  cells  can  act  as 
helper T cells when and lead to the activation of naïve B cells. 
 
In CVID patients the lack of iNKT cells, may impact upon the activation of 
antigen  presenting  cells  to  support  a  cognate  engagement  of  conventional  T 
helper cells. This may also occur within the B cell follicle through direct cognate 
interaction.  Alternatively  an  iNKT  cell  absence  may  impair  the  non-cognate 
activation  of  memory  B  cells  that  are  important  for  sustaining  antibody 
production and survival. These possible consequences of iNKT cell absence will 
require further targeted experiments in future work. Finally further studies are 
required to assess whether the iNKT defects described are primary or secondary     
 
to  the  CVID  disease  course.  Longitudinal  studies  of  such  cohorts  and  an 











































     
 
 
During the tenure of this project several new areas of iNKT biology have been 
addressed and novel observations made regarding human iNKT cell behavior in 
health and disease. The first observation to consider in more detail concerns the 
demonstration that the previous dogma regarding the association between the 
CD4  co-receptor  usage  of  individual  iNKT  cell  lines  and  their  cytokine 
production, is part of a larger interrelationship between iNKT cells, conventional 
T cells and their respective enumeration and CD4 co receptor dominance. We 
have confirmed the cytokine skewing of CD4 positive iNKT cells towards a Th2 
response, compared to DN iNKT cells, on ex vivo cells but have now linked this 
co  receptor  phenotype  to  the  absolute  number  of  iNKT  cells  present  in  an 
individual. Indeed at a population level, high and low iNKT donors are seen to 
exist and this co associates with a fixed phenotype and functional imprinting 
(Figure  8.1).  Furthermore  this  skewed  co  receptor  usage  is  shared  with 
conventional T cells such that those individuals with a CD4:CD8 ratio of >2.5, 
which is normal in the population, reproducibly have a low number of iNKT 
cells which are CD4 biased. Conversely those with a high number of iNKT cells 
have a reduced CD4:CD8 ratio in their conventional T cells and a paucity of 




    
 
 
Figure 8.1. Relationship between iNKT cell number, iNKT co receptor phenotype and conventional T 
cell CD4:CD8 ratio. 
Number of iNKT cells 
High DN: CD4 iNKT ratio; 
Th1 Bias Cytokine secretion; 
Low  CD4:CD8  Conventional 
iNKT ratio 
Low DN: CD4 iNKT ratio; 
Th2 Bias Cytokine secretion; 
High CD4:CD8 Conventional 
iNKT ratio 
CD4:CD8 T cells ratio     
 
In addition to predicting the multi cytokine profile potential of an individual 
from the number of iNKT cells present, our study has also shown that on a one to 
one  cell  basis  identical  phenotypic  iNKT  subsets  differ  in  the  amount  of 
cytokines they express across high and low donors. This suggests that parameters 
such as iNKT TCR affinity or functional affinity differs between donors and that 
this relates to the central selection or peripheral maintenance mechanisms that 
influence the homeostatic number of iNKT cells that are present.  
Several  hypotheses  may  be  evaluated  from  these  observations  and  we  would 
initially propose a central thymic selection mechanism which links these iNKT 
and conventional T cells observations (Figure 8.2). It is known that in chimeric 
mice, artificial expression of MHC class II on thymocytes reduces iNKT cell 
numbers  compared  to  wild  type  mice  (238).  It  has  also  become  recently 
recognized that the transcription factor ThPOK is essential for CD4 iNKT and 
CD4  conventional  T  cell  selection  (367-369).  Therefore  it  is  tempting  to 
speculate that the expression of MHC class II and signaling through CD4 may 
modify both iNKT selection and CD4 skewing across a population.  The typical 
DN phenotype of iNKT cells has been previously attributed to the redundancy of 
co receptor usage for T cells that posses a relatively high affinity for self ligand-
CD1d complexes, thus avoiding negative selection imposed by integrated TCR 
and co receptor signaling. In the case of most healthy individuals a CD4:CD8 
ratio of greater than 2 is often seen and we have co associated this with the 
presence of a low number of iNKT cells that are CD4 biased. We propose that 
the expression of MHC class II on DP thymocytes influences iNKT selection 
through  a  non  polymorphic  interaction  with  CD4  and  downstream  ThPOK 
signaling leading to a notable negative selection of iNKT cells which have a high 
affinity for co expressed CD1d on double positive thymocytes. The iNKT cells 
that do emerge have an attenuated affinity for the CD1d complex through their 
TCR which is also supported by a dominant CD4 MHC class II interaction. It is 
this  CD4  MHC  class  II  interaction  that  shapes  the  CD4  repertoire  of 
conventional  T  cells  in  association  with  their  recognition  of  distinct  peptides 
presented in the context of the polymorphic binding groove of MHC class II. In 
the case of those individuals with a high number of iNKT cells this CD4-MHC     
 
class II ‘gain of function’ interaction is not apparent and therefore this is little 
negative  selection.  The  negative  selection  process  of  these  iNKT  cells  can 
tolerate  a  higher  affinity  TCR  CD1d  lipid  interaction  leading  to  distinct 
functional features in the periphery. The absent of a dominating CD4 MHC class 




Figure  8.2.  Hypothetical  model  of  the  factors  that  may  influence  the 
selection of iNKT cells and the CD4:CD8 ratio of conventional T cells.  
 
This distinction between those with high numbers of iNKT cells and those with 
low numbers was further developed in Chapter 4 through a review of the CD1d 
APC dependence of the 2 groups of individuals. It was a surprise to find that 
most individuals, i.e. low donors, failed to proliferate (or produce cytokines) in 
the presence of CD1d positive B cells whilst those with higher numbers of iNKT 
cells were unaffected (370). This monocyte dependence for iNKT cells of low     
 
donors  is  again  difficult  to  reconcile  with  our  understanding  of  antigen 
presentation to iNKT cells. We do not believe it was simply an effect of too few 
iNKT cells for a putatively reduced antigen expression of B cells. Indeed B cells 
express more surface CD1d than monocytes and when we corrected the iNKT 
numbers in vitro, there was no rescue of iNKT proliferation. It is unlikely that 
the B cells of high donors are different to those of low donors, but this could be 
tested  with  criss-cross  experiments  using  B  cells  of  high  and  low  donors, 
however, alloreactivity might be present (370) . It is notable that the processing 
of  lipids  by  B  cells  is  different  to  that  of  monocytes  as  B  cells  are  poor  at 
internalizing  exogenous  lipid  but  may  bind  at  the  cell  surface.  Previous 
experiments have established that lipids with shorter acyl and sphingosine chains 
are more easily loaded at the cell surface of B cells but this observation was not 
relevant to our studies that used  -GC, as an optimal ligand (271).  The influence 
of other factors to effective iNKT responses in low and high donors may also 
relate to the differences between these two APC populations. We show that the 
activity of IL-15 upon iNKT cells is monocyte dependent in both high and low 
donors. This appears to relate to the expression of the IL15R  in monocytes and 
it is possible that differences such as this influence the iNKT populations in high 
and low donors. Future experiments would look at transfecting the IL15R  gene 
into B cells to see if this would permit iNKT proliferation of low donors. Lastly, 
it  is  worth  considering  the  iNKT  themselves  as  showing  selectivity  for  the 
manner in which lipids are presented to them. It is possible that the low donors 
have been selected to recognize only endogenously processed lipid, typically by 
phagocytic APC i.e. monocytes, whilst high donors may respond to that loaded at 
the cell surface (B cells) or following uptake and intracellular loading. Future 
studies  could  explore  this  through  a  number  of  experimental  approaches 
including artificially loaded CD1d dimmers, B cell lipid transfection or inhibition 
of phagocytosis in monocytes. 
 
Having established that the iNKT responses of healthy controls are multilayered, 
we sought to reduce this variability to evaluate novel analogues for differences in     
 
functional readouts. The overarching principle that emerges from our work is 
that no single assay can be used to identify a ‘good ligand’. Our exploration of 
proliferative  capacity,  multicytokine  productivity,  cytotoxicity  and  anergy 
revealed a complex effector response portfolio to the ligands tested. The acyl and 
sphingosine compounds were perhaps the most interesting as these uncoupled 
proliferation  from  cytokine  production  whilst  increasing  the  previously  under 
explored  IL-17  cytokine.  Our  assessment  of  the  6’  derivatised  galactose 
analogues revealed a surprising effectiveness of all the ligands with an intriguing 
relationship between the induction of PD-1 and proliferation potential for some 
of the ligands. It is also worth noting that the comparison of our results with 
those  previously  published  on  the  6’  derivatised  galactose  analogues  in  mice 
argues for a screening platform for both mice and humans as the responses to the 
ligands  are  not  identical  across  the  species  (293).  Our  future  work  will  be 
directed at utilising these different ligands to influence the cytokine milieu at the 
time  of  priming  to  a  protein  antigen  to  establish  whether  they  may  be  truly 
adjunctive  in  skewing  conventional  T  cell  responses  to  a  Th1,  Th2  or  Th17 
direction. 
Another interesting aspect of iNKT biology we have identified with our ligands 
is  that  iNKT  cells  can  be  ligand  specific,  despite  minor  differences  in  the 
antigenic structure of individual glycolipids. This specificity showed a partial 
recognition across the 2 most similar analogues but limited reactivity to  -GC. 
How such invariant cells develop antigen specificity is intriguing and follow up 
studies should identify if this specificity is through TCR differences in the V  or 
V  CDRs or reflects important CD1d ligand conformations that can be explored 
through  crystal  structures  or  in  silico  modeling.  The  derivation  of  CD1d-
analogue specific tetramers would also be a useful approach to evaluate if they 
may bind to the respective iNKT cell lines. A reciprocal experiment may also be 
undertaken where the TCR’s of the different lines are cloned and used to probe 
analogue loaded complexes for cross reactivity.  
Lastly  we  chose  to  look  at  iNKT  cells  in  a  human  disease  characterized  by 
antibody deficiency and immune dysregulation, where iNKT deficiency had been     
 
previously noted in related disorder. Our examination of these cells in a pure B 
cell disorder (XLA) revealed a numerical and functional similarity to healthy 
controls.  In  our  CVID  patients  a  profound  deficiency  of  iNKT  cells  was 
identified in the majority of patients. This correlated with the absence of memory 
B  cells,  an  association  normally  linked  to  a  more  severe  clinical  outcome. 
Whether this abnormality is a primary or secondary event to the underlying cause 
of  CVID  is  unclear  but  future  studies  may  now  assess  whether  this  cellular 
deficiency  is  a  risk  factor  for  more  severe  clinical  disease  or  additional 
complications i.e. malignancy.  An examination of known monogenic forms of 
CVID  will  also  illuminate  whether  this  iNKT  deficiency  is  common  to  the 
disease progression or its onset. 
 
In summary our evaluation of iNKT biology has provided novel insights into 
iNKT development, function, and manipulation in a newly configured ex vivo 
testing  platform.  Our  ligand  evaluation  programme  has  identified  the 
complexities of monitoring iNKT responses and the limited potential of single 
assay readouts of function. Lastly our formal assessment of these cells in one 
disease setting provides a template to further explore this intriguing T cell subset 
in  the  other  diverse  immunological  diseases  of  host  defence,  autoimmunity, 
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V 11 T cells 
CD4:CD8 ratio in 
conventional V  
24 T cells 
%CD4 
Conventional 
V  11T cells 
%CD4 
Conventional
V 24 T cells 
1  3.6  6.8  63.4  66.9 
1  1.9  4.2  54.5  41.2 
3  2.6  3.9  38.7  57 
4  1.1  2.3  50.6  54.9 
4  8.4  21.9  87.4  94 
7  3.2  10.2  76.2  89 
19  3.7  4.4  55.3  56.4 
19  8.5  17.7  89.3  93.6 
22  7.4  19.7  85.2  86.7 
23  3.0  2.1  71.4  65.9 
25  1.6  10.1  42.9  18.2 
32  5.7  14.0  80  80 
35  3.2  5.3  73.4  80.6 
37  1.3  1.1  49.3  40.9 
39  4.0  5.0  75  79.5 
43  4.1  2.8  78  70.4 
44  1.9  2.6  63.9  70.2     
 
45  1.4  0.9  44  21.5 
53  2.6  3.1  68.6  63.4 
57  4.1  5.6  76.9  78.7 
87  0.6  4.0  36.7  56.7 
89  3.6  3.4  71.4  69.8 
99  2.0  3.3  62.3  68.9 
106  4.5  3.1  79  76.4 
123  2.8  3.5  62.2  56.6 
128  1.5  1.6  33.4  23.6 
161  2.3  4.4  61.9  67.6 
163  2.8  11.9  56.6  33.3 
192  2.2  3.3  62.8  55.6 
198  8.1  7.3  81.1  58.9 
213  3.9  5.3  75.7  72.5 
221  1.9  1.3  47.1  27.2 
235  1.9  2.8  51.4  54.8 
245  1.2  7.1  53.7  83.3 
275  0.4  1.1  25.2  36.6 
283  2.1  2.7  45.4  39 
345  3.9  5.6  61.8  59.6 
379  2.0  2.1  35.5  22     
 
Table 1 CD4/CD8 analysis on V 24 and V 11
406  3.6  4.3  31.6  17.9 
476  3.0  0.9  41.9  13.8 
646  0.7  3.2  27.5  29.7 
646  2.1  2.1  36.3  32.9 
659  1.2  1.7  25.2  23.8 
669  4.1  10.7  62.9  63.9 
692  1.5  1.9  39.3  29.2 
1110  2.1  2.2  36.1  33.6 
1329  1.8  2.2  43.1  42.5     
 
 